

ZIKA VIRUS VACCINE

FIELD OF INVENTION

5 The disclosure relates to methods for the purification of Zika viruses for use in vaccines and in particular relates to an improved sucrose gradient process step allowing the separation of impurities such as protamine sulphate. The disclosure also relates to Zika virus vaccines and compositions and methods for producing said vaccines and administering the vaccines to subjects for the generation of an anti-Zika virus immune response.

10

BACKGROUND OF THE INVENTION

Adverse responses to protamine sulfate have been known for many years. Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug. Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal anaphylaxis upon receiving large doses of protamine intravenously. Severe reactions to intravenous protamine can occur in the absence of local or systemic allergic reactions to subcutaneous injection of protamine-containing insulin. Although there is no clear evidence for hypersensitivity reactions of protamine sulphate linked to vaccination, vaccines containing protamine impurities have a precaution and contraindication warning in their labels stating that a serious allergic reaction after a previous dose of such a protamine containing vaccine (e.g. IXIARO®, see CDC site <http://www.cdc.gov/japanesencecephalitis/vaccine/>) is a contraindication to further doses. Thus elimination of said impurity is a medical request for an improved safety profile. On the other hand protamine sulphate is an excellent tool (and often better than other tools such as benzonase) to purify crude harvests of viruses grown on cell substrates.

In 2007, Zika virus was detected for the first time outside of the endemic regions of Asia and Africa since its discovery in a Rhesus monkey in Uganda in 1947. Since then, the virus has caused a large epidemic in French Polynesia, spreading through islands in the Pacific and into South and Central America by 2015 (WHO “Zika Situation Report” February 5, 2016). Evidence suggests that in addition to being transmitted by *Aedes* species mosquitos, other vectors may exist, and the virus may be transmitted by blood transfusion, transplacentally, and through sexual transmission (WHO Zika Virus Fact Sheet, Feb. 2016). Though the symptoms of Zika virus infection include mild fever, rash, and conjunctivitis, there is a likely correlation between infection and neurological disorders, including

Guillain-Barré syndrome and microcephaly in fetuses/neonates subsequent to infection during pregnancy. There is currently no specific treatment or vaccine for Zika virus and the only preventative measures involve control of the mosquito vector. Zika virus presents a substantial public health threat due to the wide circulation of the *Aedes* mosquito, multiple routes of transmission, and
5 potentially severe neurological effects of infection.

A preventative vaccine against Zika virus is a pressing medical need in endemic areas and in geographical areas where the vector is spreading. Furthermore, as Zika infection has dire consequences on embryonic and fetal development, a safe and effective vaccine for women of child-
10 bearing potential or pregnant women is needed. Vaccines administered during pregnancy must be very safe for both the mother and the developing fetus. While live attenuated viral vaccines are highly effective, they are often not considered safe enough for administration to pregnant women. In this regard, inactivated viral vaccines, which lack the ability to propagate in the vaccinated subject, are considered much safer. Development of an inactivated Zika virus vaccine for administration to at-
15 risk patients would fill this need.

SUMMARY OF THE INVENTION

During the course of virus purification, it was observed that addition of protamine sulfate to a virus
20 harvest produced on a cell substrate removed not only contaminating DNA derived from host cells, as expected, but surprisingly also virtually eliminated immature and otherwise non-infectious virus particles from the preparation. This finding provided a streamlined, gentle, reproducible and broadly-applicable process for obtaining highly-purified infectious virus particles for applications such as vaccine preparation. In addition, it was surprisingly found that said protamine sulfate can be very
25 efficiently separated from the virus fraction allowing for a safer vaccine produced at high yields.

Disclosed herein are virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said Zika virus vaccines for the prevention of Zika virus infection and/or for the
30 production of an anti-virus immune response in subjects, for example subjects at risk of being exposed to Zika virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated Zika virus particle, wherein the Zika virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of
35 producing said vaccines and compositions are very efficient and provide pure compositions largely

devoid of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Detail experimental examples to the above are provided for Zika virus.

5 The herein disclosed in vivo data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was unexpectedly higher than the recently reported inactivated Zika virus vaccine candidate (Larocca, et. al, 2016, Nature doi:10.1038/nature18952.). Inactivated viruses are among the safest vaccines and especially preferred for delivery to populations where safety is especially
10 concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

15 Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention. This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other
20 embodiments and of being practiced or of being carried out in various ways.

BRIEF DESCRIPTION OF THE DRAWINGS

25 The accompanying drawings are not intended to be drawn to scale. The figures are illustrative only and are not required for enablement of the disclosure. For purposes of clarity, not every component may be labeled in every drawing, alignments were performed with the multi alignment package Jalview (Waterhouse et al., 2009, Bioinformatics 25 (9) 1189-1191). In the drawings:

30 **Figure 1:** Average distance tree (by % identity, nt), complete genomes.

Figure 2: Neighbor joining tree (by % identity, nt), complete genomes.

Figure 3: Pairwise alignment-Jalview (% identity, nt), complete genomes.

35 **Figure 4:** Average distance tree (by % identity, aa), E-protein.

Figure 5: Neighbor joining tree (by % identity, aa), E-protein.

Figure 6: Pairwise alignment-Jalview (% identity, aa), E-protein.

5

Figure 7: Alignment (shading: % identity, aa), E-protein.

Figure 8: An example of virus particle maturation in the host cell. As observed in flaviviruses, full maturation of the particles requires proteolytic cleavage of the precursor membrane glycoprotein (prM) by the host protease furin. Not all prM molecules are cleaved, resulting in the release of mature, mosaic or immature-like conformations from the cells. Mosaic and immature forms are generally not infectious—only mature virions are infective and have hemagglutinin (HA) / TCID50 activity. (Figure adapted from Plevka, et al., Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres, EMBO reports (2011) 12, 602–606).

15

Figure 9: An exemplary downstream virus purification process from the crude harvest to formulation of the drug substance (vaccine), a preferred embodiment of the process of the invention (**A**). A flow-chart of an exemplary virus inactivation process is shown in (**B**).

Figure 10: PS treatment results in selective removal of Zika virus aggregates and Vero HCP and LMW impurities (SEC-HPLC of 30x concentrated Zika Virus harvest day 5).

Figure 11: SEC-HPLC of individual 30x concentrated Zika harvest prior to PS treatment at different time points.

25

Figure 12: SEC-HPLC of individual 30x concentrated Zika harvest post PS treatment at different time points. The smaller graph indicates the observed cytopathic effect (CPE) over time.

Figure 13: Preparation of the sucrose gradient.

30

Figure 14: Representative SDS-PAGE from the sucrose gradient harvest of a Zika purification is shown.

Figure 15: Comparison of JEV and ZikaV harvest schedules/yields.

35

Figure 16: SEC-HPLC elution profile of ZikaV NIV. Data were processed on Dionex Ultimate 3000 / Superose 6 Increase column. Both panels are from the same chromatogram. The upper graph is the complete elution profile; the lower graph is an enlargement of the ZIKAV elution peak.

5 **Figure 17:** SEC-MALLS analysis of inactivated ZikaV.

Figure 18: Cumulative particle size distribution of Zika NIV.

10 **Figure 19:** Graphical representation of the neutralization of the Zika virus H/PF/2013 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

15 **Figure 20:** Graphical representation of the neutralization of the Zika virus MR766 with pooled mouse sera. The number of plaques without serum was set to 100%. The EC50 was calculated using the 3-parameter method.

Figure 21: Correlation between JEV antigen content in neutralized inactivated virus (NIV) analysed by ELISA and SEC-HPLC (Dionex Ultimate 3000, Superose 6 column).

20 DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering said virus vaccines for the prevention of virus infection and/or for the production of an anti-virus immune response in subjects, for example subjects at risk of being exposed to virus. In particular, the invention is directed to a virus vaccine comprising an optimally inactivated virus particle, wherein the virus particle in an appropriate dose is able to seroconvert a subject that is administered the virus vaccine with at least a 70% probability, preferably an 80% probability. Another advantage of the invention is that related methods of producing said vaccines and compositions are very efficient and provide pure compositions largely devoid of impurities, in particular protamine sulphate, allowing for high volume production of vaccines. Examples to the above are provided for Zika virus.

Disclosed herein are downstream processes for purifying Zika virus particles from a crude preparation. The downstream process can be applied to either a virus which has not adapted for

propagation on a particular cell substrate or for a partially / fully cell substrate adapted Zika virus particle.

Aspects of the invention provide processes for the purification of infectious Zika virus particles comprising the steps of (a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate; (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising a protamine salt, preferably a protamine sulphate, to obtain a virus preparation (b); and further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation to obtain a virus preparation (c) comprising the infectious virus particles.

In some embodiments, the concentration of protamine sulphate in step (b) is about 1 to 10 mg/ml, more preferably about 1 to 5 mg/ml, more preferably about 1 to 2 mg/ml. In one embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/mL. In one embodiment, the concentration of protamine sulphate is 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml. In a preferred embodiment, the concentration of protamine sulphate in step (b) is about 2 mg/ml.

In some embodiments, the residual host cell DNA of the virus preparation (c) is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL. In a preferred embodiment, the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL. In some embodiments, the residual host cell protein of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the residual host cell protein of the virus preparation (c) is less than 100 ng/mL. In some embodiments, the residual non-infectious virus particles of the final virus preparation (c) is less than 10 µg/mL, especially less than 9, 8, 7, 6, 5, 4, 3 or 2 µg/mL, preferably less than 1 µg/mL. In a preferred embodiment, the content of residual non-infectious virus particles of the virus preparation (c) is less than 100 ng/mL.

In some embodiments, the residual protamine is less than 1 µg/mL, especially less than 900, 800, 700, 600, 500, 400, 300 or 200 ng/mL, preferably less than 100 ng/mL, more preferably is below the detection limit of HPLC, in particular below the detection limit in the final drug substance. In some embodiments, the PS content is tested by HPLC or size exclusion chromatography (SEC). For example, HPLC is validated for PS determination in JEV sucrose gradient pool samples as a routine release assay and is very sensitive (i.e., LOQ 3 µg/mL; LOD 1 µg/mL). In the current invention, PS content in Zika virus DS samples was <LOD. In one embodiment, the HPLC assessment of PS

content can be performed on a Superdex Peptide 10/300GL column (GE: 17-5176-01) using 30% Acetonitrile, 0,1% Trifluoroacetic acid as solvent with a flow rate of 0,6 ml/min at 25°C and detection at 214 nm. A more sensitive method of measurement for residual protamine in a purified virus preparation is mass spectrometry (MS). In some embodiments, the residual PS levels in a Zika virus preparation are tested by MS or other such highly sensitive method, e.g. nuclear magnetic resonance (NMR). With this method, residual PS, as well as fragments and/or break-down products of PS, can be detected at trace amounts, such as levels as low as, for example, 10^6 , 10^7 or 10^8 molecules per typical sample load. In some embodiments, the PS levels are tested in the sucrose gradient pool. In some embodiments, the PS levels are tested in the drug product. In some embodiments, the PS levels are tested in the drug substance.

In some embodiments, the crude harvest (a) comprising the virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b). In some embodiments, the one or more pre-purification step(s) comprises digesting host cell genomic DNA in the crude harvest (a) comprising the virus particles and impurities by enzymatic treatment. In some embodiments, the one or more pre-purification step(s) comprises filtration, ultrafiltration, concentration, buffer exchange and/or diafiltration. In some embodiments, the one or more pre-purification steps is filtration using a filter having a pore size equal to or less than 1 μm . In some embodiments, the filter has a pore size equal to or less than 0.2 μm . In a preferred embodiment, the filter has a pore size of 0.2 μm . In some embodiments, the concentration and/or ultra/diafiltration and/or buffer exchange is performed by tangential flow filtration (TFF). In some embodiments, ultra/diafiltration of the crude harvest (a) comprising the virus particles and impurities is performed using a hollow fiber membrane having a cut-off of equal to or less than 300 kDa. In a preferred embodiment, the hollow fiber membrane has a cut-off of about 100 kDa.

The process according to the current invention may also comprise the use of a sucrose gradient, preferably an optimized sucrose gradient. The sucrose gradient is preferably optimized for the removal of protamine sulfate, also for the removal of immature viral particles or other viral particles which are non-infectious or host cell proteins or nucleic acids (DNA, RNA, mRNA, etc) or other host cell debris. In the current invention the optimized sucrose gradient comprises at least two, at least three, at least four layers of sucrose solutions with different densities. In one embodiment, the virus preparation to be purified is provided in a sucrose solution which has a density of about 8%, about 9%, about 10%, about 11%, about 12% sucrose (w/w), preferably about 10%. In one embodiment, one sucrose solution in the gradient has a density of about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55% sucrose (w/w),

preferably about 50%. In one embodiment, one sucrose solution in the gradient has a density of about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40% sucrose (w/w), preferably about 35%. In one embodiment, one sucrose solution in the gradient has a density of about 10%, about 11%, about 12%, about 13%, about 14%,
5 about 15%, about 16%, about 17%, about 18%, about 19%, about 20% sucrose (w/w), preferably about 15% sucrose. In a preferred embodiment, the sucrose gradient comprises three layers of sucrose solutions of about 50%, about 35% and about 15% (w/w) sucrose and the virus composition to be purified is contained in about 10% (w/w) sucrose. Because the invention provided for means to not only test for host cell DNA but also immature viral particles, the skilled person in the art is able to
10 more precisely optimize the sucrose gradient for most efficient purification and include additional tools such as PRNT assay to monitor purification success.

In some embodiments, the virus particle is a live virus, a chimeric virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In a further step, the virus particles of the invention
15 may be optionally inactivated. In some embodiments, the virus particle is an attenuated form of the virus particle. For example, the virus may have reduced infectivity, virulence, and/or replication in a host, as compared to a wild-type virus. In some embodiments, the virus is a mutated or modified virus, for example the nucleic acid of the virus may contain at least one mutation relative to the wild-type virus. In some embodiments, the virus is a recombinant live virus, meaning a virus that is
20 generated recombinantly and may contain nucleic acid from different sources.

In some embodiments, the Zika virus particle is a live virus, an attenuated live virus, a modified live virus, or a recombinant live virus. In preferred embodiments, the Zika virus is a Zika virus from the Asian lineage.
25

In some embodiments, the relative reduction of impurity of the final virus preparation relative to the liquid medium (a) comprising the virus particles and impurities is in a range from 60 to 95%. In some embodiments, the residual impurity of the final virus preparation is less than 1%.

30 In some embodiments, the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line. In some embodiments, said cell line is a duck cell line. In some embodiments, said cell line is a diploid avian

cell line. In some embodiments, said cell line is an EB66 cell line. In a preferred embodiment, said cell line is a Vero cell line.

5 Aspects of the invention provide a use of any of the processes described herein for manufacturing a composition for immunization against a viral infection. In a preferred embodiment, the composition or vaccine is directed against Zika virus such as e.g. a Zika virus of the Asian lineage.

10 Other aspects provide compositions comprising the Zika virus particles obtainable by any of the processes described herein for treating and/or preventing (i.e. protecting from) a viral infection. In a preferred embodiment, the viral infection is caused by Zika virus such as e.g. a Zika virus of the Asian lineage.

15 Furthermore, disclosed herein are Zika virus vaccines and compositions comprising an inactivated Zika virus, and related methods of producing said vaccines and compositions. Also provided are methods of administering the Zika virus vaccines for the prevention of Zika virus infection and/or for the production of an anti-Zika virus immune response in subjects, for example subjects at risk of being exposed to Zika virus.

20 Zika virus is a flavivirus closely related to Dengue virus and is similarly transmitted by the *Aedes* species mosquito, although other arthropod vectors for Zika virus are possible. Since it was first isolated from a Rhesus monkey in the Zika forest of Uganda in 1947, there were very few reported incidents of human infection, especially outside of the endemic regions of Africa and Asia until a large outbreak in French Polynesia in 2007 (Haddow *et al. PLoS Neglected Tropical Diseases* (2012) 6(2), Malone *et al. PLoS Neglected Tropical Diseases* (2016) 10(3),). The virus has since spread
25 through islands of the Pacific, including Oceania, and into South and Central America (WHO “Zika Situation Report” February 5, 2016).

30 In addition to being spread by the bite of an infected mosquito, evidence also suggests transmission may occur between individuals, such as from the blood of an infected individual, *in utero*/transplacental transmission from an infected mother to the fetus, sexual transmission between sexual partners, and possibly by other local transmission routes. There is a possible association between Zika virus infection during pregnancy and microcephaly in the fetus/neonate. Microcephaly is a rare condition in which a baby’s head circumference is significantly less than expected based on the average for their age, sex, and ethnicity. This is a result of the brain failing to undergo proper

embryonic development, and in 90% of cases is associated with mental retardation (Rocha *et al.* (2016) *Bull World Health Organ* 8 Feb. 2016).

5 There is a probable association between individuals having had a prior Zika virus infection and the incidence of Guillain-Barré syndrome, a neurological disorder in which the individual's immune system destroys the myelin sheath surrounding axons of the peripheral nervous system (WHO "Zika Situation Report" February 5, 2016).

10 No specific treatments or vaccines for Zika virus currently exist, and the only measures at this time to prevent infection are through vector control and avoiding travel to regions experiencing outbreaks.

Described herein are Zika virus vaccines and compositions comprising inactivated Zika virus that provide a safe method for generating an immune response to Zika virus, including virus-neutralizing antibodies, that may help prevent against Zika virus infection.

15 Any strain of Zika virus may be used in the methods and compositions described herein. In some embodiments, the Zika virus is an isolate from an infected subject during a Zika virus outbreak. In some embodiments, the Zika virus is a strain isolated from Africa or from the African virus lineage. In some embodiments, the Zika virus is a strain isolated from Asia or from the Asian lineage (includes
20 also strains from French Polynesia). In some embodiments, the Zika virus is a strain isolated from the Americas (South America, Central America, or North America), such as a Suriname Zika virus strain. In some embodiments, the Zika virus has an RNA genome corresponding (but not limited) to the DNA sequence provided by GenBank Accession No. AY632535.2, KU321639.1, KU497555.1, KU501215.1, KU509998.1, KU527068.1, KU681081.3, KU681082.3, KU707826.1, KU744693.1, or
25 LC002520.1 or RNA genome disclosed partially or fully herein (SEQ ID NO: 2 to 69).

In some embodiments, the process of the invention results in an enrichment of infectious Zika virus particles from the crude harvest comprising infectious Zika virus particles and non-infectious virus particles and other virus products such that the enrichment of the infectious virus particles is at least
30 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, preferably at least 80%, especially at least 85% relative to the total virus particle content of the crude harvest (a) comprising the virus particles and impurities.

In some embodiments, the residual impurity of the final virus preparation with respect to all impurities in the crude harvest is less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, preferably less than 5% as determined by SEC-HPLC (Size Exclusion Chromatography – HPLC).

- 5 A unique aspect of the current invention is the realization that know-how related to the vaccine design and purification approach used for the Japanese Encephalitis Vaccine (JEV) IXIARO® (see Srivastava A.K. et al., 2001, Vaccine 19, 4557-4565, WO99/11762) may be employed and improved upon in order to expedite the development of a Zika virus vaccine and provide it to the subjects in need as soon as possible. The industrial process as disclosed for IXIARO®, providing a very effective
- 10 vaccine against JEV, was complemented by further significant improvements disclosed herein in order to provide a more efficient (higher yield) and safer (less or no protamine sulphate with its allergic potential) Zika vaccine compared to the available JEV vaccine. A particular innovation of the herein disclosed vaccines is their greatly reduced protamine salt (SEQ ID NO: 1) content in the final drug substance facilitated by the development of an improved sucrose gradient. Said sucrose gradient
- 15 not only allowed the separation of protamine sulphate but also allowed for a very effective inactivation by formaldehyde and resulted in the case of Zika with over 90% yield with the improved process disclosed herein vs about 35% yield with the published JEV process, see experimental part for comparison).
- 20 Aspects of the disclosure relate to methods of producing a virus in Vero tissue culture cells. Vero cells are a commonly used tissue culture cell line derived from the kidney of an African green monkey. The Vero cells used in the methods described herein are the Vero (WHO) cell line, obtained from the Health Protection Agency general cell collection under catalogue number 88020401.
- 25 Vero cells can be grown to confluent monolayers, for example in tissue culture flasks; in suspension (on microcarriers), for example in roller bottles; or in any other cell culture system for viral production. In some embodiments, the Vero cells are grown in a bioreactor for viral production. For plaque assays or the plaque reduction neutralization test (PRNT), Vero cells are grown in monolayers in tissue culture flasks, dishes, or wells of a plate. To infect the Vero cells with the virus, the culture
- 30 medium is inoculated with virus and the cells are incubated with the virus for a period of time. The cells may be washed after inoculation to remove any virus that did not adsorb to the cells in a given amount of time.

- The methods provided herein involve passaging the virus in Vero cells. As used herein, the terms
- 35 “passage” or “passaging” refer to infecting a population of Vero cells with virus and subsequently

inoculating a second population of Vero cells with virus produced by infection of the first Vero cell population. In some embodiments, a portion of the culture medium from the infected Vero cells (containing virus that was released from the infected cells) is used to inoculate a second population of Vero cells. This is referred to as one passage or one round of passaging. The passaging may be
5 performed serially, for example, a portion of the culture medium from the infected second population of Vero cells is used to inoculate a third population of Vero cells, and so on. In some embodiments, virus obtained from a single plaque is used to inoculate another population of cells.

In some embodiments, the virus is passaged in Vero cells several times, such as at least 4, 5, 6, 7, 8, 9,
10 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 times. In some embodiments, the virus is passaged in Vero cells at least 4 times or 5 times. In some embodiments, the virus is passaged in Vero cells at least 30 times. It is important that the virus population, i.e. the virus sequences, stays as much as possible constant over said passaging. If adaption of the virus occurs (i.e. appearance of mutated viruses in the original virus population), it
15 is preferred that said passages are not used in the context of manufacturing of said virus, e.g. for Zika it was found that up to passage 3 and culturing to day 7 can be used without major shifts in virus population, i.e. introduction of virus population with mutations. However this observation needs to be done for each virus strain and may be different.

In some embodiments, the Vero cells are incubated for at least 2 days after inoculation with the virus at e.g. a typical 0.01 MOI (multiplicity of infection) to allow for viral production prior to passaging. In some embodiments, the Vero cells are incubated for at least 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days e.g. at least 7 days after inoculation with the virus prior to passaging. The number of days the Vero cells are incubated after viral inoculation may depend on factors such as the multiplicity of
25 infection used to inoculate the cells and the viral titer desired in the culture medium. Serial passaging of the virus in Vero cells may result in generation of a Vero cell adapted virus strain.

The culture medium from the infected Vero cells may be harvested (collected) to obtain the virus. In some embodiments, the culture medium is harvested from infected Vero cells and is replaced with
30 fresh culture medium, which is then harvested after another period of time. In some embodiments, the culture medium harvested from infected Vero cells is pooled from independent Vero cell cultures and/or from independent days. Harvesting can be repeated up to 4 times by 7 or 9 days post infection, for example, and result in a high yield of virus per unit cell culture. In order to minimize the adaption of Zika virus strain to Vero cells, it was found that Vero cells could be incubated for at least 7 days,
35 more preferably 5 days, prior to passaging and subsequently supernatants could be harvested at days

2, 3, 5 and 7 or 2, 3, and 5 (see also experimental part). The harvested culture medium can be stored at +4°C prior to purification of the virus from the culture medium up to 2 weeks.

5 In some embodiments, debris from infected and lysed Vero cells may be removed from the harvested culture medium, referred to as a “clarification” of the culture medium. The harvested culture medium may be clarified by common methods known in the art, such as low-speed centrifugation, for example, at 1500 g for 10 min, and/or by filtration through a filter of pore size of 0.45 µm. The harvested culture medium can be stored at +4°C prior to concentration.

10 To concentrate the titer of the Zika virus in the harvested culture medium, it may be subjected to concentration by any method known in the art. For example, the harvested culture medium may be concentrated by methods including, without limitation, ultrafiltration, ultracentrifugation, centrifugal concentrator, vacuum centrifugation, and lyophilization. In some embodiments, the harvested culture medium is concentrated by ultrafiltration and the retentate containing the Zika virus is collected. In
15 some embodiments, the harvested culture medium is concentrated by precipitation in which polyethylene glycol (PEG) 8000 is dissolved in the culture medium (up to 10%) and the precipitate is dissolved in a buffer, for example phosphate-buffered saline (PBS, pH 7.0).

The harvested culture medium may be precipitated to produce a virus supernatant. In some
20 embodiments, the harvested culture medium is precipitated to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. In some embodiments, the harvested culture medium is concentrated prior to precipitation. In some embodiments, the harvested culture medium is precipitated by adding protamine sulfate (e.g. SEQ ID NO: 1) to the harvested culture medium and incubating the mixture, for example at +4°C or on ice. In
25 some embodiments, the harvested culture medium is treated with benzonase to remove Vero cell DNA and other undesired material, such as Vero cell debris, from the harvested culture medium. However, it was found that the treatment with protamine sulfate is preferred (see experimental part). In some embodiments, the precipitated culture medium is centrifuged to collect precipitated material and the supernatant containing the virus, referred to as a “virus supernatant”, is collected.

30 The virus supernatant may be further purified after precipitation, for example density gradient ultracentrifugation. In some embodiments, the virus supernatant is further purified by sucrose gradient. Fractions may be collected from the sucrose gradients and assayed for presence of the virus. Methods for assaying for virus positive fractions include plaque assay, hemagglutination assay,
35 polyacrylamide gel electrophoresis, and antigen assays such as Western blotting and ELISA. The

fractions containing virus may be pooled based on titer of the virus and level of other impurities. The level or amount of impurities present in the virus supernatant can be estimated by testing for Vero cell DNA, virus aggregates and/or Vero cell protein (see experimental part). A particular embodiment of the invention is the improved sucrose gradient that allows for an efficient protamine separation as shown in the experimental part. It was surprisingly found that the addition of a virus-containing fraction with 10% (w/w) sucrose to a simple three layer sucrose density gradient (e.g. a gradient comprising a 15% (w/w) sucrose solution, a 35% (w/w) sucrose solution, and a 50% (w/w) sucrose solution) resulted in efficient separation of protamine sulphate without much loss of virus. Thus a particularly preferred embodiment of the invention is the use of a sucrose density gradient that is able to efficiently separate protamine sulphate, wherein said sucrose density gradient is used in the purification of virus such as the viruses described herein, i.e. a Zika virus.

To achieve a safe vaccine or composition for the administration to subjects, the virus supernatant may be inactivated (see experimental part for Zika virus). As used herein, the terms “inactivated” and “optimally inactivated” may be used interchangeably and refer to a process (or its result) by which the virus is rendered unable to infect a host cell (non-infectious), but that does not affect or substantially affect the antigenicity of the virus, for example, the immunogenic antigens exposed on the surface of the virus are able to stimulate an immune response in a subject (*e.g.*, antigen-specific antibodies). By “does not affect or substantially affect the antigenicity of the virus” is meant that the inactivated virus retains at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even essentially 100% of the antigenicity of a virus that is not subjected to inactivation.

A variety of methods are known in the art for inactivating viruses. In some embodiments, the virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

In some embodiments, the inactivating is by chemical inactivation and involves contacting the virus with one or more chemical inactivation agents for a period of time under conditions such that the virus is inactivated but the antigenic epitopes are substantially intact. In some embodiments, the virus is inactivated for a period of time that is longer than is required to completely inactivate the virus. In some embodiments, the virus supernatant is inactivated for the number of days required to inactivate the virus plus at least one additional day. Samples of the virus supernatant may be taken at one or more times throughout the inactivation process and assessed for viral viability (infectivity) by any method known in the art, such as by infecting a monolayer of host cells (*i.e.*, plaque assay). Using

such a procedure, the period of time that is required to completely inactivate the virus can be determined, and a longer period of time is selected to ensure complete inactivation.

- In some embodiments, the virus is contacted with a chemical inactivation agent for between 1 day and 50 days, between 2 days and 40 days, between 2 days and 30 days, between 2 days and 20 days, between 2 days and 10 days, between 3 days and 9 days, between 4 days and 8 days, between 5 days and 7 days, between 2 days and 5 days, or between 5 and 10 days. In some embodiments, the virus is contacted with one or more chemical inactivation agents for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, or at least 50 days.
- 15 In some embodiments, the chemical inactivation is performed at about +5°C, +10°C, +15°C, +20°C, +25°C, +30°C, +35°C, +40°C, or about +45°C. In some embodiments, the chemical inactivation is performed at about +4°C. In some embodiments, the chemical inactivation is performed at about +22°C.
- 20 Any chemical inactivation agent known in the art may be suitable for inactivating the virus in the methods described herein. It will be appreciated by one of skill in the art that factors such as the chemical inactivation agent and the temperature at which inactivation is performed may affect the length of time (number of days) required to completely inactivate the virus. Examples of chemical inactivation agents include, without limitation, formaldehyde, enzymes, β -propiolactone, ethanol,
- 25 trifluoroacetic acid, acetonitrile, bleach, urea, guanidine hydrochloride, tri-n-butyl phosphate, ethyleneimine or a derivatives thereof, and organic solvents such as Tween, Triton, sodium deoxycholate, and sulphobetaine. A preferred inactivation is inactivation with formaldehyde at 22°C +/-2°C for about 10 days.
- 30 In some embodiments, the inactivating agent is neutralized after chemical inactivation of the virus. In some embodiments, the inactivating agent is formaldehyde and is neutralized after chemical inactivation using sodium thiosulphate or sodium metabisulfite.

- In some embodiments, the virus is inactivated by thermal inactivation. In some embodiments, the thermal inactivation involves exposing the virus to heat, such as dry heat or vapor heat, for a period of
- 35

time. In some embodiments, the thermal inactivation involves exposing the virus to temperatures of about +40°C, +45°C, +50°C, +55°C, +60°C, +65°C, +70°C, +75°C, +80°C, +85°C, +90°C, +95°C, or about +100°C. In some embodiments, the virus is exposed to heat for at least 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, about 96 hours, or longer. A preferred thermal inactivation involves exposing the virus to temperatures of about +56°C for 60 minutes.

In some embodiments, the virus is inactivated by exposing the virus to acidic or alkaline conditions for a period of time such that the virus is completely inactivated. The pH of a virus preparation may be adjusted to a desired pH, for example by the addition of an acid, a base, or a buffer with a particular pH to the virus preparation. In some embodiments, the virus is inactivated at an acidic pH of about 2, 2.5, 3, 3.5, 4, 4.5, 5 or about 5.5. In other embodiments, the virus is inactivated at an alkaline pH of about 8, 8.5, 9, 9.5, 10, or about 10.5.

In some embodiments, the virus is inactivated using UV inactivation. UV inactivation involves exposing the virus to energy-rich radiation, such as UV-A, UV-B, or UV-C light for a period of time. It will be appreciated that any two or more methods of inactivation may be combined and performed concurrently or serially.

The inactivated virus may be subsequently dialyzed to remove any undesired material, including the inactivating agent and any neutralizing agent, and/or to replace the buffer with a buffer that is pharmaceutically acceptable for administration to subjects. In some embodiments, the inactivated virus is dialyzed with PBS. In addition or alternatively, the inactivated virus may be filtered, such as sterile filtered, through a 0.22 µm filter.

Any of the methods or uses described herein may be for the prevention of a Zika virus infection in a subject. As used herein, the terms “prevent,” “preventing” and “protection from” include the administration of a virus vaccine or composition to a subject to reduce, or delay the onset of the manifestation of clinical or subclinical symptoms, complications, pathologies or biochemical indicia of a disease or infection, or to reduce or inhibit the spread/transmission of the Zika virus. As used herein, antigen(s), such as an inactivated Zika virus, that is administered to a subject prophylactically (e.g., prior to infection) may be referred to as a vaccine.

Zika Vaccine

As described herein Zika virus may cause any of a variety of symptoms upon infection of a subject, and is generally characterized by mild fever; rash (exanthema) on face, neck, trunk, upper arms; headache; sensitivity to light; non-inflammatory joint pain; conjunctivitis; lack of appetite; diarrhea; abdominal pain; and/or dizziness. Zika virus infection during pregnancy is associated with microcephaly in the fetus/neonate. There is also a probable association between the onset of Guillain-Barré syndrome or symptoms thereof. Diagnosis of Zika virus infection in subjects exposed to Zika virus or suspected of being exposed to Zika virus involves detecting the presence of virus-specific antibodies and/or molecular testing, such as PCR or real-time PCR detection of Zika virus.

Provided herein are methods for administering a dose of a therapeutically effective amount of a Zika virus vaccine to a subject in need thereof. In some embodiments, the subject is a mammalian subject, such as a human, non-human primate, rodent, rabbit, sheep, dog, cat, horse, or cow. In some embodiments, the subject is a mouse. In some embodiments, the subject is a human subject, such as a child, an adult, or an elderly adult. In some embodiments, the subject is a female subject. In some embodiments, the subject is pregnant or planning on becoming pregnant. In some embodiments, the subject is at risk of being exposed to Zika virus. In some embodiments, the subject is living in or traveling to an area where Zika virus is present or is thought to be present. In some embodiments, the subject has been previously infected with or vaccinated against Dengue virus; i.e., at risk for antibody-dependent enhancement of disease. In some embodiments, the subject is living in or traveling to an area that is experiencing a Zika virus infection outbreak. In some embodiments, the subject is living in or traveling to an area where an arthropod vector capable of transmitting the Zika virus vector is present or is thought to be present.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject in a therapeutically effective amount or a dose of a therapeutically effective amount. As used herein, a “therapeutically effective amount” of vaccine is any amount that results in a desired response or outcome in a subject, such as those described herein, including but not limited to prevention of infection, an immune response or an enhanced immune response to Zika virus, or prevention or reduction of symptoms associated with Zika disease.

In some embodiments, the therapeutically effective amount of a Zika virus vaccine or composition described herein is an amount sufficient to generate antigen-specific antibodies (*e.g.*, anti-Zika virus antibodies). In some embodiments, the therapeutically effective amount is sufficient to provide seroprotection in a subject; i.e., to generate sufficient antigen-specific antibodies to prevent/protect

from infection. In some embodiments, seroprotection is conferred on at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of vaccinated subjects. In some embodiments, seroprotection is defined by a reduction in the number of Zika virus plaques by 50% or more in a plaque reduction neutralization test (PRNT) by a 1:10 or higher dilution of sera from a vaccinated subject. In some
5 embodiments, an effective amount of the Zika vaccine is sufficient to seroconvert a subject with at least 70% probability. In some embodiments, the therapeutically effective amount is sufficient to seroconvert a subject with at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or at least 99% probability. Whether a subject has been seroconverted can be assessed by any method known in the art, such as obtaining a serum sample from the subject and performing an assay to detect anti-Zika
10 virus antibodies. In some embodiments, a subject is seroconverted if a serum sample from the subject contains an amount of anti-Zika virus antibodies that surpasses a threshold or predetermined baseline. A subject is generally considered seroconverted if there is at least a 4-fold increase in anti-Zika virus antibodies (*i.e.*, anti-Zika E protein IgG antibodies) in a serum sample from the subject as compared to a serum sample previously taken from the same subject.

15 In some embodiments, seroconversion of a subject is assessed by performing a plaque reduction neutralization test (PRNT). Briefly, PRNT is used to determine the serum titer required to reduce the number of Zika virus plaques by 50% (PRNT50) as compared to a control serum/antibody. The PRNT50 may be carried out using monolayers of Vero cells or any other cell type/line that can be
20 infected with Zika virus. Sera from subjects are diluted and incubated with live, non-inactivated Zika virus. The serum/virus mixture may be applied to the Vero cells and incubated for a period of time. Plaques formed on the Vero cell monolayers are counted and compared to the number of plaques formed by the Zika virus in the absence of serum or a control antibody. A threshold of neutralizing antibodies of 1:10 dilution of serum in a PRNT50 is generally accepted as evidence of protection
25 (Hombach *et. al.* Vaccine (2005) 23:5205-5211).

In some embodiments, the Zika virus may be formulated for administration in a composition, such as a pharmaceutical composition. The term “pharmaceutical composition” as used herein means a
30 product that results from the mixing or combining of at least one active ingredient, such as an inactivated Zika virus, and one or more inactive ingredients, which may include one or more pharmaceutically acceptable excipient.

Pharmaceutical compositions of the invention, including vaccines, can be prepared in accordance with methods well known and routinely practiced in the art (see *e.g.*, Remington: The Science and Practice
35 of Pharmacy, Mack Publishing Co. 20th ed. 2000; and Ingredients of Vaccines – Fact Sheet from the

- Centers for Disease Control and Prevention, e.g., adjuvants and enhancers such as alum to help the vaccine improve its work, preservatives and stabilizers to help the vaccine remain unchanged (e.g., albumin, phenols, glycine)). Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically a therapeutically effective dose of the inactivated Zika virus preparation is employed in the pharmaceutical composition of the invention. The inactivated Zika virus is formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (e.g., the prophylactic response).
- 10 Dosages of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired pharmaceutical response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors.
- 20 A physician, veterinarian or other trained practitioner, can start doses of the inactivated Zika virus vaccine employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect (e.g., production of anti-Zika virus antibodies) is achieved. In general, effective doses of the compositions of the present invention, for the prophylactic treatment of groups of people as described herein vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and the titer of anti-Zika virus antibodies desired. Dosages need to be titrated to optimize safety and efficacy. In some embodiments, the dosing regimen entails subcutaneous or intramuscular administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 7. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 14. In some embodiments, the dosing regimen entails subcutaneous administration of a dose of inactivated Zika virus twice, once at day 0 and once at about day 28. In some embodiments, the inactivated Zika virus is administered to the subject once.

Any of the Zika virus vaccines or compositions described herein may be administered to a subject with, prior to, or after administration of one or more adjuvants. An adjuvant is a molecule that enhances a response in a subject, such as an immune response, to an antigen or other molecule. In some embodiments, an adjuvant may stabilize an antigen or other molecule. Determining whether a
5 Zika virus vaccine or compositions thereof are administered with an adjuvant depends on various factors (e.g., type and extent of response desired) and will be evident to one of skill in the art. In some embodiments, administering any of the Zika virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may enhance the production of virus neutralizing (anti-Zika virus) antibodies. In some embodiments, a subject that is administered any of the Zika
10 virus vaccines or compositions described herein with, prior to, or after administration of an adjuvant may only require a single administration of the Zika virus vaccine or composition to be seroconverted (produce a level of anti-Zika virus antibodies). Examples of adjuvants may include, without limitation, aluminium salt (aluminium hydroxide or aluminium phosphate), calcium phosphate hydroxide, paraffin oil, killed bacteria, bacterial toxins, toxoids, subunits of bacteria, squalene,
15 thimerosal, detergents, IL-1, IL-2, IL-12, 2-component adjuvants, such as 2-component adjuvants containing an antibacterial peptide and a TLR9 agonist (e.g., IC31®), and combinations such as Freund's complete adjuvant and Freund's incomplete adjuvant. In some embodiments, the Zika virus vaccines or compositions is administered with aluminium hydroxide. In some embodiments, the inactivated Zika virus vaccine or composition is administered with aluminium phosphate salt. A
20 preferred aluminium salt is the aluminium hydroxide with reduced Cu content, e.g. lower than 1,25ppb based on the weight of the Zika composition, an adjuvant described in detail in WO 2013/083726 or Schlegl et al., Vaccine 33 (2015) 5989-5996.

In some embodiments, the adjuvant is comprised of two components. In some embodiments, the 2-
25 component adjuvant comprises an antibacterial peptide and a TLR9 agonist. In some embodiments, the antibacterial peptide is provided by the amino acid sequence KLKL₅KLK (SEQ ID NO: 71). In some embodiments, the TLR9 agonist is a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN). In some embodiments, the I-ODN comprises the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70). In some embodiments, the adjuvant is IC31®. In some
30 embodiments, the adjuvant is in nanoparticle form (See, e.g., US Patent No. 8,765,148 B2, incorporated by reference in its entirety). In some embodiments, the adjuvant is IC31®, i.e. KLKL₅KLK (SEQ ID NO: 71) and the nucleic acid sequence (dIdC)₁₃ (SEQ ID NO: 70), in combination with an aluminium salt such as aluminium hydroxide.

The Zika virus vaccines or compositions described herein may be administered to a subject concomitantly with one or more vaccines to another infectious agent, such as another infectious agent is that present or thought to be present in the same geographic area as Zika virus. In some embodiments, the other infectious agent is one that the subject is also at risk of being in contact with.

5 In some embodiments, the other infectious agent is transmitted by the same arthropod vector as Zika virus. In some embodiments, the other infectious agent is Japanese Encephalitis virus, Yellow Fever virus, Dengue virus and/or Chikungunya virus.

Also within the scope of the present disclosure are kits for use in prophylactically administering to a
10 subject, for example to prevent or reduce the severity of Zika virus infection. Such kits can include one or more containers comprising a composition containing inactivated Zika virus, such as an inactivated Zika virus vaccine. In some embodiments, the kit may further include one or more additional containing comprising a second composition, such as a second vaccine. In some
15 embodiments, the second vaccine is a vaccine for another arbovirus. In some embodiments, the second vaccine is a Dengue virus vaccine and/or a Chikungunya virus vaccine.

In some embodiments, the kit can comprise instructions for use in accordance with any of the methods described herein. The included instructions can comprise a description of administration of the composition containing inactivated Zika virus to prevent, delay the onset, or reduce the severity of
20 Zika virus infection. The kit may further comprise a description of selecting a subject suitable for administration based on identifying whether that subject is at risk for exposure to Zika virus or contracting a Zika virus infection. In still other embodiments, the instructions comprise a description of administering a composition containing inactivated Zika virus to a subject at risk of exposure to Zika virus or contracting Zika virus infection.

25 The instructions relating to the use of the composition containing inactivated Zika virus generally include information as to the dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (*e.g.*, multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the invention are typically written instructions on a label or
30 package insert (*e.g.*, a paper sheet included in the kit), but machine readable instructions are also acceptable.

The kits of the present disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like. Also contemplated are packages for use
35 in combination with a specific device, such as a syringe or an infusion device. The container may

have a sterile access port, for example the container may be a vial having a stopper pierceable by a hypodermic injection needle. At least one active agent in the composition is an inactivated Zika virus, as described herein.

- 5 This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including”, “comprising”, or “having”, “containing”, “involving”,
 10 and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

- Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art.
- 15 Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art. Generally, nomenclatures used in connection with, and techniques of biochemistry, enzymology, molecular and cellular biology, microbiology, virology, cell or tissue culture, genetics and protein and nucleic chemistry described
 20 herein are those well-known and commonly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.
- 25 The present invention is further illustrated by the following examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference, in particular for the teaching that is referenced hereinabove. However, the citation of any reference is not intended to be
 30 an admission that the reference is prior art.

Table 1. Overview of process buffers and stock solutions.

Buffer	Composition	Final pH	Final conductivity [mS/cm]
A	0.5 M NaOH		n.a.
B	0.1 M NaOH		n.a.

C	25 mM Tris, 150 mM NaCl	7.4±0.2	16.5
D	1 M Tris	7.4±0.2	n.a.
E	4.5 M NaCl	n.a.	n.a.
F	1 M NaCl	n.a.	n.a.
G	1 % SDS	n.a.	n.a.
H	50 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
I	35 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
J	15 % (w/w) Sucrose in 25 mM Tris, 150 mM NaCl	7.4±0.2	n.a.
K	10 x PBS	7.4±0.2	n.a.
L	50 mg/mL Protamine sulphate	7.4±0.2	n.a.
M	Drug substance formulation buffer (10mM Tris(hydroxymethyl)-aminomethan, 5 % Sucrose, 1% (10 mg/mL) rHSA)	7.4±0.2	1.3

Table 2. Abbreviations.

°Bx	Degrees Brix = sugar content (w/w) of an aqueous solution*
BSA	Bovine serum albumin
CC700	Capto™ Core 700
CPE	Cytopathic effect
EtOH	Ethanol
EU	Endotoxin units
DS	Drug Substance
DP	Drug Product
DSP	Downstream Process
HCP	Host cell protein
hcDNA	Host cell DNA
hpi	Hours post infection
HPLC	High Performance Liquid Chromatography
ID	Inner diameter
JEV	Japanese Encephalitis virus
LAL	Limulus amoebocyte lysate
LDS buffer	Lithium dodecyl sulfate sample loading buffer
LOD	Limit of detection
LOQ	Limit of quantitation
MALLS	Multiangle light scattering
mAU	Milli absorbance units
MS	Mass spectroscopy
NIV	Neutralized inactivated virus
PBS	Phosphate buffered saline
PD	Process development
PFU	Plaque forming units
p.i.	Post-infection
PS	Protamine sulphate or protamine sulfate
rcf	Relative centrifugal force
rHSA	Recombinant human serum albumin
Rms radius	Root mean square radius
rMSB	Research master seed bank
RSD	Relative standard deviation
SEC	Size exclusion chromatography
SGC	Sucrose gradient centrifugation
SGP	Sucrose gradient purified
SDS	Sodium dodecyl sulphate

TBS	Tris buffered saline
TFF	Tangential flow filtration
TCID50	Tissue culture infectious dose 50%
UF/DF	Ultrafiltration/diafiltration
WFI	Water for injection
ZikaV	Zika virus

*Degrees Brix (°Bx) is the sugar content of an aqueous solution. One degree Brix is 1 gram of sucrose in 100 grams of solution and represents the strength of the solution as percentage by mass. °Bx corresponds to the sucrose content in percent (w/w), e.g., 45 °Bx equals 45 % (w/w) sucrose.

5

Table A. Primers for Zika virus sequencing: lower case letters indicate bases not included in ZIKA but containing restriction sites for later cloning when needed (therefore, two Tms provided).

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	T _m (gene-specific)	T _m (entire primer)	Amplicon size [bp]
1	9320_Zika_PF_1F	SEQ ID NO: 74 ttaggatccGTGTGATCTGTGTGAAT	69.9	74.6	707
	9321_Zika_PF_1R	SEQ ID NO: 75 taactcgagCGTACACAACCCAAGTT	69.3	75.6	
2	9322_Zika_PF_2F	SEQ ID NO: 76 ttaggatccTCACTAGACGTGGGAGTG	70	73.9	704
	9323_Zika_PF_2R	SEQ ID NO: 77 taactcgagAAGCCATGTCYATATTGAT	69.8	73.7	
3	9324_Zika_PF_3F	SEQ ID NO: 78 ttaggatccGCATACAGCATCAGGTG	72.3	74.5	712
	9325_Zika_PF_3R	SEQ ID NO: 79 taactcgagTGTGGAGTTCCGGTGTCT	72	76.4	
4	9326_Zika_PF_4F	SEQ ID NO: 80 ttaggatccGAATAGAGCGAARGTTGAGATA	70.9	74	712
	9327_Zika_PF_4R	SEQ ID NO: 81 taactcgAGTGGTGGGTGATCTTCTTCT	70.5	73.7	
5	9328_Zika_PF_5F	SEQ ID NO: 82 ttaggatccCAGTCACAGTGGAGGTACAGTAC	70.3	75	704
	9329_Zika_PF_5R	SEQ ID NO: 83 taactcgagCRCAGATACCATCTTCCC	71.5	77.3	
6	9330_Zika_PF_6F	SEQ ID NO: 84 ttaggatCCCTTATGTGCTTGGCCTTAG	70.7	72.7	698
	9331_Zika_PF_6R	SEQ ID NO: 85 taactcgagTCTTCAGCCTCCATGTG	70.4	76.9	
7	9332_Zika_PF_7F	SEQ ID NO: 86 ttaggatccAATGCCCACTCAAACATAGA	71.9	75	716
	9333_Zika_PF_7R	SEQ ID NO: 87 taactcgagTCATTCTCTTCTCAGCCCTT	71	74	
8	9334_Zika_PF_8F	SEQ ID NO: 88 ttaggatccAAGGGTGATCGAGGAAT	70.9	75.2	703
	9335_Zika_PF_8R	SEQ ID NO: 89 taactcgagTTCCTTCAGAGAGAGGAGC	71.9	73.4	
9	9336_Zika_PF_9F	SEQ ID NO: 90 ttaggatccTCTTTTGCAAAGTGCATC	71.9	75	699
	9337_Zika_PF_9R	SEQ ID NO: 91 taactcgagTCCAGCTGCAAAGGGTAT	71	74.9	
10	9338_Zika_PF_10F	SEQ ID NO: 92 ttaggatccGTGTGGACATGTACATTGA	71.4	75.8	706
	9339_Zika_PF_10R	SEQ ID NO: 93 taactcgagCCCATTGCCATAAAGTC	70.4	75.8	

Primer Pair	Oligoname	Primer sequence (5'-3') restriction sites (lower case)	T _m (gene-specific)	T _m (entire primer)	Amplicon size [bp]
11	9340_Zika_PF_11F	SEQ ID NO: 94 ttaggatccTCATACTGTGGTCCATGGA	71.6	78.1	692
	9341_Zika_PF_11R	SEQ ID NO: 95 taactcgagGCCCCATCTCAACCCCTTG	74	78	
12	9342_Zika_PF_12F	SEQ ID NO: 96 ttaggatccTAGAGGGCTTCCAGTGC	70.9	74	707
	9343_Zika_PF_12R	SEQ ID NO: 97 taactcgAGATACTCATCTCCAGGTTTGTGTTG	70.2	72.2	
13	9344_Zika_PF_13F	SEQ ID NO: 98 ttaggatccGAAAACAAAACATCAAGAGTG	70.6	75.4	726
	9345_Zika_PF_13R	SEQ ID NO: 99 taactcgagGAATCTCTCTGTTCATGTGTCCT	71.9	75.6	
14	9346_Zika_PF_14F	SEQ ID NO: 100 ttaggatccTTGATGGCAGACCAAC	73.1	75.6	715
	9347_Zika_PF_14R	SEQ ID NO: 101 ttaggatccGTTGTGTGATCTGTGTGAAT	70.8	77.9	
15	9348_Zika_PF_15F	SEQ ID NO: 102 taactcgagCAGGTCAATGTCCATTG	71.9	75.4	719
	9349_Zika_PF_15R	SEQ ID NO: 103 ttaggatccTGTTGTGTTCTTATGCTGGT	73.9	77.2	
16	9350_Zika_PF_16F	SEQ ID NO: 104 taactcgagGTGATCAGRGCCCCAGC	72.3	75.4	703
	9351_Zika_PF_16R	SEQ ID NO: 105 ttaggatccTGCTGCCAGAAAGAGAA	72	76.3	
17	9352_Zika_PF_17F	SEQ ID NO: 106 taactcgagGCACCAACAYGGGTTCTT	73.6	76	705
	9353_Zika_PF_17R	SEQ ID NO: 107 ttaggatccCTCAAGGACGGTGTGGC	72	75.5	
18	9354_Zika_PF_18F	SEQ ID NO: 108 taactcgagCAATGATCTTCATGTGGG	71.7	75.8	699
	9355_Zika_PF_18R	SEQ ID NO: 109 ttaggatccTATGGGGGAGGACTGGT	71	74.1	
19	9356_Zika_PF_19F	SEQ ID NO: 110 taactcgAGCCCAAGACCTTGATC	73.3	75.5	711
	9357_Zika_PF_19R	SEQ ID NO: 111 ttaggatccCAGACCCCAAGAAGGC	71.3	76.9	
20	9358_Zika_PF_20F	SEQ ID NO: 112 taactcgagCCCCTTGTGCTTGTCT	71.7	75	706
	9359_Zika_PF_20R	SEQ ID NO: 113 ttaggatccAGGAAGGATGTATGCAGATG	71.9	73.9	
21	9360_Zika_PF_21F	SEQ ID NO: 114 taactcgagACATTGCGCATATGATTTTG	70.4	75.7	709
	9361_Zika_PF_21R	SEQ ID NO: 115 ttaggatccAGGAAGGACACACAAGAGT	71.8	75	
22	9362_Zika_PF_22F	SEQ ID NO: 116 taactcgagACAGGCTGCACAGCTTT	70	79.1	581
	9363_Zika_PF_22R	SEQ ID NO: 117 ttaggatccTCTCTCATAGGGCACAGAC	74.8	81.1	

SEQUENCES

- 5 SEQ ID NO: 1
A typical form of protamine
PRRRSSSRP VRRRRPRVS RRRRRRGRR RR

Provided below are examples of nucleic acid sequences of the genomes of Zika viruses that may be used in the methods, compositions, and/or vaccines described herein.

SEQ ID NO: 2

5 KU321639.1 Zika virus strain ZikaSPH2015, Brazil, complete genome
GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGG
ATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
CGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTATGGGCCCATCAGG
ATGGTCTTGGCAATTCTAGCCTTTTGAAGTTACAGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTG
10 GGGAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
AGGAGAAGAAGAGACGGGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGAGG
TCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGATGTGGGGAGGCCATATCTTTCCAACCACATTG
GGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
GGATGAGGGGGTGAACCATGACGTCGATTGTTGGTGCAACACGACGTCACCTGGGTTGTGTACGGAACCTGCCAT
15 CACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCATTCAGTGAAGCTGCAAAACGCGGT
CGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTC
GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
GATTGCCCCGGCATAACGATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
GTTGATATTGCTTGGACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTAC
20 AACACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
GCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGC
TGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTTTGCATGTCCAAGAAAATGACCG
GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCAGCACAGTGGGATGATCGT
TAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACC
25 CTGGGGGGTTTTGGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCTTGACTTTTCAGATTTGTATTACTTGACTATG
AATAACAAGCACTGGTTGGTTCACAAGGAGTGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
TCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGG
AGTCAAGAAGGAGCAGTTCACACGGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCT
CTGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCATACTCCTTGTGTACCGCAGCGTTCA
30 CATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTG
CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
CTGAAAGCACTGAGAATCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTTTACATTGTATAGGAGTCGGG
GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAGAGGTGCCA
AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCAAACTCATTGGGCAAGGGCAT
35 CCATCAAAATTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCAAAATCTCATTGGAACTGTGCTG
ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTATCC
ACAGCCGTCTCTGCTGATGTGGGTGCTCGGTGGACTTCTCAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
AGCCTGGGAAGATGGTATCTGCGGGATCTCCTGTGTTCAAGAAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAG
40 CTCAACGCAATCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCATGTGGAGAGGTC
CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCGTGAGAGCAGC
AAAGACAAATAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCACTCAAACATAGAGCATGGAACAGCTTTC
TTGTGGAGGATCATGGGTTGCGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
CCAGCCGTTATTGGAACAGCTGTTAAGGGAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGA
45 ATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAAATGTGAATGGCCAAAGTCCACACATTGTGGAC
AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCAATAACAGAGAGGGCT
ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCA
CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGTTGATCGAGGAATGGTG
CTGCAGGGAGTGACAATGCCCCACTGTCTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGG
50 AAAGAACCAGAAAGCACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCAGATGATGATCACTTCTCCCTTGGAGT
GCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCAGATCAATGGCA
GTGCTGGTAGCTATGATCCTGGGAGGATTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC

GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
TCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGCTTTTGCAAACTGCGATCTCCG
CCTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
5 CTGATAACATCACCTTGGCAATCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAGAGCAGGC
CTTGCTACTTGCAGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCAATTTGTCATGGC
CCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGGCTGCTGTTGCTCACAAGGAGTGGAAGCGG
AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
GATGGCTGGGCCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
10 AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
AGAGTGGTGATTTCTCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
TGTGGCATGAACCAATAGCCATACCCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAG
ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCAGTCCAAAAAGGA
TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTGC
15 CATGGAAGTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTGGCCGTGCCCCCGGAGAGAGAGCGAGGA
ACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
TTCAGGATCTCCAATCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGT
TATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
AGCAGCTAACTGTCTTAGACTTGATCTGAGAGTGGGAAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATA
20 AAAACAAGACTCCGTAAGTGTGATCTTAGCTCCAACAGGGTGTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCC
AGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCAC
TTCACGTCTACTACAGCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGGCGCTGCCATCTTCATGACCCGCCACGCCACAG
GAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCAGAGAGAGCCTGGAGCTCA
25 GGCTTTGATTGGGTGACGGATTATCTGAAAAACAGTTTGGTTTGTCCAAGCGTGAGGAACGGCAATGAGATCGCAGC
TTGTCTGACAAAGGCTGGAAAAACGGGTACACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACATC
AAGAGTGGGACTTTGTGCTGACAACTGACATTTAGAGATGGGCGCCAACCTTAAAGCTGACCGTGTATAGATTCCAGG
AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTATTCTGGCTGGACCCATGCCTGTACACATGCCAGCGCTGC
CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
30 TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTACCTCCAAGATGGCCTCATAGCCTCGCT
CTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTG
GAACTCATGAAAAGAGGAGATCTTCTGTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAG
ATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACACAGACAGGAGA
GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
35 GCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCCCAAT
TGCCGGAGACCTAGAGACCATTATGCTTTTGGGGTGTGCTGGGAACAGTCTCGCTGGGAATCTTTTCTGCTTGTATGAGG
AACAAGGGCATAGGGAAGATGGGCTTGGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
AGCCAGCCAGAATTGCATGTGCTCCTATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGAT
40 CTCCCCAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCAATGAAGTCCGGAT
GGTTGGAGAGAAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGGCAACCATGGGATTCTAATGG
ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACTTTCATTACCCCAAGCCGTCCAACATGCAGT
GACCACTTCATACAACAATACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAGGGATGC
CATTCTACGCATGGGACTTTGGAGTCCCGTCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCTAATAGTGG
45 CCATCATTTTGTCTGCTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCAGAGAGA
ACGGCAGCTGGCATCATGAAGAACCCTGTTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
AGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCCTGGGGG
TGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAATCCTC
TACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGC
50 TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCGTGGGAGAGAAATGGAAGGCCGCTTGAACCATGTG
GGCCTTGGAGTTTACTCTACAAAAAGTCAAGGCATACCGAGGTGTGACAGAGAAGAGGCCCGCCCTCAAGGAC
GGTGTGGCAACGGGAGGCCATGCTGTGTCGGAGGAAGTGCAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAG
CCCTATGGAAAGGTCAATTGATCTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAGTTCAAGA
AGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAGCTATGGGTGGAACATAGTCCGT

CTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
TAGTCTGAAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTAAAAAAGACCAGGAGCC
TTTTGTATAAAAGTGTGTGCCATACACCAGCACTATGATGAAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
GACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAA
5 AGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGAGGAGGATGTGA
ATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGG
ATCCGAGTGAGCACGCGGAAACGTGGTCTTTGACGAGAACCACCATATAGGACATGGGCTTACCATGGAAGCTATGA
GGCCCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTGTGACGGCTCTGTCAAAACCTGGGATGTGGTGACTG
GAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGT
10 GCCAGACCCCAAGAAGGTACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCAAAACACAAAC
GGCCACGAGTCTGTACCAAGAAGAGTTTCATCAACAAGTTCGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGA
AAAAGAGTGAAGACTGCAGTGAAGCTGTGAACGATCCAAGTTCCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCA
CCTGAGAGGAGAGTGCCAGAGTTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGAGG
CAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGAAGCCCTTGGATTCTTGAACGAGG
15 ATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAG
AGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCT
GGAGAATGAAGCTCTAATCACAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC
CAAAACAAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTCGAGACAAGACCAAA
GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGCGAATATGGAGGCT
20 GAGGAAGTCTAGAGATGCAAGACTTGTGGCTGTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGA
TGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGACATGCCCT
CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTCACTGGATGGGACAATGGGAA
GAAGTTCCGTTTTGTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTCCCTGCCGCCACCA
GATGAAGTATTGCCCCGGCCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCAT
25 ATGCGCAATGTGGCAGTCTCTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
TTGACTGGGTTCCAACTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGACATGCTTGT
GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCC
TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACACCTGGGCTGAGAACATTA
AAAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTGCTGCTAC
30 TTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTAAGCACCAATCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTT
GGGGAAGCTGTGCAGCTGTGACCCCCCAGGAGAAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
CACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
GGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCTGAAGTGGAGATCAGCTGTGGATCTCCAGAAGAGG
GACTAGTGGTTAGAGGAGA

35

SEQ ID NO: 3

KU497555.1 Zika virus isolate Brazil-ZKV2015, Brazil, complete genome

CCAATCTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTG
GAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACGCGGA
40 GTAGCCCGTGTGAGCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTGGGTCTATCAATAGATGGGGTTCAAGTGGGGA
TCTTGGCGATTCTAGCCTTTTGTAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAAGTGGGGA
AAAAAGAGGCTATGGAAATAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCCAGGAAGGA
GAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATCGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCCT
AGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGATGCTGGGAGGCCATATCTTTTCAACCAATTGGGGAT
45 GAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATG
AGGGGGTGAACCAAGATGACGTGATTGTTGGTGAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCATCACAA
AAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGAGCTCCCTCCATTCCACTAGGAAGCTGCAAAACGCGGTGCGAA
ACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTAGGAACCTGGCTTCGCGTT
AGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGC
50 CCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGAT
GTTGTCTTGGAACTGGGGGTTGTGTACCCGTATGGTACAGGACAAACCGACTGTCGACATAGAGCTGGTTTACAAAC
AGTCAGCAACATGGCGGAGGTAAAGATCTACTGATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAA
CACAAGGTGAAGCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGG
AAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAG

AGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAGTTCATGGCTCCCAGCACAGTGGGATGATCGTTAATGA
CACAGGACATGAACTGATGAGAATAGAGCGAAGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGG
GGTTTTGGAAGCTTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATGAATAAC
AAGCACTGGTTGGTTCACAAGGAGTGGTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACCTCCACA
5 CTGGAACAACAAGCAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTCTAGGGACTCAA
GAAGGAGCAGTTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGTGGTCAAAGGGAAGGCTGTCCTCTGGCC
ACTTGAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGCATACTCCTGTGTACCGCAGCGTTCACATTCA
CCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTGAAGGT
10 TCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCGTAATCACTGAAA
GCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTATAGGAGTCGGGGAGAAG
AAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTTGGAAGCACTTGAAGCCACTGTGAGAGGTGCCAAGAGAA
TGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGGCATCCATCAA
ATTTTTGGAGCAGCTTCAAATCATTGTTGGAGGAATGCTCTGGTTCACAAATTCATTGGAACGTTGCTGATGTGGT
TGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCTTAGGGGGAGTGTGATCTTCTTATCCACAGCCG
15 TCTCTGCTGATGTGGGTGCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGTGGTACAGGGGTGTTCTGTATAACGA
CGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCTCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGG
GAAGATGGTATCTCGGGATCTCTCTGTTCAAGAATGGAACATCATGTGGAGATCAGTAGAAGGGGAGCTTAACG
CAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAAACCCATGTGGAGAGGTCCACAGAG
ATTGCCGTGCTGTGAACGAGCTGCCCCAGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGCAAAAGACA
20 AATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTCTGTGGA
GGATCATGGGTTCGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCG
TTATTGGAACAGCTGTTAAGGGAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAGAATGACAC
ATGGAGGCTGAAGAGGGCCATCTGATCGAGATGAAACATGTGAATGGCCAAAGTCCACACATTTGTGGACAGATGGA
ATAGAAGAGAGTGATCTGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACAGAGAGGGCTACAGGAC
25 CCAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCCAGGCACTAAGGTCCACGTGGAG
GAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGTGACAG
GAGTGCACATGCCCCACTGTCGTTCCGGGCTAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAAC
CAGAAAGCACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCAGATGGATCACTTCTCCCTTGGAGTGCTGTG
ATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCAGTGCTGG
30 TAGCTATGATCCTGGGAGGATTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGAAATG
AACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTC
AGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCTTGGCTCGTGTGTTTTCGAACTGCGATCTCCGCTTGGAA
GGCGACCTGATGGTTCTCATCAATGGTTTTGCTTGGCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGACAA
ATCACCTTGGCAATCCTGGCTGCTGACCACTGGCCCGGGGACACTGCTGTGGCGTGGAGAGCAGGCCTTGCTAC
35 TTGCGGGGGTTTATGCTCTCTCTGAAGGGAAAGGCAAGTGTGAAGAAGAACTTACCATTGTGATGGCCCTGGGAC
TAACCGCTGTGAGGCTGGTGCACCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCC
CCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCT
GGGCCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAGAGTGTGGACATGTACATTGAAAGAG
CAGGTGACATCAGTGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTG
40 GTGACTTCTCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGC
ATGAACCAATAGCCATACCTTTGAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGTCTATG
GGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTA
GGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAAAAAGGATCCGCGC
TGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTACTATGTGGTCCATGGAA
45 GCTAGATGCCGCTGGGACGGGACAGCGAGGTGACGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCA
GACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGA
TCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTATAAAAAATGGGAGTTATGTTA
GTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGTGAAGAAGAAGCAGCT
AACTGTCTTAGACTTGATCTCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACA
50 GACTCCGTAAGTGTGATCTTAGCTCAACAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGT
TATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTACGT
CTACTACAGCAATCAGAGTCCCAACTATACTGTATATATGGATGAGGCCCACTTACAGATCCCTTCAAGCATAGCA
GCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACAGGAACCC
GTGACGCATTTCCGACTCCAACCTACCAATTATGGACACCGAAGTGGAAAGTCCAGAGAGAGCCTGGAGCTCAGGCTTT

GATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTTC AAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCT
GACAAAGGCTGAAAAACGGGTCTACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACATCAAGAG
TGGGACTTTGTCGTGACAACTGACATTTAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTATAGATTCCAGGAGATG
CCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCACACATGCCAGCGCTGCCAGA
5 GGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTACCTGTATGGAGGTGGGTGCGCAGAGACTGACG
AAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATC
GACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAAC
TCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAAGATGG
TGCTTTGATGGCAGCACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAA
10 AGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTGAGATCATGCGGCCCTGAAGTCAATCAAGGAGTTTGCCG
TGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGA
AGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCG
GAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCTTGATGAGGAACAA
GGGCATAGGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCA
15 GCCAGAATTGCATGTGTCCTCATTGTTGTGTTCTATTGCTGGTGGTGTCTACCTGAGCCAGAAAAGCAAAGATCTCCC
CAGGACAACCAATGGCAATCATCATGAGTGTAGTGTCTTCTGGGCTTGATTACCGCCAATGAACCTCGGATGGTT
GGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACAT
TGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGCTCCAACATGCAGTGAC
CACTTCATACAACTACTCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAGGGATGCCAT
20 TCTACGCTGAGGACTTTGGAGTCCCGCTGTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATAGTGGCCA
TCATTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTGCCAGAGAGAACG
GCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCAAGT
GGAGAAAAGATGGGACAGGTGCTACTATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCCGCTGGGGGTGG
GGGAGGCTGGGGCCCTGATCAGCGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTTAC
25 AGCCACTTCACTGTGTAACATTTTAGGGGAAGTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGCTGG
CTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCGCTTGAACAGATGTGGC
CCTGGAGTTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCTCAAGGACGGT
GTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCC
TATGGAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAG
30 TGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCT
TAAGAGTGGGGTGGACGTCTTTATATGGCGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTA
GTCTGAAAGTGAAGAAGCAGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAGACCAGGAGCCTT
TTGCATAAAAGTGTGTGCCATACACCAGCACTATGATGGAAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGA
CTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAAAAG
35 TGTGTCCACCACGAGCCAGCTCCTTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAAATATGAGGAGGATGTGAAT
CTCGGCTCTGGCAGCGGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGAT
CCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAAAACACCATATAGGACATGGGCTTACCATGGAAGCTATGTG
GCCCCACACAAGGGTCAGCGTCTCTAATAAACGGGGTGTGAGGCTCCTGTCAAACCTGGGATGTGGTGACTGG
AGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTG
40 CCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCAACACAAACG
ACCACGAGTCTGTACAAAGAAGAGTTCATCAACAAGGTTCTGATGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAA
AAAGAGTGGAAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGACACCAC
CTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCC
AAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTGGAAGCCCTTGGATTCTTGAACGAGGA
45 TCACTGGATGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGA
GATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGTCTG
GAGAATGAAGCTCTAATCACCACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACC
AAAACAAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTGAGACAAAGACCAAAG
GGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTATTCGGAATATGGAGGCTG
50 AGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGAT
GGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCTGTGAGGCAATTGATGATGGTTGCACATGCCCTC
AGGTTCTTGAATGATATGGGAAAAAGTTAGGAAGGACACACAAGAGTGGAAGCCCTCACTGGATGGGACAACCTGGGAA
GAAGTTCGTTTTGCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTCCCTGCCGCCACCAA
GATGAAGTATTGGCCGGGCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCAT

ATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTTCATCTGTGCCAG
TTGACTGGGTTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGACATGCTTGT
GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCC
TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTA
5 AAAATACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTTCGTAC
TTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGTGAGCACCAATCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTT
GGGGAAGCTGTGCAGCTGTGACCCCTCCAGGAGAAGCTGGGTAACCAAGCCTATAGTCAGGCCGAGAAGCCATGGC
ACGGAAGAAGCCATGCTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATG
GGAAAAGAAGGTGGCGACCTTCCCACCTTCAATCTGGGGCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGG
10 ACTAGTGTTAGAGGAGACCCCCGAAAAACGAAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCATGAGTTT
CCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCGGTGTGGGAAATCCA

SEQ ID NO: 4

KU501215.1 Zika virus strain PRVABC59, Puerto Rico, complete genome
15 GTTGTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTTG
GATTTGGAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAC
GCGGAGTAGCCCGTGTGAGCCCTTTGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCATCAG
GATGGTCTTGGCGATTCTAGCCTTTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCACT
GGGAAAAAAGAGGCTATGGAACAATAAAGAAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGG
20 AAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAG
GTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCACATT
GGGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGC
TGGATGAGGGGGTGGAAACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGACGGAACTGCCA
TCACAAAAAAGGTGAAGCACGAGATCTAGAAGAGCTGTGACGCTCCCTCCCTTCCACAGGAAGCTGCAACGCGG
25 TCGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTT
CGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
GATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTGTGGAAGGTATGTGAGGTGGGACTTGG
GTTGATGTTGTCTTGGAAATGGAAGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTAC
AACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCTGACAGCCGCT
30 GCCCAACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGC
TGGGGAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCG
GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCACTTCCAGCAGAGTGGGATGATCGT
TAATGACACAGGACATGAACTGATGAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCGAGAGCCGAAGCCACC
CTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAATTTGATTACTTGACTATG
35 AATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
TCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGCTGTTGTTCTAGGG
AGTCAAGAAGGAGCAGTTCACACGGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGCTCT
CTGGCCACTTGAAATGTCGCCTGAAATGGATAAACTTAGATTGAAGGGCGTGTACATACTCTTGTGTACTGCAGCGTTCA
CATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTG
40 CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
CTGAAAGCACTGAGAATCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGACTTTACATTGTATAGGAGTCCGG
GAGAAGAAGATCAACCACTGAGGAGTGGCAGCAGCATTGGAAAAGCATTTGAAGCACTGTGAGAGGTGCCA
AGAGAATGGCAGTCTTGGGAGACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCAT
CCATCAAAATTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCAAAATCTCATTGGAACGTTGCTG
45 ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTGATCTTCTATCC
ACAGCCGTCTCTGCTGATGTGGGGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCT
ATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
AGCCTGGGAAGATGGTATCTGCGGGATCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAG
CTCAACGCAATCTGGAAGAGAATGGAGTTCAACTGACGGTCTGTTGGGATCTGTAAAAAACCCATGTGGAGAGGTC
50 CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCACGCTGGAAGGCTTGGGGGAAATCGTATTTCTGTCAGAGCAGC
AAAGACAAATAACAGCTTTGTCTGGTGGTGACACACTGAAGGAATGCCACTCAACATAGAGCATGGAACAGCTTTC
TTGTGGAGGATGTTGGGTTTGGGGTATTTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAGA
ATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGAC

AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCT
ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCA
CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
CTGCAGGGAGTGCACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGG
5 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCAGATGGACCACTCTCCCTTGAGT
GCTTGTGATCCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCA
GTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTATGAGGTGCCACCTTCGC
GGAATGAACACTGGAGGAGATGTAGCTCATCTGGCGTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
TCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACCTCGATCTCCG
10 CCTTGGAGGGCGACCTGATGGTTCTCATCAATGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
CTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAGGC
CTTGCTACTTGCAGGGGGTTTATGCTCCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTTGTCATGGC
CCTGGGACTAACCGCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGG
AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATGGCTGGAGGGTTGCGCAAGGCAGATATAGA
15 GATGGCTGGGCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAGAGTGTGGACATGTACATTG
AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
TGTGGCATGAACCAATAGCCATACCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTG
CTCTATGGGATGTGCTGCTCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAACTGCTCGTAG
20 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTACAAAAAGGA
TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGGTC
CATGGAAGCTAGATGCCGCTGGGATGGGCACAGCGAGGTGCAGCTCTTGCCGTGCCCGGGAGAGAGAGCGAGGA
ACATCCAGACTCTGCCCGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
TTCAGGATCTCCAATCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTATCAAAAACGGGAGT
25 TATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTCGAGCCCTCGATGCTGAAGAAGA
AGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTCTTCTGAAATAGTCCGTGAAGCCATA
AAAAAAGACTCCGTAAGTGTGATCTTAGCTCAACCAAGGGTTGTCGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCC
AGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTAC
TTCACGTCTACTACAGCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
30 ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTATGACCGCCACGCCACCAG
GAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCCAGAGAGAGCCTGGAGCTCA
GGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTCCAGCGTGAGGAACGGCAATGAGATCGCAGC
TTGTCTGACAAAAGGCTGGAACCGGGTCATACAGCTCAGCAGAAAGACTTTTGGAGACAGAGTCCAGAAAAACAAACATC
AAGAGTGGGACTTTGTCGTGACAACCTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTCTAGATTCCAGG
35 AGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCACTTGGCTGGACCCATGCCTGTACACATGCCAGCGCTGC
CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCT
CTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTG
GAACTCATGAAAAGAGGAGATCTTCTGTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAG
40 ATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGCGCAGAGGTGTGGACCAGACACGGAGA
GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
GCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTTC
CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCAAT
TGCCGGAGACCCTAGAGACCATAATGCTTTTGGGGTGTGGGAACAGTCTCGTGGAATCTTCTGCTTGTATGAGG
45 AACAAGGGCATAGGGAAGATGGGCTTGGAAATGGTGACTCTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
AGCCAGCCAGAATTGCATGTCTCCTCATTGTTGTGTTCTATTGCTGGTGGTGCTACCTGAGCCAGAAAAGCAAAGAT
CTCCCCAGGACAACCAATGGCAATCATCATGCTAGCAGTAGGTTCTTGGGCTTGATTACCGCCAATGAACCTCGGAT
GGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTAATGG
ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCACATGCAGT
50 GACCACCTACATAACAATACTCCTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGCATGGGCAAGGGATGC
CATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCTTAATAGTGG
CCATCATTTTGTCTGTGGCGACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCGAGAGAGA
ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
AGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGG

TGGGGGGAGGCTGGGGCTCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTC
TACAGCCACTTCACTGTGTAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGC
TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCAGATGTC
GGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCTCAAGGAC
5 GGTGTGGCAACGGGAGGCCATGCTGTGCCGAGGAAGTGCAAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAG
CCCTATGGAAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGTCGCCACCATCCGCAAAGTTCAAGA
AGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGT
CTTAAGAGTGGGGTGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATC
TAGTCCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGA AAAAAGACCAGGAGCC
10 TTTTGTATAAAAGTGTGTGCCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
GACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAA
AGTGTGTCCACCACGAGCCAGCTCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAATATGAGGAGGATGTGA
ATCTCGGCTCTGGCAGCGGGCTGTGGTAAGTGCCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGG
ATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGA
15 GGCCCCACACAAGGTCAGCGTCTCTCTAATAAACGGGTTGTGAGGCTCCTGTCAAAACCTGGGATGTGGTGACTG
GAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGT
GCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCAACACAAAC
GGCCACGAGTCTGCACAAAGAAGAGTTCATCAACAAGTTCGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGA
AAAAGAGTGAAGACTGCAGTGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGACCA
20 CCTGAGAGGAGAGTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGC
CAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTGCAAGCCCTTGGATTCTTGAACGAGG
ATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAAGGCTGGGATTACAAAGACTCGGATATGTCTAGAAG
AGATGATCGTATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCAATTAGCAGGTTTGATCT
GGAGAATGAAGCTCTAATCACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC
25 CAAAACAAAGTGGTAAAGTCTTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTTGAGACAAGACCAAA
GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCT
GAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGTGCGGAGGTGAGAGAAAGTGACCAACTGGTGCAGAGCAACGGA
TGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCACATGCCCT
CAGGTTCTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTCAACTGGATGGGACAACCTGGGAA
30 GAAGTTCGGTTTTGCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCA
GATGAACCTGATTGGCCGGGCGCGTCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCAT
ATGCGCAAAATGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTCATCTGTGCCAG
TTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGT
GGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCC
35 TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTA
AAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTGCTGCTAC
TTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTGAAGCACAATCTTAATGTTGTGAGGCTGCTAGTCAGCCACAGCTT
GGGGAAGCTGTGCAGCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
CACGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
40 GGGAAAAGAAGTGGCGACCTTCCCCACCCTTCAATCTGGGGCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGG
GACTAGTGGTTAGAGGA

SEQ ID NO: 5

KU509998.1 Zika virus strain Haiti/1225/2014, Haiti, complete genome

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTGG
45 ATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
CGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTGATGGGCCATCAGG
ATGGTCTTGGCAATTCTAGCCTTTTGTGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTG
GGGAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
50 AGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTTGTTGGCTCCTGCTGACCACAGCTATGGCAGCGGAGG
TCACTAGACGTGGGAGTGCATACTATGTACTTGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCAATTG
GGGATGAATAAGTGTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
GGATGAGGGGGTGAACACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCAT
CACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCATCTCACTAGGAAGCTGCAACACGCGT

CGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTC
GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
GATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
5 GTTGATGTTGTCTTGGAAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTAC
AACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
GCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGC
TGGGGAAATGGATGTGGACTTTTTGGCAAAGGGAGTCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCG
GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGACGTTTATGGCTCCAGCACAGTGGGATGATCGT
10 TAATGACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACC
CTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATG
AATAACAAGCACTGGTTGGTTCACAAGGAGTGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAAC
TCCACACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGG
AGTCAAGAAGGAGCAGTTACACGGCCCTTGTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAAGGGAAGGCTGTCCT
CTGGCCACTTGAAATGTGCCTGAAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCGCAGCGTTCA
15 CATTACCAAGATCCCGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACCTTG
CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTTTACATTGTATAGGAGTCGGG
GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGAAAAGCATTGAAAGCCACTGTGAGAGGTGCCA
AGAGAATGGCAGTCTTGGGAGACACAGCTGGGACTTTGGATCAGTTGGAGGGCGTCTCAACTCATTGGCAAGGGCAT
20 CCATCAAAATTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAATGTCCTGGTCTCACAAATCTCATTGGAACGTTGCTG
ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCC
ACAGCCGTCTCTGCTGATGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
ATAACGACGTTGAAGCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCATCAAGCA
AGCCTGGGAAGATGGTATCTGCGGGATCTCCTGTTTCAAGAATGGAACATCATGTGGAGATCAGTAGAAGGGGAG
25 CTCAACGCAATCTGGAAGAGAATGGAGTTCAACTGACGGTCTGTTGGGATCTGTAAAAAACCCCATGTGGAGAGGTC
CACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGCACTTCTGTCAGAGCAGC
AAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTTTC
TTGTGGAGGATCATGGGTTGCGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGAT
CCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAGA
30 ATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGAC
AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACAGAGAGGGCT
ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCA
CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTG
CTGCAGGGAGTGACAATGCCCCACTGTCTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGG
35 AAAGAACCAGAAAGCAACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGT
GCTTGTGATTCTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATGGCA
GTGCTGGTAGCTATGATCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGTATGGGTGCCACCTTCGC
GGAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
TCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGCTTTTGCAAACTGCGATCTCCG
40 CTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
CTGATAACATCACCTTGGCAATCCTGGCTGCTGACACCACTGGCCGGGGCAGCTGCTTGTGGCGTGAGAGCAGGC
CTTGCTACTTGCAGGGGGTTTATGCTCCTCTCTGTAAGGGAAAAAGGCAAGTGTGAAGAAGAACTTACCAATTTGTCATGGC
CCTGGGACTAACCGCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGGCTGCTGTTGCTCACAAGGAGTGGAAGCGG
AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATGCGCATTGGCTGGAGGGTTGCCAAGGCAGATATAGA
45 GATGGCTGGGCCATGGCCGCGTCTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATG
AGAGTGGTGAATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAAGTGGTCTGATGACCATC
TGTGGCATGAACCAATAGCCATACCTTTGACGTGGAGCGTGGTACGTATACGTGAAGACTGGAAGGAGGAGTGGTG
CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAG
50 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGA
TCCGCTGAGAGCGGTGAAGGGAGAGCTTGATCCATAGTGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGCTG
CATGGAAGCTAGATGCCGCTGGGACGGCACAGCGAGGTGACGCTCTTGGCCGTGCCCGGAGAGAGAGCGGAGGA
ACATCCAGACTCTGCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAAC
TTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAATGGGAGT

TATGTTAGTGCCATCACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
AGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACAGGAGAGTTCCTCCTGAAATAGTCCGTGAAGCCATA
AAAAAAGACTCCGTA CTGTGATCTTAGCTCCAACCAAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCC
AGTGCGTTATATGACAACAGCAGTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCAC
5 TTACGCTCTACTACAGCCAATCAGAGTCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
ATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAG
GAACCCGTGACGCATTTCCGGA CTCAACTCACAATTATGGACACCGAAGTGAAGTCCCAGAGAGAGCCTGGAGCTCA
GGCTTTGATTGGGTGACGGATTATTCTGAAAAACAGTTTGGTTTGTCCAAGCGTGAGGAACGGCAATGAGATCGCAGC
TTGTCTGACAAAGCTGGAAACGGGT CATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAACATC
10 AAGAGTGGGACTTTGTCGTGACAACTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGT CATAGATTCCAGG
AGATGCCTAAAGCCGGTCATCTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGT CACACATGCCAGCGCTGC
CCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGAC
TGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTACCTCCAAGATGGCCTCATAGCCTCGCT
CTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGACAAAGGAAGACCTTTGTG
15 GAACTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAG
ATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGCGAGAGGTGTGGACCAGACACGGAGA
GAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTT
GCCGCTGGGAAAAGAGGAGCGGCTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTC
CAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCCCAAT
20 TGCCGGAGACCCTAGAGACCATTATGCTTTTGGGGTGTGCTGGGAACAGTCTCGCTGGGAATCTTTTTCGTCTTGATGAGG
AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
AGCCAGCCAGAATTGCATGTGTCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGAT
CTCCCCAGGACAAACCAATGGCAATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCATGAATCTCGGAT
GGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGAGGGGGCAACCATGGGATTCTCAATGG
25 ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACTTTCATTACCCAGCCGCTCAACATGCAGT
GACCACTTCATAACAACACTACTCCTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAGGGATGC
CATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCTGACCCTAATAGTGG
CCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAAGAGA
ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCA
30 AGTGGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGGACCGCCTGGGGG
TGGGGGGAGGGCTGGGGCCCTGATCACAGCCGCAACTTCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAATCCTC
TACAGCCACTTCACTGTGTAAACATTTTAGGGGAAGTACTTGGCTGGAGCTTCTAATCTACACAGTAAACAAGAAACGC
TGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCGCTTGAACCATGATGTC
GGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCGCCCTCAAGGAC
35 GGTGTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGAAAGCTGAGATGTTGGTGGAGCGGGGATACCTGCAG
CCCTATGGAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAGTTCAAGA
AGTGAAAGGATACACAAAGGAGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGT
CTTAAGAGTGGGGTGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATATC
TAGTCTGAAGTGAAGAAGCACGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTGAAAAAAGACCAGGAGCC
40 TTTTGTATAAAAGTGTGTGCCCATACACCAGCACTATGATGGAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAG
GACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGACTGGGTCTCTGGAGCGAAAAGCAACACCATAAAA
AGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAATATGAGGAGGATGTGA
ATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGG
ATCCGCAGTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCATATAGGACATGGGCTTACCATGGAAGCTATGA
45 GGCCCCCACAAAGGTCAGCGTCTCTCTAATAAACGGGGTTGTCAGGCTCCTGTCAAAACCTGGGATGTGGTGACTG
GAGTCACAGGAATAGCCATGACCGACACCACCCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGT
GCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAGCTAGGCAAAACAAAC
GGCCACGAGTCTGTACAAAGAAGAGTTTCATCAACAAGTTCTGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGA
AAAAGAGTGAAGACTGCAGTGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGAGAGCACCA
50 CCTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGAAAGGC
CAAGGGCAGCCGCGCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCAAGCCCTTGGATTCTTGAACGAGG
ATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAG
AGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCT
GGAGAATGAAGCTCTAATCACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATAC

5 CAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTGAGACAAGACCAAA
GGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCT
GAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGA
TGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTTGCACATGCCCT
10 CAGGTTCTTGAATGATATGGGAAAAGTTAGGAAAGGACACACAAGAGTGGAACCCTCACTGGATGGGACAACTGGGAA
GAAGTTCCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAA
GATGAACTGATTGGCCGGGCCGCTCTCCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCAAAATCAT
ATGCGCAAATGTGGCAGCTCCTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTCATCTGTGCCAG
15 TTGACTGGGTTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGT
GGTGTGGAACAGAGTGTGATTGAGGAGAACGACCACATGGAAGACAAGACCCCACTTACGAAATGGACAGACATTCCC
TATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGACACAGACCGCGCACCACTGGGCTGAGAACATTA
AAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTGCTGCTAC
TTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTAAGCACCAATCTTAATGTTGTCAGGCTGCTAGTCAGCCACAGCTT
20 GGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGG
CACGGAAGAAGCCATGCTGCCTGTGAGCCCCCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGAT
15 GGGGAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGCGCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGG
GACTAGTGGTTAGAGGAGA

SEQ ID NO: 6

20 KU527068.1 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, complete genome
AGTTGTTGATCTGTGTAATCAGACTGCGACAGTTGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTT
GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAA
CGCGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTGGGTGATGGGCCCTCAG
25 GGATGGTCTTGGCAATTCTAGCCTTTTGTGATTACGCGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTGAG
TGGGGAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAG
GAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTTGTTGGCCTCTGCTGACCACAGCTATGGCAGCGGA
GGTCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTCCAACCAT
30 TGGGGATGAATAAGTGTATATACAGATCATGGATCTTGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATG
CTGGATGAGGGGGTGAACAGATGACGTCGATTGTTGGTGTCAACACGACGTCACCTGGGTTGTGTACGGAACCTGCC
ATCACAAAAAGGTGAAGCAGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCTCCCTAGGAAGCTGCAACCGCG
35 GTCGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCT
TCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGC
TGATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTACAGGTGGGACTTG
GGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTA
40 CAACAACAGTCAGCAACATGGCGGAGGTAAGATCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGC
TGCCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAAGCTTAGTGACAGAGG
CTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCAAGAAAATGACC
GGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTTATGGCTCCACAGCAGTGGGATGATCG
TTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCAATTACCAAGAGCCGAAGCCAC
45 CCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTAT
GAATAACAAGCACTGGTTGGTCCACAAGGAGTGGTCCACGACATTCATTACCTTGGCAGCTGGGGCAGACACCGGAA
CTCCACACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCTGGTTCTAGG
GAGTCAAGAAGGAGCAGTTACACGCGCCCTTGTGAGGCTCTGGAGGCTGAGATGGATGGTGCAAGGGAAGGCTGTC
CTCTGGCCACTTGAAATGTCGCTGAAATGGATAAACTTAGATTGAAGGGCGTGTACTACTCTTGTGTACCGCAGCGTT
50 CACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGACGGGACAGATGGACCT
TGCAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGTAACCCCGTAAT
CACTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTGATCCACCATTTGGGGACTTTACATTGTATAGGAGTCG
GGGAGAAGAAGATCACCCCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTGGAAGCCACTGTGAGAGGTG
CCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGG
CATCCATCAAAATTTTGGAGCAGCTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCACAATCTCATTGGAACGTTG
CTAGTGTGGTTGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCTTAGGGGAGGTGATTGATCTTCTTA
TCCACAGCCGTCTCTGCTGATGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTG
TCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAG
CAAGCCTGGGAAGATGGTATCTGCGGGATCTCTCTGTTTCAAGAATGGAGAACATCATGTGGAGATCAGTAGAAGGGG

AGCTCAACGCAATCTTGGAAGAGAATGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGG
TCCACAGAGATTGCCCGTGCCTGTGAACGAGCTGCCCCAGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCA
GCAAAGACAAATAACAGCTTTGTCTGGATGGTGACACACTGAAGGAATGCCCACTCGAACATAGAGCATGGAACAGCT
TTCTTGTGGAGGATCATGGGTTTCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGT
5 GATCCAGCCGTTATTGGAACAGCTGTTAAGGGGAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGA
AGAATGACACATGGAGGCTGAAGAGGGCCCATCTAATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTG
GGCAGATGGAATAGAAGAGAGTGATCTGATCATTCCCAAGTCTTGTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGG
GCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCCGGGCACTAAGGT
CCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATG
10 GTGCTGCAAGGGAGTGACAATGCCCCCACTGTCGTTCCGGGGTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCC
AGGAAAGAACCAGAAAGCAACTTAGTAAGGTCAGTGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGG
AGTGCTTGTGATTCTGCTCATGGTGACGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCAATG
GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGAATTTTGTGGGCGCCACCTT
GCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAAGCGTTGCTGGTA
15 TCTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTTGAAACTGCGATCT
CCGCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCAC
GCACTGATAACATCACCTTGGCAATCCTGGCTGCTGTACACCACTGGCCGGGGCACACTGCTTGTGGCGTGGAGAGCA
GGCCTTGTACTTGTGGGGGGTTTATGCTCCTCTCTGAAGGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGCAT
GGCCTTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAG
20 CGGAGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATAT
AGAGATGGCTGGGCCCATGGCCGCGGTGGTCTGCTAATTGTCAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTAC
ATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAG
ATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGTATGACC
ATCTGTGGCATGAACCAATAGCCATACCTTTGACAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTG
25 GTGCTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCG
TAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAAAAA
GGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGTATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTG
GTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGCCGTGCCCCCGGAGAGAGAGCGA
GGAACATCCAGACTCTGCCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGG
30 AACTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTATCAAAAAATGGG
AGTTATGTTAGTCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGA
AGAAGCAGTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCC
ATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCAACCAAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCT
TCCAGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTT
35 CACTTCACGTCTACTACAGCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCCACTTCACAGATCCCTCA
AGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCAC
CAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAG
CTCAGGCTTTGATTGGGTGACGGATCATTCTGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCG
CAGCTTGTCTGACAAAGGCTGGAAAACGGGTCTACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAA
40 ACATCAAGAGTGGGACTTTGTCTGACAACCTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTATAGATT
CCAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTTTGGCTGGACCCATGCCTGTACACATGCCAGC
GCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCA
GAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTATAGC
CTCGCTCTATCGACTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAGGAAGACC
45 TTTGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTGGCTGGCCTATCAGTTGATCTGCCGGAATAACCTACACAGAT
AGAAGATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGCGAGAGGTGTGGACCAGACAC
GGAGAGAAAAGAGTGCTCAAAACGAGGTGGATGGACGCGAGATTTGTTGAGATCATGCGGCCCTGAAGTCATTCAAGG
AGTTTGGCGTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGA
GATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGC
50 CCAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTCTGCTTGT
GAGGAACAAGGGCATAGGGAAGATGGGCTTGGAAATGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCGGA
AATTGAGCCAGCCAGAATTGCATGTCTCATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCA
AAGATCTCCCCAGGACAACCAATGGCAATCATCATGTTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACT
CGGATGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGAGCAACCATAGGATTCTC

AATGGACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCCAACA
TGCAGTGACCACTTCATACAACAACACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTGGTATGGGCAAAAG
GGATGCCATTCTACGCATGGGACTTTGGAGTCCCCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAA
TAGTGGCCATCATTTTCTCGTGCGCACTACATGTAATGATCCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAG
5 AAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAAGTACATTGACACAATGACAATTG
ACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCAGTCTCCAGCGCCATACTGTCGCGGACCGC
CTGGGGGTGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGG
AACTCCTCTACAGCCACTTCACTGTGAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACATAGTAACAA
GAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAAC
10 CAGATGTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCC
TCAAGGATGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGAT
ACCTGCAGCCCTATGGAAAGGTCACTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAA
GTTCAAGAAGTGAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGTGGAAC
ATAGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGA
15 GTCATCATCTAGTCTGAAGTGGAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGA AAAAAGA
CCAGGAGCCTTTTGTATAAAAGTGTGTGCCATACACCAGCACTATGATGGAAACCCTGGAGCGACTGCAGCGTAGGTA
TGGGGGAGGACTGGTCAGAGTGCCACTCTCCGCAACTTACACATGAGATGTAAGTGGTCTCTGGAGCGAAAAGCAAC
ACCATAAAAAGTGTGTCACCACGAGCCAGCTCCTTGGGGCGCATGGACGGGCTAGGAGGCCAGTGAATATGAGG
AGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGC
20 ATTGAAGGATCCGAGTGAGCACGCGGAAACGTGGTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATG
GAAGCTATGAGGCCCCACACAAGGTGAGCGTCTCTTAATAAACGGGGTGTGACGGCTCTGTCAAACCCCTGGGAT
GTGGTGAAGTGGAGTACAGGAATAGCCATGACCGACACCACCCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGG
ACACTAGGGTGCCAGACCCCAAGAGCACTCGTCAAGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGC
AAACACAACGGCCACGAGTCTGTACCAAGAAGAGTTCATCAACAAGTTCTGATGCAATGAGCATTAGGGGCAATATT
25 TGAAGAGGAAAAAGAGTGGAAAGTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTAGTGGACAAGGAAAG
AGAGCACCACTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATT
TGGAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGGATTCT
TGAACGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAGACTCGGATATG
TCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAG
30 GTTCGATCTGGAGAATGAAGCTCTAATCACCAACCAATGGAGAAAGGGCATAGGGCCTTGGCATTGGCCATAATCAAGT
ACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCACTGAAAAAGGGAAAAACAGTTATGGACATTATTCGAGACAA
GACCAAGGGGGAGCGGACAAGTTGCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGAACCTATTCGGAATAT
GGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGTGCGGAGGTGAGAGAAAGTGAACCACTGGTTGCAGAG
CAACGGATGGGATAGGCTCAAACGAATGGCAGTCACTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCA
35 CATGCCCTCAGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTCACTGGATGGGACA
ACTGGGAAGAAGTTCGTTTGTCTCCACCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGTTCCCTGCC
GCCACCAAGATGAACTGATTGGCCGGGCCGCTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGC
AAAATCATATGCCAAATGTGGCAGCTCCTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTATC
TGTGCCAGTTGACTGGGTCCAACCTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGAC
40 ATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACA
GACATTCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCATAGGGCACAGACCGCGACCACTGGGCTGA
GAACATTA AAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAAG
TTGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTAAGCACCAATCTAATGTTGTAGGCCTGCTAGTCAGC
CACAGCTTGGGAAAGCTGTGCAGCCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAAC
45 GCCATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCATGCGCTTGGAGGC
GCAGGATGGGAAAAGAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCA
GAAGAGGGACTAGTGGTTAGAGGAGACCCCGGAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTC
CATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCTT

50 SEQ ID NO: 7
KU681081.3 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, complete genome
AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTT
GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAA
CGCGGAGTAGCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTGGGTGATGGGCCATCA

GGATGGTCTTGGCGATTCTAGCCTTTTGGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
TGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAG
GAAGGAGAAGAAGAGACGAGGCACAGATACTAGTGTGCGAATTGTTGGCTCCTGCTGACCACAGCTATGGCAGCGGA
GGTCACTAGACGTGGGAGTGCATACTATATGTACTTGGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCCAACACAC
5 TGGGGATGAATAAGTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATG
CTGGATGAGGGGGTAGAACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCC
ATCACAAAAAAGGTGAAGCACGGAGATCCAGAAGAGCTGTGACGCTCCCTCCCTTCCACTAGGAAGCTGCAACGCG
GTCGACAGCTGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCT
TCGCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGC
10 TGATTGCCCGGCATACAGCATCAGGTGCATAGGAGTCAGTAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTG
GGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCCGTAATGGCACAGGACAAACCGACTGTGACATAGAGCTGGTTA
CAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCG
CTGCCCCAACAAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGAACGTTAGTGACAGAG
GCTGGGGAAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGAC
15 CGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCAGCACAGTGGGATGATC
GTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCA
CCCTGGGGGGTTTGGAAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTGTATTACTTGACTA
TGAACAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCACGACATTCCATTACCTTGGCACACTGGGGCAGACACCGGA
ACTCCACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCTGTGGTTCTAG
20 GGAGTCAAGAAGGAGCAGTTACACCGCCCTTGTCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGT
CCTCTGGCCACTTGAAATGTGCGCTGAAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTTGTGTACCGCAGCGT
TCACATTACCAAGATCCCGGCTGAAACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGACC
TTGCAAGGTTCCAGTCCAGTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCTGAA
TCACTGAAGGCACTGAGAACTCTAAGATGATGCTGGAACCTGATCCACCATTGGGGACTTTACATTGTCTAGGAGTGC
25 GGGAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAGCACTTGAAGCCACTGTGAGAGGTG
CCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGTTCTTAATCATTGGGCAAGGG
CATCCATCAAATTTTGGAGCAGCTTCAAATCATTGTTTGGAGGAATGCTCTGGTTCTCACAATTTCTATTGGAACGTTG
CTGATGTGGTTGGGTCTGAATACAAAGAATGGATCTATTTCCCTATGTGCTTGGCCTTAGGGGGAGTGTGTATCTCTTA
TCCACAGCCGTCTCCGCTGATGTGGGGTGCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTCTG
30 TCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCTCGTAGATTGGCAGCAGTAGTCAAG
CAAGCCTGGGAAGATGGTATCTGTGGGATCTCCTCTGTTTCAAGAATGGAAGAACATCATGTGGAGATCAGTAGAAGGGG
AGCTCAACGCAATCCTGGAAGAGAATGGAGTTCACTGACGGCTGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGG
TCCACAGAGATTGCCGTGCTGTGAACGAGCTGCCACCGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTACAGAGCA
GCAAAGACAATAACAGCTTGTCTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGCTT
35 TCTTGTGGAGGATCATGGGTTGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATCTACTAGAGTGTG
ATCCAGCCGTCATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAA
GAACGACACATGGAGGCTGAGGAGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGG
ACAGATGGAATAGAAGAGAGTGATCTGATCATACCCAAGTCTTAGCTGGGCCACTCAGCCATCACAACACCAAGAGAGG
GCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAGGAATGCCAGGCACTAAGGT
40 CCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATG
GTGCTGCAGGGAGTGCAATGCCCCACTGCTGTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGGCC
AGGAAAGAACCAAGAAAGTAACCTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCAGATGATCACTTTCCCTTG
AGTGCTTGTGATTCTGCTCATGGTGAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATG
GCAGTGCTGGTAGCTATGATCCTGGGAGGATTTTCAATGAGTGATCTGGCTAAGCTTGCAATTTTGTGGGTGCCACCTTT
45 GCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGTGGTAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTAT
CTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTC
CGCCTTGAAGGCGACCTGATGGTTCTCATCAATGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACG
CACTGACAATATCACCTTGGCAATCCTGGCTGCTGTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGGAGAGCAG
GCCTTGCTACTTGGCGGGGGTTTATGCTCCTCTCTGAAGGGGAAAGGCAAGTGTGAAGAAGAACTTACCATTGTATG
50 GCCCTGGGACTAACCGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGC
GGAGCTGGCCCCCTAGCGAAGTACTACAGCTGTTGGCTGATATGCGCATTGGCTGGAGGGTTGCCAAGCAGATAT
AGAGATGGCTGGGCCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAGAAGAGTGTGGACATGTAC
ATTGAAAGAGCAGGTGACATCAGATGGGAAAAAGATGCGGAAGTTACTGGAACAGTCCCGGCTCGATGTGGCACTAG
ATGAGAGTGGTGATTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAAGTGGTCTGATGACC

ATCTGTGGCATGAACCCAATAGCCATACCCCTTTCAGCTGGAGCGTGGTACGTATACGTGAAAACCTGGAAAAAGGAGTG
GTGCTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCG
TAGACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCATGTCACAAAAG
5 GATCCGCGCTGAGAAGCGGTGAAGGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCTACTGTGG
TCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTGGCCGTGCCCCCGGAGAGAGAGCGAG
GAACATCCAGACTCTGCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGACTATCCAGCAGGA
ACTTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGCAATGGGGTCGTGATCAAGAATGGGA
GTTATGTCAGTGCCATCACCCAAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAA
10 GAAAGCAGCTAACTGTCTTAGACTTGCATCCTGGAGCTGGGAAAACCAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCA
TAAAAACGAGACTCCGACTGTGATCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTT
CCAGTGCGTTATATGACAACAGCAGTCAATGTCACCCATTCTGGGACAGAAATCGTTGACTTAATGTGCCATGCCACCTTC
ACTTCACGCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAA
GTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCAGCTGCCATCTTCATGACCGCCACGCCACC
15 AGGAACCCGTGACGCATTCCCGGACTCCAACCTACCAATTATGGACCCGAAGTGGAAGTCCAGAGAGAGCCTGGAGC
TCAGGCTTTGATTGGGTGACGGATCATTCTGGAACAAAGGATTTGGTTGTCCCAAGCGTGAGGAACGGCAATGAGATCGC
AGCTTGTCTGACAAAGGCTGGAAAACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAACAAAA
CATCAAGAGTGGGACTTCGTCGTGACAACTGACATTTAGAGATGGGCGCCAACTTAAAGCTGACCGTGTATAGATTC
CAGGAGATGCCTAAAGCCGGTCATACTTGATGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTACACATGCCAGCG
20 CTGCCCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAG
AGACTGATGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCT
CGCTCTATCGACTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTT
TGTGGAAGTATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATA
GAAGATGGTGCTTTGATGGCATGACAAACAACACCAATATGGAAGACAGTGTGCCGGCAGAGGTGTGGACAGACACG
25 GAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGA
GTTTGGCCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACGGAGAG
ATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCC
CAATTGCCGAGACCCTAGAGACCATTATGCTTTTGGGGTGTCTGGGAACAGTCTCGCTGGGAATCTTTTCTGCTTGATG
CGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAA
30 TTGAGCCAGCCAGAAATGTCATGCGTCTCATTGTTGTGTTCTATTGTGTTGGTGGTCTCATACCTGAGCCAGAAAAGCAAA
GATCCCCCAGGACAACCAATGGCAATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCG
GATGGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAA
TGGACATTGACCTGCGGCCAGCCTCGGCTGGCCATCTATGCTGCCCTGACAACTTTCATTACCCAGCCGTCCAACATG
35 CAGTGACCATTCTACACAACAATACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAGGG
ATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTCACAATTAACACCCCTGACCCTAATA
GTGGCTATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGTCTGCCAGAA
GAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACTATTGAC
40 CCCCAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCT
GGGGGTGGGGGGAAGCTGGGGCCCTGATCACAGCTGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAA
CTCCTCTACAGCCACTTCACTGTGCAACATTTTAGGGGAAGTTACTTGGCTGGAGCTTCTCTAATCTACACAGTAACAAGA
AACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTTGAACCA
45 GATGTCGGCCCTGGAGTTTACTCTACAAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTC
AAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCGGAGGAAAGTGCAAAGCTGAGATGTTTGGTGGAGCGGGGATAC
CTGCAGCCCTATGAAAAGGTCATTGATCTTGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAGT
TCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCTATGTTGGTGCAAAGCTATGGGTGGAACATA
50 GTCCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTC
ATCATCTAGTCTGAAGTGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGGATTGGCTTGAAAAAAGACCA
GGAGCCTTTTGTGAAAAGTGTTGTGCCATACACCAGCACTATGATGGAAACCTGGAGCGACTGCAGCGTAGGTATGG
GGGAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACC
ATAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAAATATGAGGAG
GATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCAT
TGAAAGGATCCGAGTGAACGCGGAAACGTGTTCTTTGAGCAGAAACCACTATAGGACATGGGCTTACCATGGA
AGCTATGAGGCCCCATACAAAGGGTCAGCGTCTCTCTAATAAACGGGGTGTGACGGCTCTGTCAAAACCTGGGATGT
GGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAGGAAAAAGTGGAC
ACCAGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCA

AACACAAACGGCCACGAGTCTGTACCAAAGAAGAGTTCATCAACAAGGTTCTAGCAATGCAGCATTAGGGGCAATATTT
GAAGAGGAAAAAGAGTGGAAAGACCGCAGTGGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGACAAGGAAAGA
GAGCACCACCTGAGAGGAGAGTGCCAGAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTT
GGAAAGGCCAAGGGCAGCCGCCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTGAAGCCCTTGGATTCTT
5 AAATGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGT
CCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAG
GTTTGATCTGGAGAATGAAGCTTTAATACCAACCAATGGAGAAAGGGCAGAGGGCCTTAGCATTGGCCATAATCAAGT
ACACATACCAAAACAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAA
GACCAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGCAACTCATTCGGAATAT
10 GGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTCAGAGAAAAGTGACCAACTGGTTGCAGAG
CAACGGATGGGATAGGCTCAAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGCA
CATGCCCTCAGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTCAACTGGATGGGACA
ACTGGGAAGAAGTTCCGTTTTGTCCACCACCTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTCCCTGCC
GCCACCAAGATGAAGTATTGGCCGGGCCGTGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTTAGC
15 AAAGTCATATGCGCAAATGTGGCAGCTCCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATCTGTTATC
TGTGCCAGTTGACTGGGTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAGGGGAGAATGGATGACCACTGAAGAC
ATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCAAGTTACGAAATGGACA
GACATTCCTATCTGGGAAAAAGGGAAAGACTTGTGGTGTGGATCTCTATAGGGCACAGACCGCGCACCACCTGGGCTG
AGAACATTAACCAACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAA
20 GTTCGCTACTTGGGTGAAGAAGGGTCTACACTGGAGTGCTATAAGCACCAATCTTAGTGTTCAGGCCTGCTAGTCAG
CCACAGCTTGGGGAAGCTGTGCAGCTGTGACCCCCCAGGAGAGGCTGGGAAACCAAGCCCATAGTCAGGCCGAGAA
CGCCATGGCAGGGAAGAAGCCATGCTGCCTGTGAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGG
CGCAGGATGGGAAAAAGAGGTGGCGACCTTCCACCCCTTCAATCTGGGGCCTGAAGTGGAGATCAGCTGTGGATCTCC
AGAAGAGGGAAGTGTGTTAGAGGAGACCCCCGGAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACT
25 CCATGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAATAGCGGCGCGGTGTGGGGAATCCATGGGTCT

SEQ ID NO: 8

KU681082.3 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, complete genome
AGTTGTTGATCTGTGTGAATCAGACTGCGACAGTTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTT
30 GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCCAAAAAGAAATCCGGAGGATTCGGGATTGTCAATATGCTAAAA
CGCGGAGTAGCCCTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGGACTTCTGCTGGGCCATGGGCCATCA
GGATGGTCTTGGCGATACTAGCCTTTTTGAGATTACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCA
GTGGGGAAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTA
GGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGCGTCGGAATTGTTGGCTCCTCCTGACCACAGCCATGGCAGTAG
35 AGGTCACTAGACGTGGGAGTGCATACTATATGTAATTGGACAGAAGCGATGCTGGGGAGGCCATATCTTTTCAACCACA
CTGGGGATGAATAAGTGTACATACAAATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTAT
GTTGGATGAGGGGGTAGAACAGATGACGTGATTGCTGGTGCAACACGACATCAACTGGGTTGTGTATGGAACCTGC
CACCACAAAAAGGTGAAGCAGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCATTCCTAGGAAGCTGCAACCGC
GGTCGCAGACCTGGTTGGAATCAAGAGAATACACAAAGCACCTGATTAGAGTTGAAAATTGGATATTCAGGAACCTGG
40 CTTGCGTTAGCAGCAGCTGTATCGCTTGGCTTTTGGGAAGTTCAACGAGCCAAAAAGTCATATATCTGGTCATGATACT
GCTGATTGCCCCGGCATAACAGTATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACT
TGGGTTGATGTTGCTTGGAAACATGGAGGTTGTGTTACCGTAATGGCACAGGACAAACCGACTGTCCGACATAGAGCTGGT
TACAACAACAGTCAGCAACATGGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGATATGGCTTCGGACAGCC
GCTGCCAACACAAGGTGAGGCCTACCTTGACAAGCAGTCAGACACTCAATATGTCTGCAAAAGAAGCTTAGTGACAGA
45 GGCTGGGGAATGGATGTGACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGA
CCGGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTCATGGCTCCAGCAGAGTGGGATGAT
CGTTAATGACACAGGACATGAAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCC
ACCCTGGGGGGTTTTGGGAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACCTGACT
ATGAATAACAAGCACTGGTTGGTTCACAAGGAGTGGTTCCACGACATTCATTACCTTGGCATGCTGGGGCAGACACTGG
50 AACTCCACATTTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCAAAAAGGCAAACTGCTGTTCTA
GGGAGTCAAGAAAGGAGCAGTTACACGGCCCTTCTGGAGCTCTGGAGGCTGAGATGGATGGAGGCAAGGGAAGGCTG
TCCTCTGGCCACTTGAATGTCGCTGAAAATGGATAAACTAGATTGAAGGGCGTGTACATCTCTTGTGCACTGCAGCG
TTCACATTCACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAGGTACAGTACGCAGGGACAGATGGAC
CTTGCAAGGTTCCAGCTCAGATGGCGGTGGATATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCTGTA

ATCACTGAAAGCACCGAGAAGCTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTC
GGGGAGAAGAAGATCACCCATCACTGGCACAGGAGTGGCAGCACCATTTGAAAAGCATTGGAAGCCACTGTGAGAGGT
GCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGGGGTGCTCTCAACTCATTGGGCAAGG
GCATCCATCAAAATTTTTGGAGCAGCTTTCAAATCATTGTTCCGGAGGAATGCTCTGGTTCTCAAAATTCATTGGAACGTT
5 GCTGGTGTGGTTGGGTCTGAATACAAAGAATGGATCTATTTCCCTTACGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTT
ATCCACAGCCGTTTCTGCTGATGTGGGGTCTCGGTGGACTTCTCAAAGAAGGAAACGAGATGCGGTACAGGGGTGTTT
GTCTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCTCGTAGATTGGCAGCAGCAGTCAA
GCAAGCCTGGGAAGATGGGATCTGTGGGATCTCCTGTCTCAAGAATGAAAAACATCATGTGGAGATCAGTAGAAGGG
GAGCTCAACGCAATCCTGGAAGAGAATGGAGTTCAACTGACGGTCTGTGGGATCTGTAAAAACCCCATGTGGAGAG
10 GTCCACAGAGATTGCCCCTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGC
AGCAAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACATAGAGCATGGAACAGC
TTTCTTGTGGAGGATCATGGGTTTGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGT
GATCCAGCCGTCATTGGAACAGCTGCTAAGGGAAAGGAGGCTGTGCACAGCGATCTAGGCTACTGGATTGAGAGTGAGA
AGAACGACACATGGAGGCTGAAGAGGGGCCACCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTG
15 GACAGATGGAGTAGAAGAAAGTGTCTGATCATACCAAGTCTTTAGCTGGGCCACTCAGCCATCACAACACCAGAGAG
GGCTACAGGACTCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGAAGGAATGCCAGGCACTAAGG
TCCACGTGGAGGAAACATGTGGGACAAGAGGACCATCCCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAAT
GGTGCTGCAGGGAATGCACAATGCCCCCACTGCTGTTCCGAGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCC
CAGGAAAGAACCAGAAAAGTAAGTAAAGGTCAATGGTGAAGTGCAGGATCAACTGATCACATGGATCACTTCTCTCTTG
20 GAGTGCTTGTGATTTTGTCTATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAAT
GGCAGTGCTGGTAGCCATGATCCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGAATTTTGTGAGGTGCCACCT
TCGCGGAAATGAACACTGGAGGAGATGTAGCTCATTTGGCGTGATAGCGGCATTCAAAGTCAGACCTGCGTTGCTGGTA
TCTTTCACTTTCAGAGCTAATTGGACACCCCGTGAGAGCATGCTGCTGGCCTTGGCCTCGTGTCTTCTGCAAACTCGCATCT
CCGCTTGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCAC
25 GCACTGACAACATCACCTTGGAATCCTGGCTGCTGACACCACTGGCCCGGGGCACACTGCTTGTGGCGTGAGAGCA
GGCCTTGTACTTGTGGGGGGTTCATGCTCCTCTCTGAAAGGGGAAAGGCAGTGTGAAGAAGAACTACCATTGTGCAT
GGCCTTGGGACTAACTGCTGTGAGGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAG
CGGAGCTGGCCCCCTAGTGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCAAGGCGGATA
TAGAGATGGCTGGGCCCATGGCCGCGGTCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTA
30 CATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAATCACTGGAAACAGTCCCCGGCTCGATGTGGCACTA
GATGAGAGTGGTGATTTCTCCCTAGTGGAGGATGATGGTCCACCATGAGAGAGATCATACTCAAAGTGGTCTGATGAC
CATCTGCGGCATGAACCAATAGCCATACCTTTGCAGCTGGAGCGTGGTACGTGTATGTGAAGACTGGAAAAAGGAGT
GGTGCTCTATGGGATGTGCCTGCTCCCAAGGAAGTAAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTC
GTAGACTGCTTGGTTCAACACAAGTTGGAGTGGGAGTCAAGAGAGGGGGTCTTCCACACTATGTGGCACGTCAAAA
35 AGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGCTACTGT
GGTCCGTGGAAGCTAGACGCCGCTGGGACGGGCACAGCGAGGTGCAGCTTTGGCCGTGCCCCCGGAGAGAGAGCG
AGGAACATCCAGACTCTGCCGGAACATTTAAGACAAAGGATGGGGACATTGGAGCAGTTGCGCTGGACTACCCAGCAG
GAACCTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTCTATGGTAATGGGGTCTGTATAAAAAATGG
GAGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAG
40 AAGAAGCAGCTAACTGTCTTAGACCTGCATCCTGGAGCCGGGAAAAACCAGGAGAGTTCCTTCTGAAATAGTCCGTGAAGC
CATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACAGGGTCTGCTGCTGCTGAAATGGAGGAAGCCCTTAGAGGGC
TTCCAGTTCTGTTATATGACAACAGCAGTCAATGTCAACCATCTGGGACAGAAATCGTTGACTTAATGTGCCATGCTACCTT
CACTTCACGCCTACTACAACCAATCAGAGTCCCCAACTATAATTTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCA
AGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCAC
45 CAGGAACCCGTGACGCATTTCCGGACTCAACTACCAATTATGGACACCGAGGTGGAAGTCCAGAGAGAGCCTGGAG
CACAGGCTTTGATTGGGTGACGGATCATTCTGGGAAAAACAGTCTGTTTGTTCGAAGCGTGAGGAACGCAATGAGATC
GCAGCTTGTCTGACAAAGGCTGAAAAACGGGTACACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCCAGAAAAACGA
AAAATCAAGAGTGGGACTTCGTCTGTGACAACCGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTATAGAT
TCCAGGAGATGCTTAAAGCCGGTACATCTGATGGCGAGAGAGTCATTTGGCTGGACCATGCCTGTACACATGCCAG
50 CGCTGCTCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGC
AGAGACTGATGAAGATCACGCACACTGGCTTGAAGCAAGAATGCTTCTGACAACATTTACCTCCAAGATGGCCTCATAG
CTTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGTATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAGGAAGAC
CTTTGTGGAACATCATGAAAAGAGGAGATCTCCGGTTTGGTTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAG
ATAGAAGATGGTGCTTTGATGGCATGACCAACAACACCATAATGGAAGACAGTGTGCCGCGAGAGGTGTGGACCAGATA

CGGAGAGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAA
GAGTTTGCCGCTGGGAAAAGAGGAGCGGCCCTTTGGAGTGATAGAAGCCCTGGGAACACTGCCAGGACACATGACAGAG
AGATTCCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGG
5 CCCAATTGCCGAGACCCCTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTCGTCTTGA
TGCGGAACAAGGGCATGGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTTATGTGGCTCTCGGA
AATTGAGCCAGCCAGAATTGCATGTGCTCTATTGCTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCA
AAGATCTCTCAGGACAACCAAATGGCAATCATCATGTTAGCAGTGGGTCTTCTGGGCTTGATTACCGCCAATGAACT
CGGATGGTTGGAGAGAACAAAAAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCACAGGATTCTC
10 AATGGACATTGACCTGCGGCAGCCTCAGCTTGGGCTATCTATGCTGCTCTGACAACTTTCATCACCCAGCCGTCCAACA
TGCGGTGACCACTTCATACAACAACTACTCCTTAATGGCGATGGCCACGCAAGCTGGGGTGTGTTTGGTATGGGCAAG
GGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATGGGTTGCTACTCACAATTAACACCTCTGACCCTAA
TAGTGGCCATCATTTTGTCTGTGGCGCACTACATGTACTTGATCCCAGGGCTGCAGGCAGCAGCTGCGCGGGCTGCCAG
AAGAGAACGGCAGCTGGCATCATGAAGAACCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTG
ACCCCAAGTGGAAGAAAAAGATGGGGCAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGC
15 CTGGGGGTGGGGGAGGCTGGGGCCCTGATCACAGCTGCAACTTCCACCTTGTTGGGAAGGCTCTCGGAACAAGTACTGG
AACTCTCCACAGCCACTTCACTGTGAACATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAA
GAAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACGGGAGAGACCCTGGGAGAGAAATGGAAGGCCCGCTGAAC
CAGATGTCGGCCCTGGAGTTCTACTCTACAAAAAGTCAGGCATCACGAGGTGTGCAGAGAAGAGGCCCGCGCTGCCCT
CAAGGACGGTGTGGCAACAGGAGGCCATGCTGTGTCGAGGAAGTGCAAAGCTTAGATGGCTGGTGAGAGAGGATA
20 CCTGCAGCCCTATGGAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTATGCCGCCACCATCCGCAAAG
TTCAGGAAGTGAAAGGATACACAAAGGAGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACAT
AGTCCGTCTTAAGAGTGGGGTGGACGTCTTTCACATGGCGGCTGAGCCGTGTGACACTTGTCTGTGTATAGGTGAGT
CATCATCTAGTCTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCCATGGTGGGGATTGGCTTGAAAAAGACC
AGGAGCCTTTTGATAAAAGTGTTGTGCCATACACGCACTATGATGGAACCTGGAGCGACTGCAGCGTAGGTATG
25 GGGGAGGACTGGTCAGGGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTTGGAGCGAAAAGCAACAC
CATAAAAGTGTGTCCACCAGAGCCAGTCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAAATATGAGGAG
GATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCAT
TGAGAGGATCCGCACTGAGCACGCGGAAACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGA
AGCTATGAGGCCCCATACAAAGGTGAGCGTCTCTAATAAACGGGGTGTGTCAGGCTCTGTCAAAACCTGGGATGT
30 GGTGACTGGAGTCACAGGAATAGCCATGACTGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGAC
ACTAGGGTGCCAGACCCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTTCTCTGGTTATGGAAGGAGCTAGGCAA
ACACAAACGGCCACGAGTCTGTACCAAGAAGAGTTTCATCAACAAGGTTCTGATGCAATGCAGCATTAGGGGCAATATTTG
AAGAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAATGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAG
AGCATCACCTGAGAGGAGAGTGTGAGAGTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTG
35 GAAAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGAAGCCCTTGATTCTTG
AATGAGGATCATTGGATGGGGAGAGAGAATTGAGGAGTGGTGTGAAGGACTGGGATTACAAAGACTCGGATATGTC
CTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGATACTGCTGGCTGGGACCCGCATCAGCAGGT
TTGATCTGGAGAATGAAGCTCTAATCACCACCAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTAC
ACATACCAAAACAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTCAAGACAAG
40 ACCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTTAATACATTACCAACCTGGTGGTGCAGCTCATTGGAATATG
GAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGCCAGAGAAAGTGACCAACTGGTTGCAAAAGC
AACGGATGGGATAGGCTCAAAAGAATGGCAGTCAGTGAGATGATTGCGTTGTGAAACCAATTGATGATAGTTTGCAC
ATGCCCTCAGGTTCTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCTCAACTGGATGGGACAA
CTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAACTCCATCTAAGGACGGGAGGTCCATTGTGGTTCCCTGCCG
45 CCACCAAGATGAATGATTGGCCGAGCCGCGTATCACCAGGGCGGGATGGAGCATCCGGGAGACTGCTTGCTAGCA
AAATCATATGCGCAAATGTGGCAGTCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCCATTTGTTCTCT
GTGCCAGTTGATTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGACA
TGCTTGTGGTATGGAACAGAGTGTGGATTGAGGAAAACGACCACATGGAAGACAAGACCCAGTTACAAAATGGACAGA
CATTCCCTATTTGGGAAAAAGAGAAGACTTGTGGTGTGGATCTCTATAGGGCAGAGCCGCTACTACCTGGGCTGAGA
50 ACATCAAAAATACAGTCAACATGATGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTTACCCAGGTT
CGCTATTGGGTGAAGAAGGGTCCACACCTGGAGTGTGAAGCACCAATCTTAGTGTGTCAGGCTGCTAGTCAGCCA
CAGCTTGGGGAAGCTGTGCAGCTGTGACCCCCCAGGAGAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGC
CATGGCACGGAAGAAGCCATGCTGCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGAGGCGC
AGGATGGGAAAAAGAGGTGGCGACCTTCCCACTTCAATCTGGGCTGAACTGGAGATCAGCTGTGGATCTCCAGA

AGAGGGACTAGTGGTTAGAGGAGACCCCCGAAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCA
TGAGTTTCACCACGCTGGCCGCCAGGCACAGATCGCCAATAGCGGCGGCCGGTGTGGGGAAATCCATGGGTCT

SEQ ID NO: 9

- 5 KU707826.1 Zika virus isolate SSABR1, Brazil, complete genome
GACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTGGAAACGAGAGTTTCTGGTCAT
GAAAAACCCAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAACGCGGAGTAGCCCGTGTGAGCCCTTT
GGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAGAGGCTATGGAAATA
10 ATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAAGAGACGAGGCGCA
GATACTAGTGTGGGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTA
TATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACCACATTGGGGATGAATAAGTGTATATACAGA
TCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGAACCCAGATGAC
15 GTCGATTGTTGGTGAACACGACGTCACACTTGGGTTGTGTACGGAACCTGCCATCACAAAAAGGTGAAGCACGGAGAT
CTAGAAGAGCTGTGACGCTCCCTCCCTCCATTCCACTAGGAAGCTGCAAAACGCGGTCGAAACCTGGTTGGAATCAAGAGAA
TACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCCATCGCTTG
GCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCGGCATACAGCATCAGGT
GCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACCTGGGTTGATGTTGTCTTGGAAACATGGAGG
TTGTGTACCCTAATGGCACAGGACAAACCGACTGTGCACATAGAGCTGTTACAACAACAGTCAGCAACATGGCGGAG
20 GTAAGATCCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCTGCCCAACACAAGGTGAAGCCTACCT
TGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACGTTAGTGGACAGAGGCTGGGGAAATGGATGTGGACTTTTT
GGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCCAGAGAATC
TGGAGTACCGGATAATGCTGCAGTTCATGGCTCCAGCACAGTGGGATGATTGTTAATGACACAGGACATGAAACTGAT
GAGAATAGAGCGAAAGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGAC
25 TTGATTGTGAACCGAGGACAGGCCTTGACTTTTTCAGATTGTATTACTTGACTATGAATAACAAGCACTGGTTGGTTTACA
AGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAAGAGC
ACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTCACACG
GCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAGGGGAAGGCTGTCCTCTGGCCACTTGAAATGTCGCTGA
AAATGGATAAACTTAGATTGAAGGGCGTGTCTACTCCTGTGTACTGCAGCGTTCACATTACCAAGATCCCGGCTGAAA
30 CACTGCACGGGACAGTCACAGTGGAGGTACAGTACGACGGGACAGATGGACCTTGCAAGGTTCCAGCTCAGATGGCGGT
GGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCACTGAAAGCACTGAGAACTCTAAGA
TGATGCTGGAACCTTGATCCACCATTTGGGGACTTTACATTGTCTAGGAGTTCGGGGAGAGAAAGATCACCCACCATGG
CACAGGAGTGGCAGCACCAATTGGAAGCAATTTGAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGAC
ACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTATTGGGCAAGGGCATCCATCAAAATTTTGGAGCAGCTTT
35 CAAATCATTTGTTGGAGGAATGTCCTGGTTCTCACAATTTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAA
GAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCCACAGCCGTCTCTGCTGATGTGGG
GTGCTCGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCTATAACGACGTTGAAGCCTGGAGG
GACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTATCTGCG
GGATCTCCTCTGTTTCAAGAATGGAAAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAGAGAA
40 TGGAGTTCAACTGACGGTCGTTGTGGGATCTGTAAAAACCCCATGTGGAGAGGTCCACAGAGATTGCCCCGTGCTGTGA
ACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTAGAGCAGCAAAGACAAATAACAGCTTTGTCTGT
GGATGGTGACACACTGAAGGAATGCCCACTCAACATAGAGCATGGAACAGCTTTCTGTGGAGGATCATGGGTTGCGG
GTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTT
AAGGGAAAGGAGGCTGTACACAGTGTACTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGG
45 GCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGATC
TGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCA
TGGCAGAGTGAAGAGCTTGAAATTCGGTTTGAGGAATGCCAGGCACTAAGGTCCAGTGGAGGAAACATGTGGAACAA
GAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGCTGCAGGGAGTGCAATGCCCCC
ACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGGAAAGAACAGAAAGCAACTTAGTA
50 AGGTCAATGGTGACTGCAGGATCAACTGATCAGTGGACCATCTCCCTTGGAGTGCTTGTGATTCTGCTCATGGTGCAG
GAAGGGCTGAAGAAGAGAAATGACCACAAAGATCATATAAGCACATCAATGGCAGTGCTGGTAGCTATGATCTGGGAG
GATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTA
GCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTTCAGAGCTAATTGGACACCC
CGTGAAAGCATGCTGCTGGCCTTGGCCTCGTCTTTTCAAACCTGCGATCTCCGCTTGGAAAGGCGACCTGATGGTTCTC

ATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGCCAATCCTG
GCTGCTCTGACACCACTGGCCCCGGGCACACTGCTTGTGGCGTGGAGAGCAGGCCTTGCTACTTGCGGGGGGTTTATGCT
CCTCTCTCTGAAGGAAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGTCATGGCCCTGGGACTAACCGCTGTGAGGCTGG
TCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGTACTCAC
5 AGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCATGGCCGCGGT
GGTCTGTAATTGTCACTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCACATGGG
AAAAAGATGCGGAAGTCACTGGAAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGA
GGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATAC
10 CCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAAAAGGAGTGGTGTCTATGGGATGTGCCTGCTCCCAA
GGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACACAAGTTGG
AGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCAAAAAGGATCCGCGCTGAGAAGCGGTGAAGG
GAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCTGG
GACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTTGCCCCGAATAT
TTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACTTCAGGATCTCCAATCTAGACAA
15 GTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGTATCAAAAATGGGAGTTATGTTAGTGCCATCACCAAGGG
AGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGTGAAGAAGAGCAGCTAACTGTCTTAGACTTGC
ATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAACAAGACTCCGTACTGTGATC
TTAGTCCAACAGGGTTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCCAGTGCCTTATATGACAACAGCAGT
CAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTACGTCTACTACAGCCAATCAGA
20 GTCCCCAATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCA
ACAAGGGTTGAGATGGGCGAGGGCGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACT
CCAATCACCAATTATGGACACCGAAGTGGAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCA
TTCTGGAAAAACAGTTTGGTTTGTCCAAGCGTGAAGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGTGGAAAAAC
GGTGCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAAACATCAAGAGTGGGACTTTGTCTGTGAC
25 AACTGACATTTAGAGATGGGCGCCAACTTTAAAGCTGACCGTGTCTAGATTCCAGGAGATGCCTAAAGCCGGTGCATAC
TTGATGGCGAGAGAGTCACTTGGCTGGACCCATGCTGTGCACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGG
CAGGAATCCCAACAACTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGG
CTTGAAGCAAGAATGCTCCTTGACAATATTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAA
GTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAGGAAGACCTTTGTGGAACCTATGAAAAGAGGAGAT
30 CTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGACC
AACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAGAGAAAAGAGTGCTCAAACCGAGG
TGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCAATTCAAGGAGTTTGGCGCTGGGAAAAGAGGAGCGG
CTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGC
TGTGCTCATGCGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCCCAATTGCGGAGACCCTAGAGACCATT
35 ATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTCTCTGCTTGTGATGAGGAACAAGGCATAGGGAAGATGG
GCTTTGGAATGGTGACTCTTGGGGCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTC
CTCATTGTTGTGTTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAAGCAAGATCTCCCAGGACAACCAATGGCA
ATCATCATCATGGTAGCAGTAGGCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAACAAAGAGTGA
CCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTCA
40 GCTTGGGCCATCTATGCTGCCTTGACAACCTTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACAACTACT
CCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGTATGGGCAAGGGATGCCATTCTACGCATGGGACTTTGGA
GTCCCGCTGCTAATGATAGGTTGCTACTCACAAATTAACACCCCTGACCCTAATAGTGCCATCATTTTGTCTGTCGCGCACT
ACATGTAATTGATCCCAGGGCTGCAGGCAGAGCTGCGCGTGCTGCCAGAAAGAGAAGCGCAGCTGGCATCATGAAGAA
CCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCCAAGTGGAGAAAAAGATGGGACAG
45 GTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTGCGGACCGCTGGGGGTGGGGGGAGGCTGGGGCCCTGA
TCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTCTACAGCCACTTCACTGTGTAACA
TTTTTAGGGGAAGTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGGG
GGTGGAAACAGGAGAGACCTGGGAGAGAAATGGAAGGCCCGCTTGAACAGATGTGCGCCCTGGAGTTCTACTCTTACA
AAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATG
50 CTGTGTCCGAGGAAGTGCAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAAGGTCATTGATCT
TGGATGTGGCAGAGGGGCTGGAGTTACTACGCCCACTCCGCAAGGTTCAAGAAGTGAAAGGATACACAAAAGG
AGGCCCTGGTCATGAAGAACCCTGTTGGTGCAAAAGCTATGGGTGGAACATAGTCCGCTTAAGAGTGGGGTGACGTC
TTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCTGAAGTGGAAGAAGC
ACGGACGCTCAGAGTCTCTCATGGTGGGGATTGGCTTAAAAAAGACCAGGAGCCTTTGTATAAAGGTGTTGTGCC

CATACACCAGCACTATGATGGAAACCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTC
CCGCAACTCTACACATGAGATGTATTGGGTCTCTGGAGCGAAAGCAACACCATAAAAAGTGTGTCCACCACGAGCCAGC
TCCTCTTGGGGCGCATGGACGGGCCTAGGAGGCCAGTGAATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGGC
TGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGAGTGAGCACGCGGAA
5 ACGTGGTTCTTTGACGAGAACCCACATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGC
GTCCTCTCTAATAACGGGGTTGTCAAGGCTCTGTCAAAACCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGA
CCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGCAC
TCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAAGAGCTAGGCAAACACAAACGGCCACGAGTCTGTACCAAAG
AAGAGTTCATCAACAAGGTTCTGATGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGACTGCAGT
10 GGAAGCTGTGAACGATCCAAGTTCTGGGCTCTAGTGGATAAGGAAAGAGAGCACCACCTGAGAGGAGAGTGCCAGAG
TTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGAAACAAGGGGAATTTGGAAGGCCAAGGGCAGCCGCGCCATCTG
GTATATGTGGCTAGGGGCTAGATTTCTAGAGTTTCAAGGCCCTTGATTCTTGAACGAGGATCACTGGATGGGGAGAGAG
AACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCTAGAAGAGATGAGTCGTATACCAGGAG
GAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCACC
15 AACCAATGGAAAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCC
TTAGACCAGCTGAAAAAGGGAAAAACAGTTATGGACATTATTCGAGACAAGACCAAGGGGGAGCGGACAAGTTGTCAC
TTACGCTCTTAACACATTTACCACTAGTGGTCACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAG
ACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTACCAACTGTTGTCAGAGCAACGGATGGGATAGGCTCAAACGAATGG
CAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTGCACATGCCCTCAGGTTCTTGAATGATATGGGA
20 AAAGTTAGGAAGGACACACAAGAGTGGAAACCTCAACTGGATGGGACAACCTGGGAAGAAGTTCCGTTTGTCTCCACC
ACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGCCACCAAGATGAACTGATTGGCCGGGCC
CGCGTCTCTCAGGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCTT
TTATTTCCACAGAAGGGACCTCGACTGATGGCCAATGCCATTTGTTTCTGTGCCAGTTGACTGGGTTCCAAGTGGGAG
AACTACTGTTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGATGTGGATT
25 GAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATCCCTATTTGGGAAAAAGGGAAGACT
TGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGAACATTAACAAACAGTCAACATGGTGCAC
AGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACACC
TGGAGTGTGTGAAGCACCAGTCTTAATGTTGTGAGGCTGTAGTACGCCACAGCTTGGGGAAGCTGTGCAGCCTGTGA
CCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGTGCTCTGT
30 GAGCCCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAAGGTGGCGACCTTC
CCCACCTTCAATCTGGGCTGAACTGGAGATCAGCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAG

SEQ ID NO: 10

KU744693.1 Zika virus isolate VE_Ganxian, China, complete genome

GTTGTTACTGTTGCTGACTCAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTGG
35 ATTTGGAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAAACG
CGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTGATGGGCCATCAGG
ATGGTCTTGGCAATTCTAGCCTTTTGTGATTACGCGCAATCAAGCCATCACTGGGTCTCATATAGATGGGGTTCAGTG
GGGAAAAAAGATGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGA
40 AGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTTGTTGGCTCCTGCTGACCACAGCTATGGCAGCGGAGG
TCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGATGCTGGGGAGGCCATATCTTTTCAACACATTG
GGGATGAATAAGTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCT
GGATGAGGGGGTGAACACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTTGGGTTGTGTACGGAACCTGCCAT
CACAAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCCATCTCACTAGGAAGCTGCAAACGCGGT
45 CGCAAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTC
GCGTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCT
GATTGCCCCGGCATACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGG
GTTGATGTTGCTTGGAAACATGGAGGTTGTGTACCGCAATGGCACAGGACAAACCGACTGTGCACATAGAGCTGGTTAC
AACAACAGTCAGCAACATGGCGGAGGTAAGATCTACTGCTATGAGGCATCAATATCAGACATGGCTTCGGACAGCCGCT
50 GCCCAACACAAGGTGAAGCTACCTTGACAAGCAATCAGACACTCAATATGTTTGCAAAAGAAGCTTGTGACAGAGGC
TGGGGAAATGGATGTGACTTTTTGGCAAGGGAGTCTGTTGACATGCGCTAAGTTTGCATGCTCCAAGAAAAATGACCG
GGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTGAGTTATGGCTCCAGCACAGGGATGCTCGTT
AATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTCACCAAGAGCCGAAGCCACCC
TGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGTATTACTTGACTATGA

ATAACAAGCACTGGTTGGCTCACAAGGAGTGGTTCCACGACATTCCATTACCTTGGCACGCTGGGGCAGCCACCGGAACT
CCCACTGGAACAACAAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCAAACCTGTCGTGGTTCTAGGGA
GTCAAGAAGGAGCAGTTCACACGGCCCTTGTCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTC
5 TGGCCACTTGAAATGTCGCTGAAAATGGATAAACTTAGATTGAAGGGCGTGCATACTCCTTGTGTACCGCAGCGTTCAC
ATTACCAAGATCCCGGCTGAAAACAGTGGACGGGACAGTCAAGTGGAGGGACAGTACGGAGGGACAGATGGACCTTG
CAAGGTTCCAGCTCAGATGGCGGTGGACATGCAGACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCCGTAATCA
CTGAAAGCACTGAGAACTCTAAGATGATGCTGGAACCTTGATCCACCATTGGGGACTCTTACATTGTCATAGGAGTCCGG
GAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTGTAAGCCACTGTGAGAGGTGCCA
10 AGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTCAACTCATTGGGCAAGGGCAT
CCATCAAATTATTGGAGCAGCTTTCAAATCATTGTTTGGAGGAATGTCCTGGTCTCACAAATTCTCATTGGGACGTTGCTG
ATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTTATCC
ACAGCCGTCTCAGGTGGTGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGTCT
ATAACGATGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCA
AGCCTGGGAAGATGGTATCTGCGGGATCTCCTCTGTTTCAAGAATGGAACATCATGTGGAGATCAGTAGAAGGGGAG
15 CTCAACGCAATCTGGAAGAGAATGGAGTTCAACTGACGGTCTGTGGGATCTGTAAAAACCCCATGTGGAGAGGTG
CACAGAGATTGCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGGAAATCGTACTTCGTGAGAGCAGC
AAAGACAAATAACAGCTTTGTCGTGGATGGTGACACTGAAGGAATGCCACTCAAACATAGAGCATGGAACAGCTTTC
TTGTGGAGGATCATGGGTTGCGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGACTATTGGTTAGAGTGTGAT
CCAGCCGTATTGGAACAGCTGTTAAGGGAAGGAGGCTGTACACAGTGTCTAGGCTACTGGATTGAGAGTGAGAAAGA
20 ATGACACATGGTGGCTGAAGAGGGCCCATCTGATCGAGATGAAACATGTGAATGGCCAAAGTCCACACATTGTGGAC
AGATGGAATAGAAGAGAGTGATCTGATCATACCAAGTCTTAGCTGGGCCACTCAGCCATCAATGCCAGAGAGGGCT
ACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGTTTGAGGAATGCCAGGCACTAAGGTCCA
CGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCATGCAAGCGGAAGGGTGATCGAGGAATGGTG
CTCCAGGGAGTGACAATGCCCCACTGTCTTCCAGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCAGG
25 AAAGAACCAGAAAGCACTTAGTAAGGTCAATGGTGACTGCAGGATCAACTGATCACATGGATCACTTCTCCCTTGGAGT
GCTTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATCATAAGCACATCAATGGCA
GTGCTGGTAGCTATGATCCTGGGAGGATTTCAATGAGTGACCTGGCTAAGCTTGCAATTTTGATGGGTGCCACCTTCGC
GGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTT
TCATCTTCAGAGCTAATTGGACACCCCGTGAAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTCCG
30 CTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCA
CTGATAACATCACCTTAGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGCAGACTGCTTGTGGCGTGAGAGCAGGC
CTTGCTACTTGCGGGGGTTATGCTCTCTCTCTGAAGGGGAAAAGGCAGTGTGAAGAAGAACTTACCATTGTGATGGC
CCTGGGACTAACCCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGACTGCTGTTGCTCAAGAGGAGTGGGAAGCGG
AGCTGGCCCCCTAGCGAAGTACTCACAGCTGTTGGCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGA
35 GATGGCTGGGCCCATGGCCGCGGTGCTGCTAATTGTGAGTTACGTGGTCTCAGGAAAGAGTGTGGACATGTACATTG
AAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATG
AGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATC
TGTGGCATGAACCAATAGCCATACCTTTGACGTGGAGCGTGGTACGTATACGTGAAGACTGGAAGAGGAGTGGTG
CTCTATGGGATGTGCTGCTCCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTACAGAGTAATGACTCGCAG
40 ACTGCTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGTCTTTCACACTATGTGGCACGTCACAAAAGGA
TCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGAGATGTCAAGCAGGATCTGGTGTACTACTGTGGTC
CATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGACGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGA
ACATCCAGACTCTGCCGGAATATTGAAGACAAAGGATGGGACATTGGAGCGGTTGCACTGGATTACCCAGCAGGAAC
TTCAGGATCTCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCTGATCAAAAATGGGAGT
45 TATGTTAGTGCCATACCCAAGGGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGA
AGCAGCTAACTGTCTTAGACTTGATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATA
AAAACAAGACTCCGTACTGTGATCTTGGCTCAACAGGGTGTGCTGCTGAAATGGAGGAGGCCCTTAGAGGGCTTCC
AGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTAC
TTCACGTCTACTACAGCAATTAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGT
50 ATAGACGAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTATGACCGCCACGCCACCAG
GAACCCGTGACGCATTTCCGGACTCCAACACCAATTATGGACACCGAAGTGAAGTCCAGAGAGAGCCTGGAGCTCA
GGCTTTGATTGGGTGACGGAGTATTCTGGAAGAACATGTTGGTTTGTCCACGCGTGAGGAACGGCAATGAGATCGCAG
CTTGTCTGACAAAGGCTGGAACGGGTGATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACAT
CAAGAGTGGGACTTTGCTGTGACAACTGACATTTAGAGATGGGCGCAACTTTAAAGCTGACCGTGTATAGATTCCAG

GAGATGCCTAAAGCCGGTCATACTTGGTGGCGAGAGAGTCATTCTGGCTGGACCCATGCCTGTCACACATGCCAGCGCTG
CCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGGTGCGCAGAGA
CTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGC
TCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGT
5 GGAACCTCATGAAAAGAGGAGATCTTCCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAATAACCTACACAGATAGAA
GATGGTGCTTTGATGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTGTGGACCAGACACGGAG
AGAAAAGAGTGCTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTT
TGCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATT
CCAGGAAGCCATTGACAACCTCGCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGCGGCCCAA
10 TTGCCGGAGACCTTAGAGACCATTATGCTTTTGGGGTTGCTGGGAACAGTCTCGCTGGGAATCTTTTCGTCTTGATGAGG
AACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGACTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTG
AGCCAGCCAGAATTGCATGTGTCTCTATTGTTGTGTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGAT
CTCCCCAGGACAACCAAATGGCCATCATCATATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACCTCGGAT
GGTTGGAGAGAACAAAGAGTGACCTAAGCCATCTAATGGGAAGGAGAGAGAGGGGGCAACCATGGGATTCTCAATGG
15 ACATTGACCTGCGGCCAGCCTCAGCTTGGGCCATCTATCTGCCTTGACATCTTTCATTACCCAGCCGTCCAACATGCAGT
GACCACTTCATAACAACACTACTCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGC
CATTCTACGCTAGGACTTTGGAGTCCGCTGCTAATGATAGGTTGCTACTCACAATTAACGCCCCGACCTAATAGTGG
CCATCATTTTTGCTCGTGGCGCACTACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAGAGA
ACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGAGGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCC
20 AAGTGAGAAAAAGATGGGACAGGTGCTACTCATGGCAGTAGCCGTCTCCAGCGCCATACTGTGAGGACCGCCTGGGG
GTGGGGGGAGGCTGGGGCCCTGATCACAGCCGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAACCTC
TCTACAGCCACCTCACTGTGTAAATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAAC
GTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCGCTTGAACCCAGAT
GTCGGCCCTGGAGTTCTACTCTACAAAAGTCAGGCATCACCGAGGTGTGAGAGAAGAGGCCCGCCGCGCCCTCAAG
25 GACGGTGTGGCAACGGGAGGCCATGCTGTGTCCGAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTG
CAGCCCTATGGAAGGTCAATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCA
AGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTCATGAAGAACCCGTGTTGGTGCAAAGCTATGGGTGGAACATAGT
CCGTCTTAAGAGTGGGGTGGACGTCTTTCATATGGCGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCAT
CATCTAGTCTGAAGTGGAAGAAGCACGGACGCTCAGAGTCTCTCATGGTGGGGGATTGGCTTGAAAAAGACACAGG
30 AGCCTTTTGTATAAAGTGTTGTGCCATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGG
GAGGACTGGTCAGAGTGCCACTCTCCCGCAACTCTACATGAGATGTACTGGGTCTCTGGAGCGAAAAGCAACACCATA
AAAAGTGTGTCCACCACGAGCCAGCTCCTTTGGGGCGCATGGACGGCCCTAGGAGGCCAGTGAAATATGAGGAGGAT
GTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAATTGGTAACCGCATTGA
AAGGATCCGCGCTGAGAAAAGCGGAAACGTGGTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGC
35 TATGATGCCGCCACACAAGGGTCAGCGTCTCTCTAATAAACGGGGTGTGTCAGGCTCTGTCAAACCCCTGGGATGTGGT
GACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACT
AGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGAAGAGCTAGGCAAAC
ACAAACGGCCACGAGTCTGTACAAAGAAGAGTTCATCAACAAGGTTCTGAGCAATGCAGCATTAGGGGCAATATTTGAA
GAGGAAAAAGAGTGGAAGACTGCAGTGGAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGTGGACAAGGAAAGAGAG
40 CACCACCTGAGAGGAGAGTGCCAGAGTTGTGTGTACATCACAATGGGAAAAAGAGAAAAGAAACAAGGGGAATTTGGA
AAGGCCAAGGGCAGCCGCGCCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTCGAAGCCCTTGATTCTTGAA
CGAGGATCACTGGATGGGGAGAGAGAACTCAGGAGGTGTTGTTGAAGGGCTGGGATTACAAAGACTCGGATATGTCCT
AGAAGAGATGAGTCGCATACAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTT
GATCTGGAGAATGAAGCTCTAATACCAACCAAATGGAGAAAGGGCACAGGGCCTTGGCATTGGCCATAATCAAGTACA
45 CATACCAAAACAAAGTGGTAAAGGTCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTTGAGACAAGA
CCAAAGGGGGAGCGGACAAGTTGTCACTTACGCTCTCAACACATTTACCAACCTAGTGGTGCAACTCATTGCGAATATGG
AGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGTGCGGAGGTGAGAGAAAGTGACCAACTGGTTGCAGAGCA
ACGGATGGGATAGGCTCAAACGAATGGCGGTGAGTGAGATGATTGCGTTGTGAAACCAATTGATGATAGGTTTGACA
TGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAACCCCTCAACTGGATGGGACAAC
50 TGGGAAGAAGTTCCTTCTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCCTGCCGC
CACCAAGATGAACTGATTGGCCGGGCCGCTCTCCAGGGCGGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAA
AATCATATGCGCAAAATGTGGCAGCTCTTTATTTCCACAGAAGGGACCTCCGACTGATGGCCAATGCTTTGTTCACTG
TGCCAGTTGACTGGGTTCCAACGGGAGAACTACCTGGTCAATCCATGGAAAGGGAGAAATGGATGACCACTGAAGACAT
GCTTGTGGCGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCAGTCACGAAATGGACAGA

CATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACTGGGCTGAGA
ACATTAACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCCAAGTT
CGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGTGTAAGCACCAATCTTAATGTTGTCAGGCCTGCTAGTCAGCCA
5 CAGCTTGGGGAAGCTGTGACGCTGTGACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGC
CATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGTTGGAGGCGC
AGGATGGGAAAAAGGTGGCGACCTTCCCCACCTTCAATCTGGGGCCTGAACTGGAGATCAGCTGTGGATCTCCAGA
AGAGGGACTAGTGGTTAGAGGAGA

SEQ ID NO: 11

10 LC002520.1 Zika virus genomic RNA, strain: MR766-NIID, Uganda, complete genome
AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACACAGTATCAACAGGTTTAAATTT
GGATTTGGAAACGAGAGTTTCTGGTCATGAAAAACCAAGAAAGAAATCCGGAGGATTCCGGATTGTCAATATGCTAAA
ACGCGGAGTAGCCCCGTGTAACCCCTTGGGAGTTTGAAGAGGTTGCCAGCCGACTTCTGCTGGGTCATGGACCCATCA
GAATGGTTTTGGCGATACTAGCCTTTTTGAGATTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTTCCG
15 TGGGGAAAAAGAGGCTATGGAATAATAAGAAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAATGCTAG
GAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGACTACAGCCATGGCAGCAGA
GATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGCGATGCCGGGAAGGCCATTTCTGTTTCTACCACAT
TGGGAGTGAACAAGTGCCACGTACAGATCATGGACCTCGGGCAGATGTGTGACGCCACCATGAGTTATGAGTGCCCTATG
CTGGATGAGGGAGTGGAACAGATGATGTCGATTGCTGGTGCAACACGACATCAACTTGGGTTGTGTACGGAACCTGTC
20 ATCACAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTCACTCTACAAGGAAGTTGCAACCGCG
GTCGCAGACCTGGTTAGAATCAAGAGAATACAGGAAGCACTTGATCAAGGTTGAAAAGTGGATATTCAGGAACCCCGGG
TTTGCCTAGTGGCGTTGCCATTGCCTGGCTTTTGGGAAGCTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTG
CTGATTGCCCGGATACAGATACAGGTGCAATTGGATCAGCAATAGAGACTTCTGGAGGGCATGCGGTGGGACCT
GGGTTGATGTTGTCTTGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTTGACATAGAGTTGGT
25 CACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTC
GTTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTGGACAGA
GGTTGGGGAACCGTTGTGGACTTTTGGCAAAGGGAGCTTGGTGACATGTGCAAGTTTACGTGTTCTAAGAAGATGA
CCGGGAAGAGCATTCAACCGGAAAATCTGGAGTATCGGATAATGCTATCAGTGATGGCTCCAGCATAGCGGGATGAC
TGTAATGATATAGGATATGAAACTGACGAAAATAGAGCGAAAGTCGAGGTTACGCCTAATTCACCAAGAGCGGAAGCA
30 ACCTTGGGAGGCTTTGGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCTGTATTACCTGACC
ATGAACAATAAGCATTGGTTGGTGCAAAAGAGTGGTTTCATGACATCCCATGCTTGGCATGCTGGGGCAGACACTGG
AACTCCACACTGGAACAACAAAGAGGCATTGGTAGAATCAAGGATGCCACGCCAAGAGGCAACCGTCGTCTGTTCTG
GGGAGCCAGGAAGGAGCCGTTACACGGCTCTCGCTGGAGCTCTAGAGGCTGAGATGGATGGTGCAAAAGGGAAGCTG
TTCTCTGGCCATTTGAAATGCCGCCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCATATTCCTTGTGCACTGCGGCA
35 TTCATTACCAAGGTCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGCAGTATGCAGGGACAGATGGAC
CCTGCAAGATCCAGTCCAGATGGCGGTGGACATGCAGACCTGACCCAGTTGGAAGGCTGATAACCGCAACCCCGTG
ATTACTGAAAGCACTGAGAACTCAAAGATGATGTTGGAGCTTGACCCACCATTTGGGGATTCTTACATTGTCATAGGAGTT
GGGGACAAGAAAATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTGAGGCCACTGTGAGAGGC
GCCAAGAGAATGGCAGTCCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTCACTGGGTAAGG
40 GCATTACACAGATTTTGGAGCAGCCTTCAAATCACTGTTTGGAGGAATGTCCTGGTTCTACAGATCCTCATAGGCACGC
TGCTAGTGTGGTTAGGTTTGAACACAAAGAATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATCTTCC
TCTCCAGGCTGTTTCTGCTGACGTGGGGTGCTCAGTGGACTTCTCAAAAAAGGAAACGAGATGTGGCAGGGGGTATTCT
ATCTATAATGATGTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGTCAA
GCAGGCCTGGGAAGAGGGGATCTGTGGGATCTATCCGTTTCAAGAATGGAACATCATGTGGAATCAGTAGAAGGG
45 GAGCTCAATGCTATCCTAGAGGAGAATGGAGTTCACTGACAGTTGTTGTGGGATCTGTAAAAACCCCATGTGGAGAG
GTCCACAAAGATTGCCAGTGCCTGTGAATGAGCTGCCCCATGGCTGGAAAGCCTGGGGGAAATCGTATTTTGTAGGGCG
GCAAAGACCAACAACAGTTTTGTTGTCGACGGTGACACACTGAAGGAATGTCCGCTTGAGCACAGAGCATGGAATAGTTT
TCTTGTGGAGGATCACGGGTTTGGAGTCTTCCACACCAAGTGTCTGGCTTAAGGTCAGAGAAGATTACTCATTAGAATGTG
ACCCAGCCGTCATAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGCACAGTGATCTGGGCTATTGGATTGAAAGTGAAAA
50 GAATGACACATGGAGGCTGAAGAGGGCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGG
ACAGATGGAGTAGAAGAAAGTGATCTTATCATACCAAGTCTTAGTGGTCACTCAGCCACCAACACCAAGAGAGGG
TTACAGAACCCAAAGTGAAGGGGCCATGGCACAGTGAAGAGCTTGAATCCGGTTTGAGGAATGTCCAGGCACCAAGGTT
TACGTGGAGGAGACATGCGGAAGTAGAGGACCATCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGT
GCTGTAGGAATGCACATGCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCACG

GAAAGAACCAGAGAGCAACTTAGTGAGGTCAATGGTGACAGCGGGGTCAACCGATCATATGGACCACTTCTCTCTTGA
GTGCTTGATTTACTCATGGTGCAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATCATGAGCACATCAATGG
CAGTGCTGGTAGTCATGATCTTGGGAGGATTTCAATGAGTGACCTGGCCAAGCTTGATCCTGATGGGTGCTACTTTCC
5 CAGAAATGAACACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTAAAGTCAGACCAGCCTTGCTGGTCTCC
TTCATTTTCAGAGCCAATTGGACACCCCGTGAGAGCATGCTGCTAGCCCTGGCTTCGTGCTTCTGCAAACTGCGATCTCT
GCTCTTGAAGGTGACTTGATGGTCTCATTAAATGGATTGCTTTGGCCTGGTTGGCAATTCGAGCAATGGCCGTGCCACGC
ACTGACAACATCGCTCTACCAATCTTGGCTGCTCTAACACCACTAGCTCGAGGCACACTGCTCGTGGCATGGAGAGCGGG
CCTGGCTACTTGTTGGAGGGATCATGCTCCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGAAGAACTGCCATTTGTATGG
10 CCTGGGATTGACAGCTGTGAGGGTAGTAGACCTATTAATGTGGTAGGACTACTGTTACTCACAAGGAGTGGGAAGCG
GAGCTGGCCCCCTAGTGAAGTTCTCACAGCCGTTGGCCTGATATGTGCACTGGCCGGAGGGTTTGGCAAGGCAGACATTG
AGATGGCTGGACCCATGGCTGCAGTAGGCTTGCTAATTGTGCACTATGTGGTCTCGGGAAGAGTGTGGACATGTACATT
GAAAGAGCAGGTGACATCACATGGGAAAAGGACGCGGAAGTCACTGGAAACAGTCTCGGCTTGACGTGGCACTGGAT
GAGAGTGGTGATTCTCTTGGTAGAGGAAGATGGTCCACCCATGAGAGAGATCATACTTAAGGTGGTCTGATGGCCAT
CTGTGGCATGAACCAATAGCTATACCTTTTGCTGCAGGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGC
15 GCCCTCTGGGACGTGCTGCTCCCAAGAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGTGACTCGCA
GACTGCTAGGTTCAACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTTCCACACCATGTGGCACGTTACAAAAGG
AGCCGCACTGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGATGTCAAGCAGGACTTGGTGTACTACTGTGG
GCCTTGAAGTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACAGCTTTTGGCCGTACCTCCCGAGAGAGGGGCCAGA
AACATTGACACCTGCCTGGAATATTCAAGACAAAGGACGCGGGACATCGGAGCAGTTGCTCTGGACTACCCTGCAGGGA
20 CCTCAGGATCTCCGATCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAATGGAAG
CTATGTTAGTGCTATAACCCAGGGAAAGAGGGAGGAGGAGTCCGGTTGAATGTTTGAACCCCTCGATGCTGAAGAAG
AAGCAGCTAACTGCTTGGATCTGCATCCAGGAGCCGGAAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCAT
AAAAAAGAGTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTCGCTGCTGAGATGGAGGAGGCTTGAGAGGACTT
CCGGTGCCTTACATGACAACAGCAGTCAACGTCACCCATTCTGGGACAGAAATCGTTGATTGTGCTGCTGCCACTTTC
25 ACTTACGCTTACTACAACCCATCAGAGTCCCTAATTACAATCTCTACATCATGGATGAAGCCCACTTACAGACCCCTCAA
GTATAGCTGCAAGAGGATATATATCAACAAGGTTGAAATGGGCGAGGCGGCTGCCATTTTATGACTGCCACACCACCA
GGAACCCGTGATGCGTTTCTGACTCTAACTACCAATCATGGACACAGAAGTGAAGTCCAGAGAGAGCCTGGAGCTC
AGGCTTTGATTGGGTGACAGACCATTTCTGGGAAAACAGTTTGGTTTCGTTCCAAGCGTGAGAAACGGAATGAAATCGCA
GCCTGTCTGACAAAGGCTGGAAGCGGGTCATACAGCTCAGCAGGAAGACTTTTGAGACAGAAATTCAGAAAAACAAAA
30 ATCAAGAGTGGGACTTTGTACATAACAACTGACATCTCAGAGATGGGCGCAACTTCAAGGCTGACCGGGTCATAGACTCT
AGGAGATGCCTAAACCACTGATCTTGGTGGAGAGTCACTTGGCTGGGCCATGCCTGTCACGCATGCTAGTGC
TGCTCAGAGGAGAGGACGTATAGGCAGGAACCTAACAACCTGGAGATGAGTACATGTATGGAGGTGGGTGTGCAGA
GACTGATGAAGGCCATGCACACTGGCTTGAAGCAAGAATGCTTCTGACAACATCTACCTCCAGGATGGCCTCATAGCCTC
GCTCTATCGGCTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTAAGCTGAGGACAGAGCAAAGGAAGACCTTC
35 GTGGAACCTCATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGTTGCTGCTGCCGGAATAACTTACACAGACAG
AAGATGGTGCTTTGATGGCACAACCAACAACACCATAATGGAAGACAGCGTACCAGCAGAGGTGTGGACAAAGTATGGA
GAGAAGAGAGTGCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTACAGACATGCGGCCCTGAAGTCGTTCAAAGAAT
TCGCCGTGGAAGAGAGGAGCGGCTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGT
TTCAGGAAGCCATTGACAACCTCGCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCTTATAAGGCAGCGGCAGCCCA
40 ACTGCCGAGACCTAGAGACCATTTATGCTCTTAGGTTTGTGGGAACAGTTTCACTGGGGATCTTCTCGTCTTGATGCG
GAATAAGGGCATCGGGAAGATGGGCTTGGAAATGGTAACCTTGGGCCAGTGCATGGCTCATGTGGCTTTCGGAAT
GAACCAAGCCAGAAATGATGTGCTCATTGTTGTGTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAAGA
TCTCCCAAGATAACCAAGATGGCAATTATCATCATGGTGGCAGTGGGCTTCTAGGTTTGATAACTGCAACGAACCTTGA
TGGCTGGAAGAACAACAAATGACATAGCTCATTAATGGGAAGGAGAGAAGAAGGAGCAACCATGGGATTCTCAATG
45 GACATTGATCTGCGGCCAGCCTCCGCTGGGCTATCTATGCCGATTGACAACTCTCATACCCAGCTGTCCAACATGCG
GTAACCACTTCATACAACAACTACTCTTAATGGCGATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAGGGAT
GCCATTTTATGATGGGACCTTGGAGTCCCGCTGCTAATGATGGGTTGCTATTCACAATTAACACCCCTGACTCTGATAGT
AGCTATCATTCTGCTTGTGGCGCACTACATGTACTTGATCCAGGCCTACAAGCGGCAGCAGCGGTGCTGCCAGAAAA
GGACAGCAGCTGGCATCATGAAGAATCCCGTTGTGGATGGAATAGTGGTAAGTACATTGACACAATGACAATAGACCC
50 CCAGGTGGAGAAGAAGATGGGACAAGTGTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCCGACCGCCTGG
GGATGGGGGGAGCTGGAGCTGATCAGCAGCAGCTCCACCTTGTGGGAAGGCTCTCCAAACAAACTGCGAAGT
CCTCTACAGCCACCTACTGTGCAACACTTACAGGAAGCTATGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAA
ACGCTGGCCTGGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGA
TGTCGGCCCTGGAGTTTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCCCTCAAG

GATGGAGTGGCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAAGCTCAGATGGTTGGTGGAGAGAGGATATCTG
CAGCCCTATGGGAAGGTTGTTGACCTCGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAAGTGC
AGGAGGTGAGAGGATACACAAAGGGAGGTCCCGGTATGAAGAACCCTGCTGGTGCAAAGCTATGGGTGGAACATAG
TTCGTCTCAAGAGTGGAGTGGACGTCTTCCACATGGCGGTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAGTCA
5 TCATCTAGTCTGAAGTGGAAAGAGACACGAACACTCAGAGTGCTCTATGGTGGGGGACTGGCTTGAAAAAAGACCAG
GGGCCTTCTGTATAAAGGTGCTGTGCCCATACACCAGCACTATGATGGAAACCATGGAGCGACTGCAACGTAGGCATGG
GGGAGGATTAGTCAGAGTGCCATTGTCTCGCAACTCCACACATGAGATGTACTGGGTCTCTGGGGCAAAGAGCAACATCA
TAAAAAGTGTGTCCACCACAAGTCAGCTCCTCCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAAATATGAGGAGGA
10 TGTGAACCTCGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAAATCATCGGCAGGCGCATTG
AGAGAATCCGCAATGAACATGCAGAAACATGTTTCTTGATGAAAACCCCATACAGGACATGGGCCTACCATGGGAGC
TACGAAGCCCCACGCAAGGATCAGCGTCTTCCCTCGTGAACGGGGTGTAGACTCCTGTCAAAGCCTTGGGACGTGGT
GACTGGAGTTACAGGAATAGCCATGACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACC
AGGGTGCCAGATCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTTCTCGGCTGTGGAAGGAGCTGGGGAAC
GCAAGCGGCCACGCGTCTGCACCAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGCACTGGGAGCAATATTTGA
15 AGAGGAAAAAGAAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCAAGGTTTTGGGCCCTAGTGGATAGGGAGAGAGA
ACACCACCTGAGAGGAGAGTGTACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGCAAGGAGAGTTCGG
GAAAGCAAAGGTAGCCGCGCCATCTGGTACATGTGGTGGGAGCCAGATTCTGGAGTTTGAAGCCCTTGGATTCTTGA
ACGAGGACCATTGGATGGGAAGAGAAAACCTCAGGAGGTGGAGTGAAGGGTATAGGATTGCAAAGACTTGGATACATTC
TAGAAGAAATGAATCGGGCACCAGGAGGAAAGATGTACGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTT
20 TGATCTGGAGAATGAAGCTCTGATTACCAACCAATGGAGGAAGGGCACAGAACTCTGGCGTTGGCCGTGATTAAATAC
ACATACCAAAACAAAGTGGTGAAGGTTCTCAGACCAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAG
ACCAGAGAGGGAGTGGACAAGTTGTCATTATGCTCTCAACACATTACCAACTTGGTGGTGCAGTTATCCGGAACATG
GAAGCTGAGGAAGTGTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAGTGACCAAGTGGTTGCAGAGC
AATGGATGGGATAGACTCAAACGAATGGCGGTCACTGGAGATGACTGCGTTGTGAAGCCAATCGATGATAGTTTGCAC
25 ATGCCCTCAGGTTCTTGAATGACATGGGAAAAGTTAGGAAAGACACACAGGAGTGGAAACCCTCGACTGGATGGAGCAA
TTGGGAAGAAGTCCCGTTCTGCTCCACCACCTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTCCG
CCACCAAGATGAATGATTGGCCGAGCTCGCTCTCACCAGGGGAGGATGGAGCATCCGGGAGACTGCCTGTCTTGCA
AAATCATATGCGCAGATGTGGCAGCTCCTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGCCATTTGCTCGGCT
GTGCCAGTTGACTGGGTACCAACTGGGAGAACCCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAGGACA
30 TGCTCATGGTGTGGAATAGAGTGTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAATGGACAGA
CATTCCCTATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCAGACCCCGCACCATTGGGCTGAAA
ACATCAAAGACACAGTCAACATGGTGCGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCTACCCCAAGTC
CGCTACTTGGGTGAGGAAGGGTCCACACCCGGAGTGTGTGAAGCACCAATTTAGTGTGTCAGGCCTGCTAGTCAGCCA
CAGTTTGGGGAAGCTGTGCAGCCTGTAACCCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAACGC
35 CATGGCACGGAAGAAGCCATGCTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGAAGCGC
AGGATGGGAAAAAGAGGTGGCGACCTTCCCACCTTCAATCTGGGCTGAACTGGAGACTAGCTGTGAATCTCCAGC
AGAGGGACTAGTGGTTAGAGGAGACCCCGGAAAAACGCAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCA
TGAGTTTCCACCACGCTGGCCGCCAGGCACAGATCGCCGAACAGCGGCGGCCGGTGTGGGGAAATCCATGTTTCT

40 SEQ ID NO: 12
AY632535.2 NC_012532.1 Zika virus strain MR 766, Uganda, complete genome
AGTTGTTGATCTGTGTGAGTCAGACTGCGACAGTTCGAGTCTGAAGCGAGAGCTAACACAGTATCAACAGGTTTAATTT
GGATTTGGAACGAGAGTTTCTGGTCATGAAAAACCCCAAAGAAGAAATCCGGAGGATCCGGATTGTCAATATGCTAAA
45 ACGCGGAGTAGCCCCGTGTAACCCCTTGGGAGGTTTGAAGAGGTTGCCAGCCGGACTTCTGCTGGGTGATGGACCATCA
GAATGGTTTTGGCGATACTAGCCTTTTTGAGATTTACAGCAATCAAGCCATCACTGGGCCTTATCAACAGATGGGGTCCG
TGGGGAAAAAGAGGCTATGGAATAATAAAGAAGTTCAAGAAAGATCTTGCTGCCATGTTGAGAATAATCAATGCTAG
GAAAGAGAGGAAGAGACGTGGCGCAGACACCAGCATCGGAATCATTGGCCTCCTGCTGACTACAGCCATGGCAGCAGA
GATCACTAGACGCGGGAGTGCATACTACATGTACTTGGATAGGAGCGATGCCGGGAAGGCCATTTCTGTTTGTACCAT
50 TGGGAGTGAACAAGTGCCACGTACAGATCATGGACCTCGGGCAGATGTGTGACGCCACCATGAGTTATGAGTGCCTATG
CTGGATGAGGGAGTGAACACAGATGATGTCGATTGCTGGTGAACACGACATCAACTTGGGTTGTGTACGGAACTGTC
ATCAGAAAAAGGTGAGGCACGGCGATCTAGAAGAGCCGTGACGCTCCCTTCTACTCTACAAGGAAGTTGCAACACGCG
GTCGACAGCCTGGTTAGAATCAAGAGAATAACAGCAAGCACTTGATCAAGGTTGAAAAGTGGATATTAGGAAACCCCGG
TTTGCCTAGTGGCCGTTGCCATTGCTGGCTTTTGGGAAGCTCGACGAGCCAAAAAGTCATATACTTGGTCATGATACTG
CTGATTGCCCCGCATACAGTATCAGGTGCATTGGAGTCAGCAATAGAGACTTCGTGGAGGGCATGTCAGGTGGGACCT

GGGTTGATGTTGTCTTGGAACATGGAGGCTGCGTTACCGTGATGGCACAGGACAAGCCAACAGTCGACATAGAGTTGGT
CACGACGACGGTTAGTAACATGGCCGAGGTAAGATCCTATTGCTACGAGGCATCGATATCGGACATGGCTTCGGACAGTC
GTTGCCAACACAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAGAACATTAGTGGACAGA
GGTTGGGGAACCGTTGTGGACTTTTGGCAAAGGGAGCTTGGTGACATGTGCCAAGTTTACGTGTTCTAAGAAGATGA
5 CCGGGAAGAGCATTCAACCGGAAAAATCTGGAGTATCGGATAATGCTATCAGTGCAATGGCTCCAGCATAGCGGGATGAT
TGGATATGAAACTGACGAAGATAGAGCGAAAGTCGAGGTTACGCTAATTCACCAAGAGCGGAAGCAACCTTGGGAGGC
TTTGAAGCTTAGGACTTGACTGTGAACCAAGGACAGGCCTTGACTTTTCAGATCTGTATTACCTGACCATGAACAATAAG
CATTGGTTGGTGACAAAGAGTGGTTTCATGACATCCATTGCTTGGCATGCTGGGGCAGACACCGGAACTCCACTG
GAACAACAAGAGGCATTGGTAGAATCAAGGATGCCACGCCAAGAGGCAAACCGTCGTCGTTCTGGGGAGCCAGGAA
10 GGAGCCGTTACACGGCTCTCGCTGGAGCTTAGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTTCTCTGGCCATT
TGAAATGCCGCTAAAAATGGACAAGCTTAGATTGAAGGGCGTGTCAATTCTTGTGCACTGCGGCATTACATTCACCA
AGGTCCAGCTGAAACACTGCATGGAACAGTCACAGTGGAGGTGCAGTATGCAGGGACAGATGGACCCTGCAAGATCCC
AGTCCAGATGGCGGTGGACATGCAGACCCTGACCCAGTTGGAAGGCTGATAACCGCAACCCCGTGATTACTGAAAGC
ACTGAGAACTCAAAGATGATGTTGGAGCTTGACCCACCATTGGGGATTCTTACATTGTCTATAGGAGTTGGGGACAAGAA
15 AATCACCCACCACTGGCATAGGAGTGGTAGCACCATCGGAAAGGCATTTGAGGCCACTGTGAGAGGCGCCAAGAGAATG
GCAGTCTGGGGGATACAGCCTGGGACTTCGGATCAGTCGGGGGTGTGTTCAACTACTGGGTAAAGGGCATTACACAGA
TTTTTGGAGCAGCCTTCAAATCACTGTTGGAGGAATGTCCTGGTTCTCACAGATCCTCATAGGCACGCTGCTAGTGTGGT
TAGGTTTGAACACAAAGAATGGATCTATCTCCCTCACATGCTTGGCCCTGGGGGGAGTGATGATCTTCTCTCCACGGCTG
TTTCTGCTGACGTGGGGTGTCTAGTGGACTTCTAAAAAAGGAAACGAGATGTGGCACGGGGGTATTCTCTATAATGAT
20 GTTGAAGCCTGGAGGGACCGGTACAAGTACCATCCTGACTCCCCCGCAGATTGGCAGCAGCAGTCAAGCAGGCCTGGG
AAGAGGGGATCTGTGGGATCTCATCCGTTTCAAGAATGGAAAACATCATGTGGAATCAGTAGAAGGGGAGCTCAATGC
TATCTAGAGGAGAATGGAGTTCAACTGACAGTTGTTGTGGGATCTGTAAAAAACCCCATGTGGAGAGGTCCACAAAGAT
TGCCAGTGCCTGTGAATGAGCTGCCCCATGGCTGGAAGGCTGGGGGAAATCGTATTTGTGTTAGGGCGCAAGACCAA
CAACAGTTTGTGTGCGACGGTGACACACTGAAGGAATGTCGCTTGAGCACAGAGCATGGAATGTTTTCTGTGGAGG
25 ATCACGGGTTTGGAGTCTTCCACACCAGTGTCTGGCTTAAGGTGAGAGAAGATTACTCATTAGAATGTGACCCAGCCGTCA
TAGGAACAGCTGTTAAGGGAAGGGAGGCCGCGCACAGTGATCTGGGCTATTGGATTGAAAGTGAAAAGAATGACACAT
GGAGGCTGAAGAGGGCCACCTGATTGAGATGAAAACATGTGAATGGCCAAAGTCTCACACATTGTGGACAGATGGAGT
AGAAGAAAGTGATCTTATCATACCCAAGTCTTTAGCTGGTCCACTCAGCCACCACAACACCAGAGAGGGTTACAGAACCC
AAGTGAAAGGGCCATGGCAGTGAAAGAGCTTGAATCCGGTTTGAAGGAATGTCCAGGCACCAAGGTTTACGTGGAGG
30 AGACATGCGGAACTAGAGGACCATCTCTGAGATCAACTACTGCAAGTGGAAGGGTCATTGAGGAATGGTGCTGTAGGGA
ATGCACAATGCCCCACTATCGTTTCGAGCAAAAGACGGCTGCTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACCA
GAGAGCAACTAGTGAGGTCAATGGTGACAGCGGGTCAACCGATCATATGGACCACTTCTCTTGGAGTGCTTGTGAT
TCTACTCATGGTGACAGGAGGGGTTGAAGAAGAGAATGACCACAAAGATCATATGAGCACATCAATGGCAGTGCTGGTA
GTCATGATCTTGGGAGGATTTTCAATGAGTGACCTGGCCAAGCTTGTGATCCTGATGGGTGCTACTTTCGAGAAATGAA
35 CACTGGAGGAGATGTAGCTCACTTGGCATTGGTAGCGGCATTTAAAGTCAGACCAGCCTTGTGCTCTCTTCAATTTTTCAG
AGCCAATTGGACACCCCGTGAGAGCATGCTGCTAGCCCTGGCTTCTGTCTTCTGCAAACTGCGATCTCTGCTTGAAGG
TGACTTGATGGTCTCATTAAATGGATTTGCTTGGCCTGGTGGCAATTCGAGCAATGGCCGTGCCACGCACTGACAACAT
CGCTCTACCAATCTTGCTGCTCTAACCACTAGCTCGAGGCACACTGCTCTGGCATGGAGAGCGGGCTTGGCTACTT
GTGGAGGGGATCATGCTCTCTCCCTGAAAGGGAAAGGTAGTGTGAAGAAGAACCTGCCATTTGTATGGCCCTGGGATT
40 GACAGCTGTGAGGGTAGTAGACCCTATTAATGTGGTAGGACTACTGTTACTACAAGGAGTGGGAAGCGGAGCTGGCCC
CCTAGTGAAGTTCTACAGCCGTTGGCCTGATATGTGCACTGGCCGAGGGTTTGCCAAGGCAGACATTGAGATGGCTG
GACCCATGGCTGCAGTAGGCTTGCTAATTGTGAGCTATGTTGCTCGGGAAAGAGTGTGGACATGTACATTGAAAGAGCA
GGTGACATCATATGGGAAAAGGACGCGGAAGTCACTGGAACAGTCTCGGCTTGACGTGGCACTGGATGAGAGTGGT
GACTTCTCTTGGTAGAGGAAGATGGTCCACCATGAGAGAGATCATACTCAAGGTGGTCTGATGGCCATCTGTGGCAT
45 GAACCAATAGCTATACCTTTTGTGTCAGGAGCGTGGTATGTGTATGTGAAGACTGGGAAAAGGAGTGGCGCCCTCTGG
GACGTGCTGCTCCAAAGAAAGTGAAGAAAGGAGAGACCACAGATGGAGTGTACAGAGTGTACTCGCAGACTGCTA
GGTTCAACACAGGTTGGAGTGGGAGTCATGCAAGAGGGAGTCTCCACACCATGTGGCACGTTACAAAAGGAGCCGCAC
TGAGGAGCGGTGAGGGAAGACTTGATCCATACTGGGGGGATGTCAAGCAGGACTTGGTGTACATACTGTGGGCCTTGGA
GTTGGATGCAGCTTGGGATGGACTCAGCGAGGTACAGCTTTTGGCCGTACCTCCCGGAGAGAGGGCCAGAAACATTAG
50 ACCCTGCCTGGAATATTCAGACAAAGGACGGGGACACTCGGAGCAGTTGCTCTGGAATACCTGCAGGACCTCAGGAT
CTCCGATCTAGACAAATGTGGAAGAGTGATAGGACTCTATGGCAATGGGGTTGTGATCAAGAAATGGAAGCTATGTTAGT
GCTATAACCCAGGGAAGAGGGAGGAGAGTCCGGTTGAATGTTTGAACCTCGATGCTGAAGAAAGAGCAAGCA
ACTGTCTTGGATCTGCATCCAGGAGCCGGAACCAAGGAGAGTCTTCTGAAATAGTCCGTGAAGCCATAAAAAAGAG
ACTCCGGACAGTGATCTTGGCACCAACTAGGGTTGTCGCTGCTGAGATGGAGGAGGCCTTGAGAGGACTTCCGGTGCCT

TACATGACAACAGCAGTCAACGTCACCCATTCTGGGACAGAAATCGTTGATTGATGTGCCATGCCACTTTCACTTCACGC
TTACTACAACCCATCAGAGTCCCTAATTACAATCTCAACATCATGGATGAAGCCCACTTCACAGACCCCTCAAGTATAGCTG
CAAGAGGATACATATCAACAAGGGTTGAAATGGGCGAGGCGGCTGCCATTTTTATGACTGCCACACCAGGAACCCGT
5 GATGCGTTTCCTGACTCTAACTACCAATCATGGACACAGAAGTGGAAATCCCAGAGAGAGCCTGGAGCTCAGGCTTTGA
TTGGGTGACAGACCATTTCTGGGAAAAACAGTTTGTTCTGTTCCAAGCGTGAGAAAACGGAAATGAAATCGCAGCCTGTCTGA
CAAAGGCTGGAAAGCGGGTCATACAGCTCAGCAGGAAGACTTTTGAGACAGAATTTAGAAAAACAAAAATCAAGAGTG
GGACTTTGTCATAACAACTGACATCTCAGAGATGGGCGCAACTTCAAGGCTGACCGGGTCATAGACTCTAGGAGATGCC
TAAACCAAGTCATACTTGATGGTGAGAGAGTCATCTGGCTGGGCCCATGCCTGTCACGCATGCTAGTGCTGCTCAGAGG
10 AGAGGACGTATAGGCAGGAACCTAACAACCTGGAGATGAGTACATGTATGGAGGTGGGTGTCAGAGACTGATGAA
GGCCATGCACACTGGCTTGAAGCAAGAATGCTTCTTGACAACATCTACCTCCAGGATGGCCTCATAGCCTCGCTCTATCGG
CCTGAGGCCGATAAGGTAGCCGCCATTGAGGGAGAGTTTAAAGCTGAGGACAGAGCAAAGGAAGACCTTCGTGGAATC
ATGAAGAGAGGAGACCTTCCCGTCTGGCTAGCCTATCAGGTTGCATCTGCCGGAATAACTTACACAGACAGAAGATGGTG
CTTTGATGGCACAACCAACACCATAATGGAAGACAGTGACAGCAGAGGTTTGGACAAAGTATGGAGAGAGAGA
GTGCTCAAACCGAGATGGATGGATGCTAGGGTCTGTTCAAGCCATGCGGCCCTGAAGTCGTTCAAAGAATTGCGCGCTGG
15 AAAAAAGAGGAGCGGCTTTGGGAGTAATGGAGGCCCTGGGAACACTGCCAGGACACATGACAGAGAGGTTTCAGGAAGC
CATTGACAACCTCGCCGTGCTCATGCGAGCAGAGACTGGAAGCAGGCCCTTATAAGGCAGCGGCAGCCAACTGCCGGAG
ACCCTAGAGACCATTATGCTCTTAGGTTTGTCTGGGAACAGTTTCACTGGGGATCTTCTCGTCTTGATGCGGAATAAGGGC
ATCGGGAAGATGGGCTTTGGAATGGTAACCTTGGGGCCAGTGCATGGCTCATGTGGCTTTCGGAAATTGAACCAAGCA
GAATTGCATGTGCTCATTGTTGTGTTTTATTACTGGTGGTGCTCATACCCGAGCCAGAGAAGCAAGATCTCCCAAG
20 ATAACCAGATGGCAATTATCATCATGGTGGCAGTGGGCCCTTAGGTTTGATAACTGCAACGAACCTTGGATGGCTGGAA
AGAACAAAAATGACATAGCTCATTAATGGGAAGGAGAGAAGAAGGAGCAACCATGGGATTCTCAATGGACATTGATC
TGCGGCCAGCCTCCGCTGGGCTATCTATGCCGATTGACAACCTCATCACCCAGCTGTCCAACATGCGGTAAACCACTT
CATACAACACTACTCTTAATGGCGATGGCCACACAAGCTGGAGTGCTGTTTGGCATGGGCAAAAGGGATGCCATTTATG
CATGGGGAACCTTGGAGTCCCGCTGCTAATGATGGGTGCTATTACAAATTAACCCCTGACTCTGATAGTAGCTATCATT
25 CTGCTTGTTGGCGCACTACATGTACTTGATCCCAGGCCATAAGCGGCAGCAGCGCTGCTGCCAGAAAAGGACAGCAG
CTGGCATCATGAAGAATCCCGTTTGGATGGAATAGTGGTAAGTACATTGACACAATGACAATAGACCCCAAGGTGGA
GAAGAAGATGGGACAAGTGTACTCATAGCAGTAGCCATCTCCAGTGCTGTGCTGCTGCGGACCGCCTGGGGATGGGG
GAGGCTGGAGCTCTGATCACAGCAGCGACCTCCACCTTGTGGGAAGGCTCTCAAACAAATACTGGAACCTCTCTACAGC
CACCTCACTGTGCAACATCTTCAGAGGAAGCTATCTGGCAGGAGCTTCCCTTATCTATACAGTGACGAGAAACGCTGGCCT
30 GGTTAAGAGACGTGGAGGTGGGACGGGAGAGACTCTGGGAGAGAAGTGGAAAGCTCGTCTGAATCAGATGTCGGCCCT
GGAGTTCTACTCTTATAAAAAGTCAGGTATCACTGAAGTGTGTAGAGAGGAGGCTCGCCGTGCCCTCAAGGATGGAGTG
GCCACAGGAGGACATGCCGTATCCCGGGGAAGTGCAAGATCAGATGGTTGGAGGAGAGAGGATATCTGCAGCCCTAT
GGGAAGGTTGTTGACCTCGGATGTGGCAGAGGGGGCTGGAGCTATTATGCCGCCACCATCCGCAAGGTGCAGGAGGTG
AGAGGATACACAAAGGGAGGTCCCGGTCTGAAGAACCCTGCTGGTGCAAGCTATGGGTGGAACATAGTTCGTCTCA
35 AGAGTGGAGTGGACGTCTCCACATGGCGGCTGAGCCGTGTGACACTCTGCTGTGTGACATAGGTGAGTCATCATCTAGT
CCTGAAGTGGAAAGAGACACGAACACTCAGAGTGCTCTCTATGGTGGGGACTGGCTTAAAAAAGACCAGGGGCCTTCT
GTATAAAGGTGCTGTGCCATACACAGCACTATGATGGAAACCATGGAGCGACTGCAACGTAGGCATGGGGGAGGATT
AGTCAGAGTGCCATTGTGTGCAACTCCACACATGAGATGTAAGTGGGTCTCTGGGGCAAAGAGCAACATCATAAAAAGTG
TGTCACCAACAAGTCAGTCTCTCTGGGACGCATGGATGGCCCCAGGAGGCCAGTGAATATGAGGAGGATGTGAACCT
40 CGGCTCGGGTACACGAGCTGTGGCAAGCTGTGCTGAGGCTCCTAACATGAAATCATCGGCAGGCGCATTGAGAGAATC
CGCAATGAACATGCAGAAACATGGTTTCTTGATGAAAACACCCATACAGGACATGGGCCTACCATGGGAGCTACGAAGC
CCCCACGAAGGATCAGCGTCTTCCCTCGTGAACGGGGTTGTTAGACTCCTGTCAAAGCCTTGGGACGTGTGACTGGAG
TTACAGGAATAGCCATGACTGACACCACACCATACGGCCAACAAAGAGTCTTCAAAGAAAAAGTGGACACCAGGGTGCC
AGATCCCCAAGAAGGCACTCGCCAGGTAATGAACATAGTCTTCTCTGGCTGTGGAAGGAGCTGGGGAACGCAAGCGG
45 CCACGCGTCTGCACCAAGAAGAGTTTATCAACAAGGTGCGCAGCAATGCAGCACTGGGAGCAATATTTGAAGAGGAAA
AAGAATGGAAGACGGCTGTGGAAGCTGTGAATGATCCAAGTTTTGGGCCCTAGTGGATAGGGAGAGAGAACACCACC
TGAGAGGAGAGTGTACAGCTGTGTGTACAACATGATGGGAAAAAGAGAAAAGAAGCAAGGAGAGTTCGGGAAAGCA
AAAGGTAGCCGCGCCATCTGGTACATGTGGTTGGGAGCCAGATTCTGGAGTTTGAAGCCCTTGGATTCTTGAACGAGGA
CCATTGGATGGGAAGAGAAAACCTCAGGAGGTGGAGTGAAGGGTTAGGATTGCAAGACTTGGATACATTCTAGAAGA
50 AATGAATCGGGCACCAGGAGGAAAAGATGTACGCAGATGACACTGCTGGCTGGGACACCCGCATTAGTAAGTTTGATCTG
GAGAATGAAGCTCTGATTACCAACCAATGGAGGAAGGGCAGAGAAGCTGCGGCTTGGCCGTGATTAATACACATACC
AAAAACAAAGTGGTGAAGGTTCTCAGACAGCTGAAGGAGGAAAAACAGTTATGGACATCATTTCAAGACAAGACCAGAG
AGGGAGTGGACAAGTTGCTACTTATGCTCTCAACACATTACCAACTTGGTGGTGCAGCTTATCCGGAACATGGAAGCTG
AGGAAGTGTAGAGATGCAAGACTTATGGTTGTTGAGGAAGCCAGAGAAAGTGACCAGATGGTTGCAGAGCAATGGAT

GGGATAGACTCAAACGAATGGCGGTCACTGGAGATGACTGCGTTGTGAAGCCAATCGATGATAGGTTTGCACATGCCCT
CAGGTTCTTGAATGACATGGGAAAAGTTAGGAAAAGACACACAGGAGTGGAAACCCTCGACTGGATGGAGCAATTGGGA
AGAAGTCCCGTTCTGCTCCCACTTCAACAAGCTGTACCTCAAGGATGGGAGATCCATTGTGGTCCCTTGCCGCCACCA
AGATGAACTGATTGGCCGAGCTCGCTCTCACCAGGGGAGGATGGAGCATCCGGGAGACTGCCTGTCTTGCAAAATCA
5 TATGCGCAGATGTGGCAGCTCCTTTATTTCCACAGAAGAGACCTTCGACTGATGGCTAATGCCATTTGCTCGGCTGTGCCA
GTTGACTGGGTACCAACTGGGAGAACCACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAGGACATGCTCA
TGGTGTGGAATAGAGTGTGGATTGAGGAGAACGACCATATGGAGGACAAGACTCCTGTAACAAAATGGACAGACATTCC
CTATCTAGGAAAAAGGGAGGACTTATGGTGTGGATCCCTTATAGGGCACAGACCCCGCACCCTTGGGCTGAAAAATCA
AAGACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGACTATCTATCCACCAAGTCCGCTAC
10 TTGGGTGAGGAAGGGTCCACACCCGAGTGTGTGAAGCACCAATTTAGTGTGTCAGGCTGCTAGTCAGCCACAGTTT
GGGGAAGCTGTGCAGCTGTAAACCCCCAGGAGAAGCTGGGAAACCAAGCTCATAGTCAGGCCGAGAAGCCATGG
CACGGAAGAAGCCATGCTGCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAAAGCGCAGGAT
GGGAAAAGAAGTGGCGACCTTCCCCACCTTCAATCTGGGGCTGAAGTGGAGACTAGCTGTGAATCTCCAGCAGAGG
GACTAGTGGTTAGAGGAGACCCCGGAAAACGCAAAACAGCATATTGACGTGGGAAAGACCAGAGACTCCATGAGTTT
15 CCACCACGCTGGCCGCCAGGCACAGATCGCCGAACCTCGCGGCCGGTGTGGGAAATCCATGGTTTCT

SEQ ID NO: 13

KJ776791.1, Zika virus strain H/PF/2013 polyprotein gene, complete cds

AGTATCAACAGGTTTTATTTGGATTGGAAACGAGAGTTTCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTTC
20 CGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTGAGCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCT
GCTGGGTCATGGGCCATCAGGATGGTCTTGGCGATTCTAGCCTTTTGGATTACGGCAATCAAGCCATCACTGGGTCT
CATCAATAGATGGGGTTCAGTGGGGAAAAAGAGGCTATGGAAATAATAAAGAAGTTCAAGAAAGATCTGGTGCCTATG
CTGGAATATCAATGCTAGGAAGGAGAAGAAGAGACGAGGCGCAGATACTAGTGTGGAATTGTGGCCTCTGTGA
CCACAGCTATGGCAGCGGAGGTCACTAGACGTGGGAGTGCATACTATGTACTTGGACAGAAACGACGCTGGGAGGC
25 CATATCTTTTCAACACATTGGGGATGAATAAGTGTTATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCAT
GAGCTATGAATGCCCTATGCTGGATGAGGGGGTGAACACAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTGG
GTTGTGTACGGAACCTGCCATCACAAAAAGGTGAAGCACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCAC
TAGGAAGCTGCAACGCGGTGCAACCTGGTTGGAATCAAGAGAATACACAAAGCACTTGATTAGAGTCAAAAAATTGG
ATATTAGGAACCTGGCTTGCCTTAGCAGCAGCTGCCATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCAT
30 ATACTTGGTCATGATACTGCTGATTGCCCCGGCATAACAGCATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAG
GTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGAACATGGAGGTTGTGTACCGTAATGGCACAGGACAAACCGACT
GTCGACATAGAGCTGTTACAACAACAGTCAGCAACATGGCGGAGGTAAAGTCTACTGCTATGAGGCATCAATATCGG
ACATGGCTTCGGACAGCCGCTGCCAACACAAAGGTGAAGCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAA
AGAACGTTAGTGACAGAGGCTGGGGAATGGATGTGGACTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTG
35 CATGCTCAAGAAATGACCGGAAGAGCATCCAGCCAGAGAATCTGGAGTACCGGATAATGCTGTCAAGTTATGGCTCC
CAGCACAGTGGGATGATCGTTAATGACACAGGACATGAACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATT
CACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAGCCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCA
GATTTGTATTACTTGAATGAATAACAAGCACTGGTTGGTTCAAGGAGTGGTTCCACGACATTCCATTACCTTGGCAC
GCTGGGGCAGACACCGGAACCTCCACTGGAACAACAAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGG
40 CAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAGTTACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATG
GTGCAAAGGGAAGGCTGCTCTGCCCCACTTGAAATGTCGCTGAAAATGGATAAACTAGATTGAAGGGCGTGCATAC
TCCTTGTGTACCGCAGCGTTACATTACCAAGATCCCGGCTGAAACACTGCACGGGACAGTCACAGTGGAAGGTACAGTA
CGCAGGGACAGATGGACCTTGAAGGTTCCAGCTCAGATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTG
ATAACCGTAACCCGTAATCACTGAAAGCACTGAGAATCTAAGATGATGCTGGAACCTTGATCCACCATTTGGGGACTCT
45 TACATTGTCATAGGAGTCGGGGAGAAGAAGATCACCCACCACTGGCACAGGAGTGGCAGCACCATTGGAAAAGCATTTG
AAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTTGGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCT
CAACTCATTGGGCAAGGGATCCATCAAAATTTTGGAGCAGCTTTCAAATCATTGTTGGAGGAATGTCCTGGTTCTCACA
AATTCTCATTGGAACGTTGCTGATGTGGTTGGGTCTGAACACAAAGAATGGATCTATTTCCCTTATGTGCTTGGCCTTAGG
GGGAGTGTTGATCTTCTATCCACAGCTGTCTGCTGATGTGGGGTGTCTGGTGGACTTCTCAAAGAAGGAGACGAGAT
50 GCGGTACAGGGGTGTTCTGTATAACGACGTTGAAGCCTGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGA
TTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGTATCTGTGGGATCTCCTCTGTTTCAAGAATGAAAAACATCATGTG
GAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAAAGAGAATGGAGTTCAACTGACGGTCTGTGGGATCTGTAAAA
AACCCCATGTGGAGAGGTCCACAGAGATTGCCGTGCTGTGAACGAGCTGCCCCACGGCTGGAAGGCTTGGGGAAAT
CGTACTTCGTAGAGCAGCAAGACAAATAACAGCTTTGTCGTGGATGGTGACACACTGAAGGAATGCCCACTCAAACAT

AGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGTTCTGGGGTATTTCACTAGTGTCTGGCTCAAGGTTAGAGAAGA
TTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAGCTGTTAAGGGAAAGGAGGCTGTACACAGTGTCTAGGCTACT
GGATTGAGAGTGAGAAGAATGACACATGGAGGCTGAAGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAA
AGTCCCACACATTGTGGACAGATGGAATAGAAGAGAGTGTCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCAT
5 CACAATACCAGAGAGGGCTACAGGACCCAAATGAAAGGGCCATGGCACAGTGAAGAGCTTGAAATTCGGTTTGAGGAAT
GCCCAGGCACTAAGTCCACGTGGAGGAAACATGTGGAACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAG
GGTGATCGAGGAATGGTGTGCAGGGAGTGCACAATGCCCCACTGTCGTTCCGGGCTAAAGATGGCTGTTGGTATGGA
ATGGAGATAAGGCCAGGAAAGAACAGAAAGTAACCTAGTAAGGTCAATGGTACTGCAGGATCAACTGATCAGATGG
ATCACTTCTCCCTTGAGTGTCTGTGATTCTGCTCATGGTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATC
10 ATAAGCACATCGATGGCAGTGTCTGGTAGCTATGATCTGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGCAATTTT
GATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGAGATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGA
CCAGCGTTGTCTGGTATCTTTTCATCTTCAGAGCTAATTGGACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTT
TGCAAAGTGCATCTCCGCTTGGAAGGCGACCTGATGGTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAG
CGATGGTTGTTCCACGCACTGATAACATCACCTTGGCAATCCTGGCTGCTCTGACACCACTGGCCCGGGCACACTGCTTG
15 TGGCGTGGAGAGCAGGCTTGTACTTGCAGGGGGTTTATGCTCTCTCTGAAGGGAAAAGGCAGTGTGAAGAAGAA
CTTACCATTGTCTATGGCCTGGGACTAACCGCTGTGAGGCTGGTGCACCCCATCAACGTGGTGGGACTGCTGTTGCTCAC
AAGGAGTGGGAAGCGGAGCTGGCCCTAGCGAAGTACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTC
GCCAAGGCAGATATAGAGATGGCTGGGCCATGGCCGCGGTGGTCTGCTAATTGTCAAGTACGTGGTCTCAGGAAAGA
GTGTGGACATGTACATTGAAAGAGCAGGTGACATCACATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCT
20 CGATGTGGCGCTAGATGAGAGTGGTGATTTCTCCCTGGTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAG
GTGGTCTGATGACCATCTGTGGCATGAACCAATAGCCATACCTTTGCAGCTGGAGCGTGGTACGTATACGTGAAGAC
TGGAAGAAAGGAGTGGTGTCTATGGGATGTGCTGTCTCCAAGGAAGTAAAAAGGGGGAGACCACAGATGGAGTGTA
CAGAGTAATGACTCGTAGACTGTAGGTTCAACACAAGTTGGAGTGGGAGTTATGCAAGAGGGGGCTTTTACACTATGT
GGCAGCTCAGAAAAGGATCCGCGCTGAGAAGCGGTGAAGGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATC
25 TGGTGTCTACTGTGGTCCATGGAAGCTAGATGCCGCTGGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCC
CGGAGAGAGAGCGAGGAACATCCAGACTCTGCCGGAATATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCT
GGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTAGACAAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTC
GTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCAAGGGAGGAGGGAGGAAGAGACTCTGTTGAGTGTCTCGAGC
CTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTTGATCTCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAA
30 ATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGATCTTAGCTCCAACAGGGTTGTGCTGCTGAAATGGAGGA
AGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCAGTCAATGTCAACCACTCTGGAACAGAAATCGTCGACTTAAT
GTGCCATGCCACCTTCACTTACGTCTACTACAGCCAATCAGAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCAC
TTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTTCAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCAT
GACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGACTCCAACCTACCAATTATGGACACCGAAGTGAAGTCCAG
35 AGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATCATTCTGGAAAAACAGTTTGGTTTGTTCAGAGCTGAGGAAC
GGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAAAACGGGTATACAGCTCAGCAGAAAGACTTTTGAGACAGAGT
TCCAGAAAAACAAACATCAAGAGTGGGACTTTGTCTGTACAAGTACATTTTCAAGATGGGCGCCAACTTTAAGCTGAC
CGTGTCTAGATTCCAGGAGATGCCTAAAGCCGGTACATCTTGATGGCGAGAGAGTCACTTGGCTGGACCCATGCCTGT
CACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATAGGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGA
40 GGTGGGTGCGCAGAGACTGACGAAGACCATGCACACTGGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCAAGA
TGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACAAAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAG
CAAAGGAAGACCTTTGTGGAACCTCATGAAAAGAGGAGATCTTCTGTTTGGCTGGCCTATCAGGTTGCATCTGCCGGAAT
AACCTACACAGATAGAAGATGGTGTCTTGTGGCACGACCAACAACACCATAATGGAAGACAGTGTGCCGGCAGAGGTG
TGGACCAGACACGGAGAGAAAAGAGTGTCAAACCGAGGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGA
45 AGTCATTCAAGGAGTTTCCGCTGGGAAAAGAGGAGCGGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACA
CATGACAGAGAGATTCCAGGAAGCCATTGACAACCTCGTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCTTACAAA
GCCGCGGGCGCCCAATTGCCGAGACCTAGAGACCATATGCTTTTGGGGTGTGCTGGGAACAGTCTCGCTGGGAATCTT
TTCTGTCTTGATGAGGAACAAGGGCATAGGGAAGATGGGCTTTGGAATGGTGAATCTTGGGGCCAGCGCATGGCTCATG
TGGCTCTCGGAAATTGAGCCAGCCAGAATTGCATGTGTCCTATTGTTGTCTTATTGCTGGTGGTGTCTACCTGAG
50 CCAGAAAAGCAAAGATCTCCCAGGACAACCAATGGCAATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTAC
CGCAATGAACTCGATGGTGGAGAGAACAAGATGACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAAC
CATAGGATTCTCAATGGACATTGACCTGCGGCCAGCTCAGCTTGGGCCATCTATGCTGCTTGACAACCTTCAATACCCCA
GCCGTCCAACATGCAGTGACCACTTCATAACAACACTACTCTTAATGGCGATGGCCACGCAAGCTGGAGTGTGTTTGGT
ATGGGCAAAGGGATGCCATTCTACGCATGGGACTTTGGAGTCCCGCTGCTAATGATAGGTTGCTACTACAATTAACACC

CCTGACCCTAATAGTGGCCATCATTTTGTCTGCTGGCGCACTACATGTAAGTCCAGGGCTGCAGGCAGCAGCTGCGC
 GTGCTGCCAGAAGAGAACGGCAGCTGGCATCATGAAGAACCCTGTTGTGGATGGAATAGTGGTGAATGACATTGACAC
 AATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACAGGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGT
 CGCGGACCGCTGGGGGTGGGGGAGGCTGGGGCCCTGATCACAGCGGCAACTTCCACTTTGTGGGAAGGCTCTCCGA
 5 ACAAGTACTGGAATCCTCTACAGCCACTTCACTGTGTAAACATTTTATAGGGGAAGTTACTTGGTGGAGCTTCTAATCTA
 CACAGTAACAAGAACGCTGGCTTGGTCAAGAGACGTGGGGGTGGAACAGGAGAGACCCTGGGAGAGAAATGGAAGG
 CCCGCTTGAACAGATGTCGGCCCTGGAGTTCTACTCTACAAAAGTCAGGCATCACCGAGGTGTGCAGAGAAGAGGCC
 CGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCATGCTGTGTCCCGAGGAAGTGCAAAGCTGAGATGGTTGGTG
 GAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATCTTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCA
 10 CCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGGAGGCCCTGGTTCATGAAGAACCCATGTTGGTGCAAAGCTA
 TGGGTGGAACATAGTCCGTCTTAAGAGTGGGTGGACGTCTTTCATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTG
 ACATAGGTGAGTCATCATCTAGTCTGAAGTGGAGAAGCACGGACGCTCAGAGTCCTCTCATGGTGGGGGATTGGCTT
 GAAAAAGACCAGGAGCCTTTGTATAAAAGTGTGTGCCATACACCAGCACTATGATGGAACCTGGAGCGACTGCA
 GCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTCCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCG
 15 AAAAGCAACACCATAAAAAGTGTGTCCACCACGAGCCAGCTCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGA
 AATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGGCTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCAT
 TGGTAACCGCATTGAAAGGATCCGAGTGAGCACGCGGAAACGTGGTCTTTGACGAGAACCCCATATAGGACATGG
 GCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAGCGTCTCTAATAAACGGGGTTGTGAGGCTCTGTCAAA
 ACCCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATGACCGACACCACACCGTATGGTCAGCAAAGAGTTTCAAG
 20 GAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGCACTCGTCAGGTTATGAGCATGGTCTCTTCTGGTTGTGGA
 AAGAGCTAGGCAAACACAACGGCCACGAGTCTGTACCAAAGAAGAGTTTCATCAACAAGGTTCTGATGCAATGCAGCATT
 AGGGGCAATATTTGAAGAGGAAAAAGAGTGGAAAGCTGCAAGTGGAAAGCTGTGAACGATCCAAGGTTCTGGGCTCTAGT
 GGACAAGGAAAGAGACACCACTGAGAGGAGAGTGCCAGAGTTGTGTGTACAACATGATGGGAAAAAGAGAAAAAGA
 AACAAAGGGGAATTTGAAAAGGCCAAGGGCAGCCGCGCATCTGGTATATGTGGCTAGGGGCTAGATTTCTAGAGTTGGA
 25 AGCCCTTGGATTCTTGAACGAGGATCACTGGATGGGAGAGAGAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACA
 AAGACTCGGATATGTCCTAGAAGAGATGAGTCGCATACCAGGAGGAAGGATGTATGCAGATGACACTGCTGGCTGGGAC
 ACCCGCATCAGCAGGTTTGTCTGGAGAATGAAGCTCTAATACCAACCAATGGAGAAAGGGCACAGGGCCTTGGCAT
 TGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGTCCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGA
 CATTATTTGAGACAAGACCAAGGGGGAGCGGACAAGTTGCACTTACGCTCTTAACACATTTACCAACCTAGTGGTGC
 30 AACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAAGACTTGTGGCTGCTGCGGAGGTGAGAGAAAGTAC
 CAAGTGGTTGAGAGCAACGGATGGGATAGGCTCAACGAATGGCAGTCAGTGGAGATGATTGCGTTGTGAAGCCAATT
 GATGATAGGTTTGCATATGCCCTCAGGTTCTTGAATGATATGGGAAAAGTTAGGAAGGACACACAAGAGTGGAAACCTT
 CAAGTGGATGGGACAACTGGGAAGAAGTTCCGTTTTGCTCCCACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCC
 ATTGTGGTTCCCTGCCGCCACCAAGATGAAGTATTGGCCGGGCGCGTCTCTCAGGGGCGGGATGGAGCATCCGGG
 35 AGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTCCTTATTTCCACAGAAGGGACCTCCGACTGATGGCCA
 ATGCCATTTGTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGGAGAACTACCTGGTCAATCCATGGAAGGGGAGAAATGG
 ATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGATTGAGGAGAACGACCACATGGAAGACAAGACCCCA
 GTTACGAAATGGACAGACATTCCCTATTTGGGAAAAAGGGAAGACTTGTGGTGTGGATCTCTCATAGGGCACAGACCGC
 GCACCACTGGGCTGAGAACATTAAAAACACAGTCAACATGGTGCAGGATCATAGGTGATGAAGAAAAGTACATGGA
 40 CTACCTATCCACCAAGTTGCTACTTGGGTGAAGAAGGGTCTACACCTGGAGTGCTGAAGCACCAATCTTAGTGTGTC
 AGGCCTGCTAGTCAGCCACAGCTTGGGGAAAGCTGTGCAGCCTGTGACCCCCAGGAGAAGCTGGGAAACCAAGCCTA
 TAGTCAGGCCGAGAACCCATGGCACGGAAGAAGCCATGTGCCTGTGAGCCCTCAGAGGACACTGAGTCAAAAAACC
 CCACGCGCTTGGAGGCGCAGGATGGGAAAAAGGTGGCGACCTTCCCACTTCAATCTGGGGCTGAACTGGAGAT
 45 CAGCTGTGGATCTCCAGAAGAGGGACTAGTGGTTAGAGGAG

In some embodiments, the Zika virus has a RNA genome corresponding to the DNA
 sequence provided by the nucleic acid sequence of any one of SEQ ID NOs: 2-13 or 72. In
 some embodiments, the Zika virus has a variant genome that is at least 80%, 81%, 82%, 83%,
 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
 50 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-13 or 72.

Provided below are amino acid sequences of the E-proteins of Zika strains that may be used in the methods, compositions, and/or vaccines described herein.

- 5 SEQ ID NO: 14
isol-ARB15076.AHF49784.1.Central_African_Republic/291-788 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDENRAKVEVT
PNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAK
10 RQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLFSGLKCRKMDKRLKGVSYSLCTAAFTFTKVP AETLHGTVTVEVQYAG
TDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAFEATVRG
AKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNTKNGSISLTCLALGGVMIFLSTA
VSA
- 15 SEQ ID NO: 15
isol-IbH_30656.AEN75265.1.Nigeria/291-788 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDENRAKVEVT
PNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAHAK
20 RQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLFSGLKCRKMDKRLKGVSYSLCTAAFTFTKVP AETLHGTVTVEVQYAG
RDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAFEATVRG
AKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNTKNGSISLTCLALGGVMIFLSTA
VSA
- 25 SEQ ID NO: 16
ArB1362.AHL43500.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDXXXXXXNR
AEVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
30 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLFSGLKCRKMDKRLKGVSYSLCTAAFTFTKVP AETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNTKNGSISLTCLALGGV
MIFLSTAVSA
- 35 SEQ ID NO: 17
ArD128000.AHL43502.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMXXXXXGHETDEN
RAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHRLVRKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
40 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLFSGLKCRKMDKRLKGVSYSLCTAAFTFTKVP AETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNTKNGSISLTCLALGG
VMIFLSTAVSA
- 45 SEQ ID NO: 18
ArD158095.AHL43505.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDIGHETDENR
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
50 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLFSGLKCRKMDKRLKGVSYSLCTAAFTFTKVP AETLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAF

EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 19

- 5 ArD158084.AHL43504.1.-/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFE GMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTV
10 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 20

- 15 isol-ARB13565.AHF49783.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFE GMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTV
20 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 21

- 25 isol-ARB7701.AHF49785.1.Central_African_Republic/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFE GMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D I G H E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTV
30 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGVHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 22

- 35 isol-ArD_41519.AEN75266.1.Senegal/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFE GMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVE
FKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVT
40 VEVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRS GSTIGKA
FEATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGG
VMIFLSTAVSA

SEQ ID NO: 23

- 45 MR766-NIID.BAP47441.1.Uganda/291-794 Flavivirus envelope glycoprotein E.
IRCI GVS NRDFE GMSGGTWVDV VLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F T C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M T V N D I G Y E T D E N R
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGKLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTV
50 EVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRS GSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
MIFLSTAVSA

SEQ ID NO: 24

- LC002520.1/326-829 Zika virus genomic RNA, strain: MR766-NIID, Uganda, Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 5 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVT
 EVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNLTNGSISLTCLALGGV
 MIFLSTAVSA
- 10 SEQ ID NO: 25
 isol-MR_766.AEN75263.1.Uganda/291-794 Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 15 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVT
 EVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNLTNGSISLTCLALGGV
 MIFLSTAVSA
- 20 SEQ ID NO: 26
 ArD7117.AHL43501.1.-/291-794 Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 25 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVT
 VEVQYAGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNLTNGSISLTCLALGGV
 VMIFLSTAVSA
- 30 SEQ ID NO: 27
 AY632535.2/326-825 NC_012532.1 Zika virus strain MR 766, Uganda, Flavivirus envelope glycoprotein E.
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 VTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH
 35 AKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQY
 AGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNLTNGSISLTCLALGGV
 STAVSA
- 40 SEQ ID NO: 28
 MR_766.AAV34151.1.Uganda/291-790 Flavivirus envelope glycoprotein E. |Q32ZE1|Q32ZE1_9FL
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 VTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH
 45 AKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGKGLFSGHLKCRKMDKRLKGVSYSLCTAAFTFTKVPAETLHGTVTVEVQY
 AGTDGPCKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSGSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGVFNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWGLNLTNGSISLTCLALGGV
 STAVSA
- 50 SEQ ID NO: 29
 MR_766.YP_009227198.1.Uganda/1-500 envelope protein E [Zika virus]
 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
 DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFTCSKKMTGKSIQPENLEYRIMLSVHGSQHSGMTVNDIGYETDENR
 VTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEFKDAH

AKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQY
AGTDGPKIPVQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSSTIGKAFATV
RGAKRMAVLGDTAWDFGSVGGVFNLSGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLTCLALGGVMIFL
STAVSA

5

SEQ ID NO: 30

KU681081.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/THA/2014/SV0127- 14, Thailand, Flavivirus
envelope glycoprotein E.

10 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPKVPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEEKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNLSGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
15 VLIFLSTAVSA

SEQ ID NO: 31

isol-Zika_virus%H.sapiens-tc%THA%2014%SV0127-_14.AMD61710.1.Thailand/291-794 Flavivirus envelope
glycoprotein E.

20 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTV
EVQYAGTDGPKVPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEEKITHHWHRSSTIGKAF
25 EATVRGAKRMAVLGDTAWDFGSVGGVFNLSGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 32

CK-ISL_2014.AIC06934.1.Cook_Islands/1-504 Flavivirus envelope glycoprotein E. (Fragment) OS=Zika virus
GN=E PE=4 SV=1

30 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTV
35 EVQYAGTDGPKVPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEEKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 33

Natal_RGN.AMB18850.1.Brazil:_Rio_Grande_do_Norte,_Natal/291-794 Flavivirus envelope glycoprotein E.]

40 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTV
45 EVQYAGTDGPKVPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEEKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 34

isol-Si323.AMC37200.1.Colombia/1-504 Flavivirus envelope glycoprotein E.

50 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRFLSGHLKCRCLKMDKRLKGVSYSLCTAAFTFTKIPAETLHGTVTV

EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

5 SEQ ID NO: 35

KU707826.1/317-820 Zika virus isolate SSABR1, Brazil, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLG GFGSLGLDCEPRTGLD FSDLYLT MN NKH W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
10 KDAHAKRQT V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

15 SEQ ID NO: 36

KU509998.1/326-829 Zika virus strain Haiti/1225/2014, Haiti, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLG GFGSLGLDCEPRTGLD FSDLYLT MN NKH W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
20 KDAHAKRQT V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

25 SEQ ID NO: 37

isol-GDZ16001.AML82110.1.China/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLG GFGSLGLDCEPRTGLD FSDLYLT MN NKH W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
30 KDAHAKRQT V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

35 SEQ ID NO: 38

BeH819015.AMA12085.1.Brazil/291-794 Flavivirus envelope glycoprotein E.]

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLG GFGSLGLDCEPRTGLD FSDLYLT MN NKH W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
40 KDAHAKRQT V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

45 SEQ ID NO: 39

MRS_OPY_Martinique_PaRi_2015.AMC33116.1.Martinique/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMAQDKPTVDIELVTTT VSNMAEVR SYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVD R G W G N G C G L F G K G S L V T C A K F A C S K K M T G K S I Q P E N L E Y R I M L S V H G S Q H S G M I V N D T G H E T D E N
RAKVEITPNSPRAEATLG GFGSLGLDCEPRTGLD FSDLYLT MN NKH W L V H K E W F H D I P L P W H A G A D T G T P H W N N K E A L V E F
50 KDAHAKRQT V V V L G S Q E G A V H T A L A G A L E A E M D G A K G R L S S G H L K C R L K M D K L R L K G V S Y S L C T A A F T F T K I P A E T L H G T V T V
EVQYAGTDGPKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 40

KU501215.1/308-811 Zika virus strain PRVABC59, Puerto Rico, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMA QDKPTVDIELVTTT VSNMAE VRSYCYEASISDMASDSRCPTQGEAYL
 5 DKQSDTQYVCKRTLVD R G WNGCGLFGK GSLVTC AKFACSKKMTGKSIQ PENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 KDAHAKRQT VVV LGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRS GSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
 VLIFLSTAVSA

SEQ ID NO: 41

Haiti%1225%2014.AMB37295.1.Haiti/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMA QDKPTVDIELVTTT VSNMAE VRSYCYEASISDMASDSRCPTQGEAYL
 15 DKQSDTQYVCKRTLVD R G WNGCGLFGK GSLVTC AKFACSKKMTGKSIQ PENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 KDAHAKRQT VVV LGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRS GSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
 VLIFLSTAVSA

SEQ ID NO: 42

KU527068.1/308-811 Zika virus strain Natal RGN, Brazil: Rio Grande do Norte, Natal, Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMA QDKPTVDIELVTTT VSNMAE VRSYCYEASISDMASDSRCPTQGEAYL
 25 DKQSDTQYVCKRTLVD R G WNGCGLFGK GSLVTC AKFACSKKMTGKSIQ PENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 KDAHAKRQT VVV LGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRS GSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
 30 VLIFLSTAVSA

SEQ ID NO: 43

isol-Z1106027.ALX35662.1.Suriname/5-508 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMA QDKPTVDIELVTTT VSNMAE VRSYCYEASISDMASDSRCPTQGEAYL
 35 DKQSDTQYVCKRTLVD R G WNGCGLFGK GSLVTC AKFACSKKMTGKSIQ PENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 KDAHAKRQT VVV LGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRS GSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
 40 VLIFLSTAVSA

SEQ ID NO: 44

isol-FLR.AMM39804.1.Colombia:_Barranquilla/291-794 Flavivirus envelope glycoprotein E.

IRCI GVS NRDFE GMSG GTWVDV VLEHGG CVTVMA QDKPTVDIELVTTT VSNMAE VRSYCYEASISDMASDSRCPTQGEAYL
 45 DKQSDTQYVCKRTLVD R G WNGCGLFGK GSLVTC AKFACSKKMTGKSIQ PENLEYRIMLSVHGSQHSGMIVNDTGHETDEN
 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
 KDAHAKRQT VVV LGSQEGAVHTALAGALEAEMDGAKRLSSGHLKCR LKMDKRLKGVSYSLCTAAFTFTKIPAE TLHGTVTV
 EVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRS GSTIGKAF
 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKIHQIFGA AFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
 50 VLIFLSTAVSA

SEQ ID NO: 45

PLCal_ZV_isol-From_Vero_E6_cells.AHL37808.1.Canada/254-757 Flavivirus envelope glycoprotein E.

- 5 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA
- 10 SEQ ID NO: 46
BeH818995.AMA12084.1.Brazil/291-794 Flavivirus envelope glycoprotein E. [Zika virus].
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
15 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA
- 20 SEQ ID NO: 47
H/PF/2013.AHZ13508.1.French_Polynesia/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
25 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA
- 30 SEQ ID NO: 48
PRVABC59.AMC13911.1.Puerto_Rico/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
35 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA
- 40 SEQ ID NO: 49
KU321639.1/326-829 Zika virus strain ZikaSPH2015, Brazil, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
45 EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA
- 50 SEQ ID NO: 50
ZikaSPH2015.ALU33341.1.Brazil/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT

EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

5 SEQ ID NO: 51
103344.AMC13912.1.Guatemala/291-794 polyprotein [Zika virus]. 103344.AMC13912.1.Guatemala Flavivirus
envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEIRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
10 RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

15 SEQ ID NO: 52
isol-Brazil-ZKV2015.AMD16557.1.Brazil/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
20 RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGTQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

25 SEQ ID NO: 53
KU497555.1/308-811 Zika virus isolate Brazil-ZKV2015, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
30 RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGTQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

35 SEQ ID NO: 54
isol-ZJ03.AMM39806.1.China/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
40 RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGARRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

45 SEQ ID NO: 55
isol-FSS13025.AFD30972.1.Cambodia/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKACSKKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
50 RAKVEITPNSPRAEATLGFGSLGLDCEPRTGLDFSDLYLTMMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 56

isol-Z1106032.ALX35660.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

5 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGFLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
10 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNKNKSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 57

isol-Z1106033.ALX35659.1.Suriname/291-794 Flavivirus envelope glycoprotein E. [Zika virus]

15 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGFLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
20 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNKNKSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 58

isol-BeH828305.AMK49165.1.Brazil/291-794 Flavivirus envelope glycoprotein E.

25 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGFLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTV
EVQYAGTDGPCKVPAQMAVDTQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
30 ATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNKSISLMCLALGGV
LIFLSTAVSA

SEQ ID NO: 59

isol-GD01.AMK79468.1.China/291-794 Flavivirus envelope glycoprotein E.

35 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGFLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQMIVNGTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTV
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
40 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNKSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 60

isol-Z1106031.ALX35661.1.Suriname/291-794 Flavivirus envelope glycoprotein E.

45 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGFLFGKGSVLTCAKFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVTV
EVQYAGTDGPCKVLAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSGSTIGKAF
50 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNKSISLMCLALGG
VLIFLSTAVSA

SEQ ID NO: 61

ACD75819.1.Micronesia/291-794 Flavivirus envelope glycoprotein E.

- 5 IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPAVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA
- 10 SEQ ID NO: 62
KU681082.3/308-811 Zika virus isolate Zika virus/H.sapiens-tc/PHL/2012/CPC-0740, Philippines, Flavivirus
envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
15 KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA
- 20 SEQ ID NO: 63
isol-Zika_virus%H.sapiens-tc%PHL%2012%CPC-0740.AMD61711.1.Philippines/291-794 Flavivirus envelope
glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
25 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA
- 30 SEQ ID NO: 64
isol-BeH823339.AMK49164.2.Brazil/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDIASDSRCPTQGEAYL
KQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDTGHETDEN
35 AKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
DAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
VQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGEKKITHHWHRSSTIGKAF
ATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCLALGGV
LIFLSTAVSA
- 40 SEQ ID NO: 65
isol-P6-740.AEN75264.1.Malaysia/291-794 Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMIVNDXGHETDEN
45 RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVHKEWFHDIPLPWHAGADTGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAAGRLSSGHLKCRKMDKRLKGVSYSLCTAAFTFTKIPAEHLHGTVT
EVQYAGTDGPCKVPAQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFGDSYIVIGVGDKKITHHWHRSSTIGKAF
EATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCLALGGV
LIFLSTAVSA
- 50 SEQ ID NO: 66
KU744693.1/326-829 Zika virus isolate VE_Ganxian, China, Flavivirus envelope glycoprotein E.
IRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTTSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDRGWNGCGLFGKGSVLTCAKFAFACSKKMTGKSIQPENLEYRIMLSVHGSQHSQSGMLVNDTGHETDEN

RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAQKRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAEVTDGTVTV
EGQYGGTDGPKVPAPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIIGAFAKSLFGGMSWFSQILIGTLLMWLGLNLTNGSISLMCLALGG
5 VLIFLSTAVSG

SEQ ID NO: 67

isol-VE_Ganxian.AMK79469.1.China/291-794 Flavivirus envelope glycoprotein E.

10 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTAMADKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFAKSKMTGKSIQENLEYRIMLSVHGSQHSQSGMLVNDTGHETDEN
RAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLAHKEWFHDIPLPWHAGAATGTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAQKRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAEVTDGTVTV
EGQYGGTDGPKVPAPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGEKKITHHWHRSGSTIGKAF
15 EATVRGAKRMAVLGDTAWDFGSVGGALNSLGKGIHQIIGAFAKSLFGGMSWFSQILIGTLLMWLGLNLTNGSISLMCLALGG
VLIFLSTAVSG

SEQ ID NO: 68

ArD157995.AHL43503.1.-/291-794 Flavivirus envelope glycoprotein E.

20 ISCIGVSNRDLVEGMSGGTWVDVLEHGGCVTEMAQDKPTVDIELVTMTVSNMAEVRSYCYEASLSMASASRCPTQGEPSL
DKQSDTQSVCKRTLVDGRWGNGCGIFGKGSVLTCSKFTCKKMPGKSIQENLEYRIMLPVHGSQHSQSGMIVNDIGHETDENR
AKVEVTPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLAHKEWFHDIPLPWHAGADTGTTPHWNNKEALVEF
KDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAQKRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAEVTDGTVTV
EVQSAGTDGPKVPAPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNLSLGKGIHQIFGAFAKSLFGGMSWFSQILIGTLLVWLGLNLTNGSISLTCLALGGV
25 MIFLSTAVSA

SEQ ID NO: 69

MR_766.ABI54475.1.Uganda/291-788 Flavivirus envelope glycoprotein E.

30 IRCIGVSNRDFVEGMSGGTWVDVLEHGGCVTMAQDKPTVDIELVTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYL
DKQSDTQYVCKRTLVDGRWGNGCGLFGKGSVLTCAKFTCSKMTGKSIQENLEYRIMLSVHGSQHSQSGMIVNDENRAKVEVT
PNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKHVLAHKEWFHDIPLPWHAGADTGTTPHWNNKEALVEFKDAHAK
RQTVVVLGSQEGAVHTALAGALEAEMDGAQKRLSSGHLKRLKMDKRLKGVSYSLCTAAFTFTKIPAEVTDGTVTV
TDGPKVPAPQMAVDMQTLTPVGRITANPVITESTENSKMMLELDPFPGDSYIVIGVGDKKITHHWHRSGSTIGKAF
EATVRGAKRMAVLGDTAWDFGSVGGVFNLSLGKGIHQIFGAFAKSLFGGMSWFSQILIGTLLVWLGLNLTNGSISLTCLALGGV
35 MIFLSTAVSA

SEQ ID NO: 70

5'-(dIdC)₁₃-3'

dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC dIdC

40

SEQ ID NO: 71

KLK peptide

KLKLLLLKLK

45 SEQ ID NO: 72

ZIKV Sequence H/PF/2013 as sequenced

50 CAGACTGCGACAGTTCGAGTTTGAAGCGAAAGCTAGCAACAGTATCAACAGGTTTTATTTGGATTGGAAACGAGAGTT
TCTGGTCATGAAAAACCAAAAAAGAAATCCGGAGGATTCGGGATTGTCAATATGCTAAAAACGCGGAGTAGCCCGTGTG
AGCCCCCTTTGGGGGCTTGAAGAGGCTGCCAGCCGACTTCTGCTGGGTCATGGGCCCATCAGGATGGTCTTGGCGATTCT
AGCCTTTTGGAGATTCACGGCAATCAAGCCATCACTGGGTCTCATCAATAGATGGGGTTCAGTGGGGAAAAAGAGGCTA
TGGAATAATAAAGAGTTCAAGAAAGATCTGGCTGCCATGCTGAGAATAATCAATGCTAGGAAGGAGAAGAAGAGAC
GAGGCGCAGATACTAGTGTGCGAATTGTTGGCCTCCTGCTGACCACAGCTATGGCAGCGGAGGTCAGTACGCTGGGAG
TGCATACTATATGTACTTGGACAGAAACGACGCTGGGGAGGCCATATCTTTCCAACACATTGGGGATGAATAAGTGT
ATATACAGATCATGGATCTTGGACACATGTGTGATGCCACCATGAGCTATGAATGCCCTATGCTGGATGAGGGGGTGGAA

CCAGATGACGTCGATTGTTGGTGCAACACGACGTCAACTGGGTTGTGTACGGAACTGCCATCACAAAAAGGTGAAGC
ACGGAGATCTAGAAGAGCTGTGACGCTCCCTCCATTCCACTAGGAAGCTGCAAAACGCGTGCAGAAACCTGGTTGGAAT
CAAGAGAATACACAAAGCACTTGATTAGAGTCGAAAATTGGATATTCAGGAACCTGGCTTCGCGTTAGCAGCAGCTGCC
ATCGCTTGGCTTTTGGGAAGCTCAACGAGCCAAAAAGTCATATACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGC
5 ATCAGGTGCATAGGAGTCAGCAATAGGGACTTTGTGGAAGGTATGTCAGGTGGGACTTGGGTTGATGTTGTCTTGGAAC
ATGGAGGTTGTGTACCCTAATGGCACAGGACAAACCGACTGTCGACATAGAGCTGGTTACAACAACAGTCAGCAACAT
GGCGGAGGTAAGATCCTACTGCTATGAGGCATCAATATCGGACATGGCTTCGGACAGCCGCTGCCAACACAAGGTGAA
GCCTACCTTGACAAGCAATCAGACACTCAATATGTCTGCAAAAAGAACGTTAGTGACAGAGGCTGGGGAAATGGATGTG
GACTTTTTGGCAAAGGGAGCCTGGTGACATGCGCTAAGTTTGCATGCTCCAAGAAAATGACCGGGAAGAGCATCCAGCC
10 AGAGAATCTGGAGTACCGGATAATGCTGTCACTTGTGGCTCCACAGCAGTGGGATGATCGTTAATGACACAGGACATG
AACTGATGAGAATAGAGCGAAGGTTGAGATAACGCCCAATTACCAAGAGCCGAAGCCACCCTGGGGGGTTTTGGAAG
CCTAGGACTTGATTGTGAACCGAGGACAGGCCTTGACTTTTCAGATTTGATTACTTGACTATGAATAACAAGCACTGGTT
GGTTCACAAGGAGTGGTTCACGACATTCCATTACCTGGCAGCTGGGGCAGACACCGGAACTCCCACTGGAACAACA
AAGAAGCACTGGTAGAGTTCAAGGACGCACATGCCAAAAGGCCAACTGTCGTGGTTCTAGGGAGTCAAGAAGGAGCAG
15 TTCACACGGCCCTTGCTGGAGCTCTGGAGGCTGAGATGGATGGTGCAAAGGGAAGGCTGTCCTTGCCACTTGAAATG
TCGCTGAAAATGGATAAACTTAGATTGAAGGCGGTGCATACTCCTGTGTACCGCAGCGTTCACATTCACCAAGATCCC
GGCTGAAACACTGACCGGGACAGTCACAGTGGAGGTACAGTACGACAGGACAGATGGACCTTGCAAGGTTCCAGCTCAG
ATGGCGGTGGACATGCAAACTCTGACCCAGTTGGGAGGTTGATAACCGCTAACCCGTAATCACTGAAAGCACTGAGAA
CTCTAAGATGATGCTGGAACCTGATCCACCATTTGGGGACTCTTACATTGTCATAGGAGTCGGGGAGAAGAAGATCACCC
20 ACCACTGGCACAGGAGTGGCAGCACCATTGAAAAAGCATTGAAGCCACTGTGAGAGGTGCCAAGAGAATGGCAGTCTT
GGGAGACACAGCCTGGGACTTTGGATCAGTTGGAGGCGCTCTAACTATTGGGCAAGGGCATCCATCAAAATTTTGGAG
CAGCTTTCAAATCATTGTTTGGAGGAATGTCCTGGTTCTCAAAATTCATTGGAACGTTGCTGATGTGTTGGGTCTGA
ACACAAAGAAATGGATCTATTCCCTTATGTGCTTGGCCTTAGGGGGAGTGTTGATCTTCTATCCACAGCTGTCTGTCTGA
TGTGGGGTGTCTCGGTGGACTTCTCAAAGAAGGAGACGAGATGCGGTACAGGGGTGTTCTGCTATAACGACGTTGAAGCC
25 TGGAGGGACAGGTACAAGTACCATCTGACTCCCCCGTAGATTGGCAGCAGCAGTCAAGCAAGCCTGGGAAGATGGTA
TCTGTGGGATCTCTCTGTTTCAAGAATGGAACATCATGTGGAGATCAGTAGAAGGGGAGCTCAACGCAATCCTGGAA
GAGAATGGAGTTCACTGACGGTCTGTGTGGGATCTGTAAAAAACCCATGTGGAGAGGTCCACAGAGATTGCCCGTGC
CTGTGAACGAGCTGCCCCAGGCTGGAAGGCTTGGGGGAAATCGTACTTCTGTCAGAGCAGCAAAGACAAATAACAGCTT
TGTCGTGGATGGTGACACACTGAAGGAATGCCACTCAAACATAGAGCATGGAACAGCTTTCTTGTGGAGGATCATGGGT
30 TCGGGGTATTTACACTAGTGTCTGGCTCAAGGTTAGAGAAGATTATTCATTAGAGTGTGATCCAGCCGTTATTGGAACAG
CTGTTAAGGGAAAGGAGGCTGTACACAGTGATCTAGGCTACTGGATTGAGAGTGAGAAGAATGACACATGGAGGCTGA
AGAGGGCCCATCTGATCGAGATGAAAACATGTGAATGGCCAAAGTCCACACATTGTGGACAGATGGAATAGAAGAGAG
TGATCTGATCATACCCAAGTCTTTAGCTGGGCCACTCAGCCATCACAATACCAGAGAGGGCTACAGGACCCAAATGAAAG
GGCCATGGCACAGTGAAGAGCTTGAATTCGGTTTGGAGAAATGCCAGGCACTAAGGTCCACGTGGAGGAAACATGTGG
35 AACAAGAGGACCATCTCTGAGATCAACCACTGCAAGCGGAAGGGTGATCGAGGAATGGTGTGACAGGAGTGCACAAT
GCCCCCACTGTGTTCCGGGCTAAAGATGGCTGTTGGTATGGAATGGAGATAAGGCCCAGGAAAGAACAGAAAGTAAC
TTAGTAAGGTCAATGGTGACTGCAGGATCACTGATCAGATGATGATCACTTCTCCCTTGGAGTGCTTGTGATTCTGCTATG
GTGCAGGAAGGGCTGAAGAAGAGAATGACCACAAAGATCATATAAGCACATCGATGGCAGTGCTGGTAGCTATGATCC
TGGGAGGATTTTCAATGAGTGACCTGGCTAAGCTTGAATTTGATGGGTGCCACCTTCGCGGAAATGAACACTGGAGGA
40 GATGTAGCTCATCTGGCGCTGATAGCGGCATTCAAAGTCAGACCAGCGTTGCTGGTATCTTTCATCTCAGAGCTAATTGG
ACACCCCGTGAAGCATGCTGCTGGCCTTGGCCTCGTGTCTTTGCAAACTGCGATCTCCGCTTGAAGGCGACCTGATG
GTTCTCATCAATGGTTTTGCTTTGGCCTGGTTGGCAATACGAGCGATGGTTGTTCCACGCACTGATAACATCACCTTGGCA
ATCCTGGCTGCTCTGACCACTGGCCCCGGGCACACTGCTTGTGGCGTGAGAGCAGGCCTTGCTACTTGCGGGGGGTT
TATGCTCCTCTCTGAAGGGAAAGGCACTGTGAAGAAGAACTTACCATTTGTCATGGCCCTGGGACTAACCGCTGTGA
45 GGCTGGTCGACCCCATCAACGTGGTGGGACTGCTGTTGCTCACAAGGAGTGGGAAGCGGAGCTGGCCCCCTAGCGAAGT
ACTCACAGCTGTTGGCCTGATATGCGCATTGGCTGGAGGGTTCGCCAAGGCAGATATAGAGATGGCTGGGCCCCATGGCC
GCGGTGCGTCTGTAATTGTCAATTACGTGGTCTCAGGAAGAGTGTGGACATGTACATTGAAAGAGCAGGTGACATCAC
ATGGGAAAAAGATGCGGAAGTCACTGGAACAGTCCCCGGCTCGATGTGGCGCTAGATGAGAGTGGTGATTCTCCCTG
GTGGAGGATGACGGTCCCCCATGAGAGAGATCATACTCAAGGTGGTCTGATGACCATCTGTGGCATGAACCAATAGC
50 CATACCTTTGAGCTGGAGCGTGGTACGTATACGTGAAGACTGGAAGGAGGAGTGGTGTCTATGGGATGTCCTGCTC
CCAAGGAAGTAAAAAGGGGGAGACACAGATGGAGTACAGAGTAATGACTCGTAGACTGCTAGGTTCAACAGCAAGT
TGGAGTGGGAGTTTGAAGAGGGGGTCTTTCACACTATGTGGCAGTCACAAAAGGATCCGCGCTGAGAAGCGGTGAA
GGGAGACTTGATCCATACTGGGGAGATGTCAAGCAGGATCTGGTGTCACTGTGGTCCATGGAAGCTAGATGCCGCT
GGGACGGGCACAGCGAGGTGCAGCTCTTGGCCGTGCCCCCGGAGAGAGAGCGAGGAACATCCAGACTCTGCCCGGAA

TATTTAAGACAAAGGATGGGGACATTGGAGCGGTTGCGCTGGATTACCCAGCAGGAACCTCAGGATCTCCAATCCTAGAC
AAGTGTGGGAGAGTGATAGGACTTTATGGCAATGGGGTCGTGATCAAAAATGGGAGTTATGTTAGTGCCATCACCCAAG
GGAGGAGGGAGGAAGAGACTCCTGTTGAGTGCTTCGAGCCTTCGATGCTGAAGAAGAAGCAGCTAACTGTCTTAGACTT
GCATCCTGGAGCTGGGAAAACAGGAGAGTTCTTCTGAAATAGTCCGTGAAGCCATAAAAAACAAGACTCCGTACTGTGA
5 TCTTAGCTCCAACCAGGGTTGTCGCTGCTGAAATGGAGGAAGCCCTTAGAGGGCTTCCAGTGCGTTATATGACAACAGCA
GTCAATGTCACCCACTCTGGAACAGAAATCGTCGACTTAATGTGCCATGCCACCTTCACTTCACGTCTACTACAGCCAATCA
GAGTCCCCAACTATAATCTGTATATTATGGATGAGGCCCACTTCACAGATCCCTCAAGTATAGCAGCAAGAGGATACATTT
CAACAAGGGTTGAGATGGGCGAGGCGGCTGCCATCTTCATGACCGCCACGCCACCAGGAACCCGTGACGCATTTCCGGA
CTCCAACCTACCAATTATGGACACCGAAGTGGAAGTCCCAGAGAGAGCCTGGAGCTCAGGCTTTGATTGGGTGACGGATC
10 ATTCTGAAAAACAGTTTGGTTTGTTCGAAGCGTGAGGAACGGCAATGAGATCGCAGCTTGTCTGACAAAGGCTGGAAA
ACGGGTCATACAGCTCAGCAGAAAGACTTTTGAGACAGAGTTCAGAAAAACAAACATCAAGAGTGGGACTTTGTCGTG
ACAACTGACATTTAGAGATGGGCGCCAACTTAAAGCTGACCGTGTCATAGATTCCAGGAGATGCCTAAAGCCGGTCAT
ACTTGATGGCAGAGAGTGATCTTGGCTGGACCATGCCTGTACACATGCCAGCGCTGCCAGAGGAGGGGGCGCATA
GGCAGGAATCCCAACAAACCTGGAGATGAGTATCTGTATGGAGGTGGTGCGCAGAGACTGACGAAGACCATGCACACT
15 GGCTTGAAGCAAGAATGCTCCTTGACAATATTTACCTCCAAGATGGCCTCATAGCCTCGCTCTATCGACCTGAGGCCGACA
AAGTAGCAGCCATTGAGGGAGAGTTCAAGCTTAGGACGGAGCAAAGGAAGACCTTTGTGGAATCATGAAAAGAGGAG
ATCTTCTGTTGGCTGGCCTATCAGGTTGCATCTGCCGAATAACCTACACAGATAGAAGATGGTGCTTTGATGGCACGA
CCAACAACACCATAATGGAAGACAGTGTGCCGCGAGAGGTGTGGACCAGACACGGAGAGAAAAAGAGTGCTCAAACCGA
GGTGGATGGACGCCAGAGTTTGTTCAGATCATGCGGCCCTGAAGTCATTCAAGGAGTTTGCCGCTGGGAAAAGAGGAGC
20 GGCTTTTGGAGTGATGGAAGCCCTGGGAACACTGCCAGGACACATGACAGAGAGATTCCAGGAAGCCATTGACAACCTC
GCTGTGCTCATGCGGGCAGAGACTGGAAGCAGGCCTTACAAAGCCGCGGCGGCCCAATTGCCGGAGACCCTAGAGACCA
TTATGCTTTTGGGGTTGCTGGGAACAGTCTCGTGGGAATCTTTTCTGCTTGTATGAGGAACAAGGGCATAGGGAAGATG
GGCTTTGGAATGGAGTCTTGGGGCCAGCGCATGGCTCATGTGGCTCTCGGAAATTGAGCCAGCAAAATGTCATGTG
CCTCATTGTTGTCTTCTATTGCTGGTGGTGCTCATACCTGAGCCAGAAAAGCAAAGATCTCCCCAGGACAACCAAATGGC
25 AATCATCATCATGGTAGCAGTAGGTCTTCTGGGCTTGATTACCGCCAATGAACTCGGATGGTTGGAGAGAAACAAAGAGTG
ACCTAAGCCATCTAATGGGAAGGAGAGAGGAGGGGGCAACCATAGGATTCTCAATGGACATTGACCTGCGGCCAGCCTC
AGCTTGGGCCATCTATGCTGCCTTGACAACCTTCATTACCCAGCCGTCCAACATGCAGTGACCACTTCATACAACACTAC
TCCTTAATGGCGATGGCCACGCAAGCTGGAGTGTTGTTTGGTATGGGCAAAGGGATGCCATTTACGCATGGGACTTTGG
AGTCCCGCTGCTAATGATAGGTTGCTACTACAATTAACCCCTGACCCTAATAGTGGCCATCATTTTGTCTGTGGCGCAC
30 TACATGTACTTGATCCAGGGCTGCAGGCAGCAGCTGCGCGTGCTGCCAGAAAGAGAACGGCAGCTGGCATCATGAAGA
ACCCTGTTGTGGATGGAATAGTGGTGACTGACATTGACACAATGACAATTGACCCCAAGTGGAGAAAAAGATGGGACA
GGTGCTACTCATAGCAGTAGCCGTCTCCAGCGCCATACTGTCGCGGACCGCCTGGGGGTGGGGGAGGCTGGGGCCCTG
ATCACAGCGGCAACTTCCACTTTGTGGGAAGGCTCTCCGAACAAGTACTGGAATCTCTACAGCCACTTCACTGTGTAAC
ATTTTTAGGGGAAGTTACTTGGCTGGAGCTTCTAATCTACACAGTAACAAGAAACGCTGGCTTGGTCAAGAGACGTGG
35 GGGTGAACAGGAGAGACCCTGGGAGAGAAATGGAAGGCCGCTTGAACCAGATGTCGGCCCTGGAGTTCTACTCTAC
AAAAAGTCAGGCATACCGAGGTGTGCAGAGAAGAGGCCCGCCGCGCCCTCAAGGACGGTGTGGCAACGGGAGGCCAT
GCTGTGTCCCAGGAAGTGCAAAGCTGAGATGGTTGGTGGAGCGGGGATACCTGCAGCCCTATGGAAGGTCATTGATC
TTGGATGTGGCAGAGGGGGCTGGAGTTACTACGCCGCCACCATCCGCAAAGTTCAAGAAGTGAAAGGATACACAAAAGG
AGGCCCTGGTCATGAAGAACCCATGTTGGTGCAAAGCTATGGGTGGAACATAGTCCGTCTTAAGAGTGGGGTGGACGTC
40 TTTATATGGCGGCTGAGCCGTGTGACACGTTGCTGTGTGACATAGGTGAGTCATCATCTAGTCTGAAGTGAAGAAGC
ACGGACGCTCAGAGTCTCTCATGGTGGGGGATTGGCTTAAAAAAGACCAGGAGCCTTTGTATAAAAGTGTGTGCC
CATACACCAGCACTATGATGGAACCCCTGGAGCGACTGCAGCGTAGGTATGGGGGAGGACTGGTCAGAGTGCCACTCTC
CCGCAACTCTACACATGAGATGTACTGGGTCTCTGGAGCGAAAAAGCAACACCATAAAAAAGTGTGTCCACCAGAGCCAGC
TCCTCTTGGGGCGCATGGACGGGCCAGGAGGCCAGTGAATATGAGGAGGATGTGAATCTCGGCTCTGGCACGCGGG
45 CTGTGGTAAGCTGCGCTGAAGCTCCCAACATGAAGATCATTGGTAACCGCATTGAAAGGATCCGAGTGAGCACGCGGA
AACGTGGTTCTTTGACGAGAACCACCCATATAGGACATGGGCTTACCATGGAAGCTATGAGGCCCCACACAAGGGTCAG
CGTCTCTCTAATAAACGGGGTTGTAGGCTCTGTCAAAACCTGGGATGTGGTGACTGGAGTCACAGGAATAGCCATG
ACCGACACCACACCGTATGGTCAGCAAAGAGTTTTCAAGGAAAAAGTGGACACTAGGGTGCCAGACCCCAAGAAGGCA
CTCGTCAGGTTATGAGCATGGTCTCTTCTGTTGTGGAAAGAGCTAGGCAAACACAACGGCCACGAGTCTGTACCAAA
50 GAAGAGTTCATCAACAAGGTTCTGTAGCAATGCAGCATTAGGGGCAATATTTGAAGAGGAAAAAGAGTGAAGACTGCAG
TGAAGCTGTGACATGATGGGAAAAAGAGAAAAAGAAAGGGAATTTGAAAGGCCAAGGGCAGCCGCGCATCT
GGTATATGTGGCTAGGGGCTAGATTCTAGAGTTCGAAGCCCTTGGATTCTGAACGAGGATCACTGGATGGGGAGAGA
GAACTCAGGAGGTGGTGTGAAGGGCTGGGATTACAAGACTCGGATATGCTCTAGAAGAGATGAGTCGCATACCAGGA

GGAAGGATGTATGCAGATGACACTGCTGGCTGGGACACCCGCATCAGCAGGTTTGATCTGGAGAATGAAGCTCTAATCA
 CCAACCAATGGAGAAAGGGACAGGGCCTTGGCATTGGCCATAATCAAGTACACATACCAAAACAAAGTGGTAAAGGT
 CCTTAGACCAGCTGAAAAAGGGAAGACAGTTATGGACATTATTCGAGACAAGACCAAGGGGGAGCGGACAAGTTGTC
 ACTTACGCTCTTAACACATTACCAACCTAGTGGTGCAACTCATTGGAATATGGAGGCTGAGGAAGTTCTAGAGATGCAA
 5 GACTTGTGGCTGCTGCGGAGGTCAGAGAAAGTGACCAACTGGTTGCAGAGCAACGGATGGGATAGGCTCAAACGAATG
 GCAGTCAGTGAGATGATTGCGTTGTGAAGCCAATTGATGATAGGTTTGACATGCCCTCAGGTTCTTGAATGATATGGG
 AAAAGTTAGGAAGGACACACAAGAGTGGAACCTCAACTGGATGGGACAACCTGGGAAGAAGTTCGGTTTTGCTCCAC
 CACTTCAACAAGCTCCATCTCAAGGACGGGAGGTCCATTGTGGTTCCTGCCGCCACCAAGATGAAGTATTGGCCGGGC
 CCGCGTCTCTCAGGGGGCGGATGGAGCATCCGGGAGACTGCTTGCCTAGCAAAATCATATGCGCAAATGTGGCAGCTC
 10 CTTTATTTCCACAGAAAGGGACCTCCGACTGATGGCCAATGCCATTGTTTCATCTGTGCCAGTTGACTGGGTTCCAAGTGGG
 AGAACTACCTGGTCAATCCATGGAAAGGGAGAATGGATGACCACTGAAGACATGCTTGTGGTGTGGAACAGAGTGTGGA
 TTGAGGAGAACGACCACATGGAAGACAAGACCCAGTTACGAAATGGACAGACATTCCTATTTGGGAAAAAGGGAAGA
 CTTGTGGTGTGGATCTCTCATAGGGCACAGACCGCGCACCACCTGGGCTGAGAACATTAACACAGTCAACATGGTGC
 GCAGGATCATAGGTGATGAAGAAAAGTACATGGACTACCTATCCACCAAGTTCGCTACTTGGGTGAAGAAGGGTCTACA
 15 CCTGGAGTGCTGTAAACCAATCTAGTGTGTGAGGCCTGCTAGTCAGCCACAGCTTGGGAAAAGCTGTGCAGCCTGT
 GACCCCCCAGGAGAAGCTGGGAAACCAAGCCTATAGTCAGGCCGAGAACGCCATGGCACGGAAGAAGCCATGCTGCCT
 GTGAGCCCTCAGAGGACACTGAGTCAAAAAACCCACGCGCTTGGAGGCGCAGGATGGGAAAAGAAGGTGGCGACCT
 TCCCCACCTTCAATCTGGGCTGAACTGGAGATCAGCTGTGGATCTCAGAAGAGGGACTAGTGGTTAGAGGAGACCC
 CCGGAAAACGAAAACAGCATATTGACGCTGGGAAAGACCAGAGACTCCATGAGTTTCCACCACGCTGGCCGCCAGGC
 20 ACAGATCGCCGAATAGCGGCGGCCGCTGTGGG

SEQ ID NO: 73

AHZ13508.1, Zika virus polyprotein from Polynesian outbreak (H/PF/2013)

MKNPKKSGGFRIVNMLKRGVARVSPFGGLKRLPAGLLGHGPIRMVLAILAFLRFTAIPSLGLINRWGSGVKKKEAMEIHKFKK
 25 DLAAMLRIINARKEKKRRGADTSVGIVGLLLTTAMAAEVTRRGSAYMYLDRNDAGEAISFPTTLGMNKCQIYQIMDLGHMCD
 TMSYECPLMDEGVEPDDVDCWCNTTSTWVVYGTCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTWLESREYTKHLIRVENWI
 FRNPGFALAAAAIAWLLGSSTSQKVIYLVILLIAPAYSIRICIGVSNRDFVEGMSGGTWVDVLEHGGCVTVMAQDKPTVDIEL
 VTTTVSNMAEVRSYCYEASISDMASDSRCPTQGEAYLDKQSDTYVCKRTLVDGRWGNGCGLFGKGLVTCAKFACSKKMTG
 KSIQPENLEYRIMLSVHGSQHSQMIVNDTGHETDENRAKVEITPNSPRAEATLGGFGSLGLDCEPRTGLDFSDLYLTMNNKH
 30 WL VHKEWFHDIPLPHAGADTGTPHWNNKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGA GR LSSGHLK
 CRLKMDKRLKGVSYSLCTAAFTFKIPAE TLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR LITANPVITESTENSKM
 MLELDPPFGDSYIVIGVEKKITHHWRSGSTIGKA FEATVRGAKRMAVLGDTAWDFGSGVGGALNSLGKIHQIFGA AFKSLF
 GGMSWFSQLIGTLLMWLGNLTNGSISLMCLALGGVLI FLSTAVSADVGCSVDFSKKETRCGTGVFVYNDVEAWRDRYKYHP
 DSPRLAAAVKQAWEDGIGCISVS RMENIMWRSVEGELNAILEENG VQLTVVVGSVKNPMWRGPQRLPVPVNLPHGWK
 35 AWGKSYFVRAAKTNN SFVVDGDTLKECP LKHAWNSFLVDHGFV FHTSVWLKVREDYSLECDPAVIGTAVKGEAVHSDL
 GYWIESEKNDTWRLKRAH LIEMKTCEWPKSHTLWTDGIEESD LIIPKSLAGPLSHHNTREGYRTQMKG PWHSEELIRFEPCG
 TKVHVEETCGTRGPSLRSTTASGRVIEEWCCRECTMPPLSFRAKDGCWYGM EIRPRKEPESNLVRSMV TAGSTDHMDHFLSG
 VLVILLMVQEG LKKRM TTKIISTMAVLVAMILGGFSMSDLAKLAILMGATFAEMNTGGDVAHLALIAAFKVRPALLVSIFRA
 NWTPRESMLLALASCLLQTAISALEGDL MV LINGFALAWLAIRAMVVPRTDNITLAILAALTPLARGTLLVAWRAGLATCGGFM
 40 LLSLKKGKSVKKNLPFVMALGLTAVRLVD PINVVG LLLLRSGKRSWPPSEVLTAVGLICALAGGFAKADIEMAGPMAAVGLLIV
 SYVVS GKSVD MYIERAGDITWEKDAEVTGNSPRLDVALDES GDFSLVEDDGPPMREIILKVLM TICGMNPIAIPFAAGAWVYV
 VKTGKRS GALWDVPAPKEVKKGETTDGVYRVMTRRL LGSTQVGVGMQEGVFHTMWHVTGKSALRS GEGRLDPYWG DVK
 QDLVSYCGPWKLDAAWDGHSEVQLLAVPPGERARNIQTLP GIFTKDG DIGAVALDYPAGTSGSPILDKCGRVIGLYGNVVIK
 NGSYVSAITQGRREEETPVECFE PSM LKKQLTVLDLHPGAGKTRRVLPEIVREAIKTRLRTVILAPTRVVAEEMEEALRGLPVRY
 45 MTTAVNVTHSGTEIVDL MCHATFTSRLLQPIRVPNYNYIMDEAHFTDPSSIAARGYISTRVEMGEAAAFMTATPPGTRDAFP
 DSNSPIMDTEVEVPERAWSSGFDWVTDHSGKT VWFVPSVRNGNEIAACLT KAGKRVIQLSRKTFETEFQKTKHQEWDFVTT
 DISEMGANFKADRVIDSRRCLKP VILDGERVILAGPMPTVTHASAAQRRGRIGRNPKNPGDEYLYGGGCAETDEDHAWLEAR
 MLLDN IYLDGLIASLRYPEADKVA AIEGEFKLRTEQRKTFVELMKRGDLPVW LAYQVASAGITYDRRWCFDGTNTNTIMEDS
 VPAEVWTRHGEKRV LKPRWMDARVCS DHAALSKFEFAAGKRGAAFGVMEALGTLPGHMTERFQEAIDNLAVLMRAETGS
 50 RPYKAAAALPETLETIMLLGLLGT VSLGIFFVLMRNKGIGKMGFGMVTLGASAWLMWLSEIEPARIACVLIVFLLVLIPEPE
 KQRS PQDNQMAIIMVAVGLLGLITANELGW LERTKSDLSHLMGRREEGATIGFSMDIDL RPASAWAIYAALTFTTIPAAVQHAV
 TTSYNNYS LAMATQAGVLFGMGKMPFYAWDFGVPLLMIGCYSQLTPLTLIVAILLVAHYMYLIPGLQAAAAAQRRTAA
 GIMKNPVVDGIVVTDIDTMTIDPQVEKKMGQVLLIAVAVSSA ILSRTAWGWGEAGALITAATSTLWEGSPNKYWNSSATSLC
 NIFRGSYLAGASLIYVTRNAGLVKRRGGGTGETLGEKW KARLNQMSALEFYSYKSGITEVCREEARALKDGVATGGHAVSR

5 GSAKLRWLVERGYLQPYGKVIDLGCGRGGWSYYAATIRKVQEVKGYTKGGPGHEEPMVLVQSYGWNIVRLKSGVDVFHMAAE
PCDTLLCDIGESSSSPEVEEARTLRVLSMVGDWLEKRPAGFICIKVLCPYTSTMMETLERLQRRYGGGLVRVPLSRNSTHEMYWV
SGAKSNTIKSVSTTSQLLLGRMDGPRRPVKYEEDVNLGSGTRAVVSCAEAPNMKIIGNRIERIRSEHAETWFFDENHPYRTWAY
HGSYEAPTQGSASSLINGVVRLLSKPWDVVTGVTGIAMTDTPYGGQQRVFKEKVDTRVPDPQEGTRQVMSMVSSWLWKELG
10 KHKRPRVCTKEEFINKVRSNAALGAIFEEKEWKTAVEAVNDPRFWALVDKEREHHLRGECQSCVYNMMGKREKKQGEFGKA
KGSRAIWYMWLGARFLEFEALGFLNEDHWMGRENSGGGVEGLQLQRLGYVLEEMSRIPGGGRMYADDTAGWDTRISRFDE
NEALITNQMEKGRHALALAIKYTYQNKVVKVLRPAEKGKTVMDIISRQDQRGSGQVVTYALNTFTNLVVQLIRNMEAEEVLEM
QDLWLLRRSEKVTNWLQSNGWDRLKRMVSGDDCVVKPIDDRFAHALRFLNDMGKVRKDTQEWKPSTGWDNWEVPFC
SHHFNLHLKDGSRIVPCRHQDELIGRARVSPGAGWSIRETACLAKSYAQMWQLLYFHRRDLRLMANAICSSVPVDWVPTG
15 RTTWSIHGKGEWMTTEDMLVVWNRVWIEENDHMEDKTPVTKWTDIPYLGKREDLWCGSLIGHRPRTTWAENIKNTVNMV
RRIIGDEEKYMDYLSTQVRYLGEEGSTPGVL

SEQ ID NO: 74
9320_Zika_PF_1F
15 ttaggatccGTTGTTGATCTGTGTGAAT

SEQ ID NO: 75
9321_Zika_PF_1R
20 taactcgagCGTACACAACCAAGTT

SEQ ID NO: 76
9322_Zika_PF_2F
ttaggatccTACTAGACGTGGGAGTG

25 SEQ ID NO: 77
9323_Zika_PF_2R
taactcgagAAGCCATGTCYGATATTGAT

SEQ ID NO: 78
30 9324_Zika_PF_3F
ttaggatccGCATACAGCATCAGGTG

SEQ ID NO: 79
9325_Zika_PF_3R
35 taactcgagTGTGGAGTCCGGTGTCT

SEQ ID NO: 80
9326_Zika_PF_4F
40 ttaggatccGAATAGAGCGAARGTTGAGATA

SEQ ID NO: 81
9327_Zika_PF_4R
taactcgAGTGGTGGGTGATCTTCTTCT

45 SEQ ID NO: 82
9328_Zika_PF_5F
ttaggatcCAGTCACAGTGGAGGTACAGTAC

50 SEQ ID NO: 83
9329_Zika_PF_5R
taactcgagCRCAGATACCATCTTCCC

SEQ ID NO: 84
9330_Zika_PF_6F

ttaggatCCCTTATGTGCTTGGCCTTAG

SEQ ID NO: 85
9331_Zika_PF_6R
5 taactcgagTCTTCAGCCTCCATGTG

SEQ ID NO: 86
9332_Zika_PF_7F
10 ttaggatccAATGCCCACTCAAACATAGA

SEQ ID NO: 87
9333_Zika_PF_7R
taactcgagTCATTCTCTTCTCAGCCCTT

15 SEQ ID NO: 88
9334_Zika_PF_8F
ttaggatccAAGGGTGATCGAGGAAT

SEQ ID NO: 89
20 9335_Zika_PF_8R
taactcgagTTCCTTCAGAGAGAGGAGC

SEQ ID NO: 90
9336_Zika_PF_9F
25 ttaggatccTCTTTGCAAAGTGCATC

SEQ ID NO: 91
9337_Zika_PF_9R
taactcgagTCCAGCTGCAAAGGGTAT

30 SEQ ID NO: 92
9338_Zika_PF_10F
ttaggatccGTGTGGACATGTACATTGA

35 SEQ ID NO: 93
9339_Zika_PF_10R
taactcgagCCCATTGCCATAAAGTC

SEQ ID NO: 94
40 9340_Zika_PF_11F
ttaggatccTCATACTGTGGTCCATGGA

SEQ ID NO: 95
9341_Zika_PF_11R
45 taactcgagGCCCATCTCAACCCTTG

SEQ ID NO: 96
9342_Zika_PF_12F
ttaggatccTAGAGGGCTTCCAGTGC

50 SEQ ID NO: 97
9343_Zika_PF_12R
taactcgAGATACTCATCTCCAGGTTTGTTG

SEQ ID NO: 98
9344_Zika_PF_13F
ttaggatccGAAAACAAAACATCAAGAGTG

5 SEQ ID NO: 99
9345_Zika_PF_13R
taactcgagGAATCTCTCTGTCATGTGTCCT

10 SEQ ID NO: 100
9346_Zika_PF_14F
ttaggatccTTGATGGCAGACCAAC

SEQ ID NO: 101
9347_Zika_PF_14R
15 ttaggatccGTTGTTGATCTGTGTGAAT

SEQ ID NO: 102
9348_Zika_PF_15F
taactcgagCAGGTCAATGTCCATTG
20

SEQ ID NO: 103
9349_Zika_PF_15R
ttaggatccTGTGTGTTCTATTGCTGGT

25 SEQ ID NO: 104
9350_Zika_PF_16F
taactcgaGTGATCAGRGCCCCAGC

SEQ ID NO: 105
9351_Zika_PF_16R
30 ttaggatccTGCTGCCAGAAGAGAA

SEQ ID NO: 106
9352_Zika_PF_17F
35 taactcgaGCACCAACAYGGTTCTT

SEQ ID NO: 107
9353_Zika_PF_17R
ttaggatccCTCAAGGACGGTGTGGC
40

SEQ ID NO: 108
9354_Zika_PF_18F
taactcgagCAATGATCTTCATGTTGGG

45 SEQ ID NO: 109
9355_Zika_PF_18R
ttaggatccTATGGGGGAGGACTGGT

50 SEQ ID NO: 110
9356_Zika_PF_19F
taactcGAGCCCAGAACCTTGGATC

SEQ ID NO: 111
9357_Zika_PF_19R

ttaggatcCAGACCCCAAGAAGGC

SEQ ID NO: 112

9358_Zika_PF_20F

5 taactcgagCCCTTTGGTCTTGTCT

SEQ ID NO: 113

9359_Zika_PF_20R

10 ttaggatccAGGAAGGATGTATGCAGATG

SEQ ID NO: 114

9360_Zika_PF_21F

taactcgagACATTTGCGCATATGATTTTG

15 SEQ ID NO: 115

9361_Zika_PF_21R

ttaggatccAGGAAGGACACACAAGAGT

SEQ ID NO: 116

20 9362_Zika_PF_22F

taactcgagACAGGCTGCACAGCTTT

SEQ ID NO: 117

9363_Zika_PF_22R

25 ttaggatccTCTCTCATAGGGCACAGAC

In some embodiments, the Zika virus has polyprotein, including an envelope (E) protein, with an amino acid sequence provided by any one of SEQ ID NOs: 14-69 or 72. In some embodiments, the polyprotein or E protein sequence is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,
30 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to any one of SEQ ID NOs: 2-69 or 72.

The terms "identical" or percent "identity" in the context of two or more nucleic acids or amino acid sequences refer to two or more sequences or subsequences that are the same. Two sequences are
35 "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (*e.g.*, at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity) over a specified region or over the entire sequence, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally,
40 the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. In some embodiments, the identity exists over the length of a protein, such as the E protein.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. Methods of alignment of sequences for comparison are well known in the art. See, *e.g.*, by the local homology algorithm of Smith and Waterman (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48:443, 1970, by the search for similarity method of Pearson and Lipman. Proc. Natl. Acad. Sci. USA 85:2444, 1988, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, Jalview and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), by multi sequence alignment implementation using *e.g.* CLUSTALW (Larkin et al., (2007). Bioinformatics, 23, 2947-2948.) or MAFFT (Katoh & Toh 2008 Briefings in Bioinformatics 9:286-298), or by manual alignment and visual inspection (see, *e.g.*, Brent et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (Ringbom ed., 2003)). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977 and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively.

EXAMPLES

20 Example 1: Production of a Zika drug substance suitable for application as a vaccine in humans and animals

Materials and Methods:

For the production of ZikaV the JEV process platform (Srivastava et al., Vaccine 19 (2001) 4557-4565; US 6,309,650B1) was used as a basis. Small changes of certain process steps were adapted to ZikaV properties and to improve purity. A short summary of the process steps is outlined below (see also Figure 9A and B). Briefly, the unexpected and novel purification properties of protamine sulphate (PS) were evaluated in purification processes for Zika Virus. As shown in Figure 10, non-infectious virus particle aggregates, HCP and other LMW impurities were removed by PS precipitation as shown by removal of aggregate shoulder in SEC-HPLC and no loss of infectious virus titer by PS treatment. Further optimization of the Zika purification protocol is provided below.

Upstream:

- Roller Bottle based Vero cell expansion (25x850cm² CellBind):

- 5% CO₂, 35°C, MEM+2mM L-Glutamine + 10% FBS
 - Infection with ZikaV research Master Seed Bank (rMSB) at MOI 0.01
 - Virus Production without serum
 - 5% CO₂, 35°C, MEM+2mM L-Glutamine
 - 5 • Multiple harvests (days 2, 3, 5 and 7) with re-feed
 - Sterile filtration of harvests and storage at 2-8°C until further processing
- Downstream:
- Pooling of harvests and concentration by ultrafiltration (100kDa)
 - Stabilization of concentrated harvest (Tris/10% sucrose) for storage if required (-80°C)
 - 10 • Removal of hcDNA by Protamine Sulphate (2 mg/mL)
 - Sucrose Gradient Purification (optimized three layered gradient)
 - Formaldehyde Inactivation (0.02%, 22°C, 10 days), neutralization with Na-metabisulfite
 - Dilution to DS antigen target content and formulation with Aluminium hydroxide (0.5mg Al/mL)

15

Zika Virus Strain H/PF/2013 was originally isolated from a 51-year-old woman (accession number KJ776791.1, also SEQ ID NO: 13 herein) from French Polynesia. A sample was obtained from the European Virus Archive (EVAg; Ref-SKU: 001v-EVA1545). Based on this material, a research master seed bank (rMSB) was prepared on Vero cells as the cell substrate and the genomic sequence

20 was checked by sequencing. Because the genomic sequence at the 5' and 3' flanking sequences of Zika virus strain H/PF/2013 was unknown, primers for sequencing were designed in those regions based on other Zika virus strains whereas the internal primers were designed from the published sequence (SEQ ID NOs: 74 to 117, see also Table A). The sequence obtained from the rMSB by use of these primers is provided by SEQ ID NO: 72. There was 100% overlap of the sequence with the published

25 sequence of Zika Virus Strain H/PF/2013 (SEQ ID NO: 13). However, we sequenced additional regions 5' (an additional 40 bp) and 3' (an additional 160 bp) represented in SEQ ID NO: 72. In a preferred embodiment, the Zika virus of the invention comprises SEQ ID NO: 72. The genomic RNA is somewhat longer than the sequence according to SEQ ID NO: 72 (perhaps an additional 200 bp). Additionally, a Zika virus adapted to a host cell such as e.g. Vero cells may be expected to contain

30 one or more mutations. For these reasons, the Zika virus of the current invention comprises the sequence of SEQ ID NO: 72 or, preferably, a sequence with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 72. Furthermore, because the viral genome is likely to contain even further flanking regions to SEQ ID NO: 72; in one embodiment, the Zika virus of the invention contains the sequence of SEQ ID NO: 72 and optionally further comprises

35 extensions at the 5' and/or 3' ends of at least 10, at least 20, at least 30, at least 40, at least 50, at least

60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120 or at least 130 nucleotides. In a preferred embodiment, the Zika virus comprises at least the coding sequence for the entire polyprotein of Zika Virus Strain H/PF/2013 of the invention i.e. the amino acid sequence of SEQ ID NO: 73 or a polyprotein with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 73. Furthermore, the Zika virus comprises at least the coding sequence for the E-protein of Zika Virus Strain H/PF/2013 of the invention SEQ ID NO: 47 or an E-protein thereof with at least 95%, 96%, 97%, 98%, or at least 99% sequence identity to the sequence provided by SEQ ID NO: 47.

10 *Virus growth on Vero Cells*

Vero cells were grown in Eagle's minimal essential medium (EMEM) containing 10% fetal bovine serum (FBS). Roller bottle cultures of Vero cell monolayers were infected with Zika Virus Strain H/PF/2013 at a multiplicity of infection (moi) of 0.01 plaque forming units (pfu) per cell. After 2 hours of virus adsorption, the cultures were washed 3 times with PBS and fed with EMEM without FBS and incubated at +35°C with 5% CO₂. Infected Vero cell cultures were incubated until the virus titer reaches a desired level.

The culture medium was harvested at days 2, 3, 5 and 7 and were pooled from those harvest days and then centrifuged in a standard centrifuge. The supernatants were then filtered. Virus culture supernatants were concentrated by TFF ultrafiltration to remove cell culture media components and to reduce batch volume.

Evaluation of harvest Procedure

The current JEV harvest process has scheduled harvests on days 3, 5, 7 and 9 post infection. To mimic the JEV process roller bottles were infected with ZIKV bank P4-FBS at an MOI of 0.01 in infection medium (MEM with 2% FBS + 2mM L-glutamine) for 2 hours. After removing the inoculum the cells were washed twice with PBS and 200 mL production medium (MEM+ 2mM L-glutamine) was added.

After taking a sample on day 2 the first virus harvest was conducted on day 3 after infection. At this point significantly higher CPE could be observed compared to cells where virus was removed on day 2. Plaque assay analysis showed that the viral titers on day 2 were in the same range as for the standard harvesting schedule. However, starting with the day 3 harvest, the observed titers were significantly lower correlating with the increased CPE observed compared to the standard harvest schedule. On day 5 post infection no more living cells could be observed at all and the experiment was terminated with a final day 5 harvest.

Table 3: The calculated titers per plaque assay are summarized in the list below.

	Log 10 PFU/mL
sample day2	7.02
harvest day 3	6.66
harvest day 5	6.26

This finding led to an optimized harvest schedule to better control of CPE and allow additional harvest day 5 and 7, see Figure 15. For both harvest days the optimized ZikaV protocol yield significant higher virus titers compared to the modified protocol showing that the time of the first harvest is crucial for production yields. Additionally first harvesting at day 3 results in maximum 2 harvest points whereas first harvesting at day 2 allows for 4 harvest points further increasing the yield gain.

Downstream Purification of Zika virus

The purification process was carried out at room temperature (18-22°C) unless stated otherwise. Virus purification started with concentration of filtered combined harvest using 100 kDa cut-off TFF ultrafiltration modules to remove cell culture media components and reduce batch volume. After concentration, the pooled filtered harvest material was adjusted to a final concentration of 25 mM Tris pH 7.5 and 10% sucrose (w/w) using stock solution of both components (see Figure 11 for SEC-HPLC of different harvests prior to PS treatment). This allowed for freezing the concentrated harvest at <-65°C if required.

Host cell DNA and protein reduction as well reduction of non-infectious virus aggregates in the concentrated material was achieved by precipitation with protamine sulphate (2 mg/mL) followed by sucrose density centrifugation (2-8°C) as final polishing step (see Figure 20 for SEC-HPLC of different harvests post PS treatment). The purification process was designed to be completed within 2 working days with SGC starting on end of day 1 followed by fractionation and SDS-PAGE analysis on day 2. The sucrose gradient fractions were stored at 2-8 °C during the SDS-PAGE analysis (Silver staining) to identify the pure fractions containing ZikaV (see Figure 21). After pooling the relevant fractions, the pool was diluted and inactivated by Formalin. After pooling the relevant fractions of sucrose gradient centrifugation, the pool was diluted 1:3 in PBS and inactivated by Formalin (0.02% v/v, 200ppm). Fractions were subjected to analysis by SDS-PAGE.

Effect of PS treatment on virus recovery

Samples of individual 30x concentrated harvests days 2, 3, 5 and 7 were analysed before (Figure 11) and after PS (Figure 12) treatment by SEC-HPLC and plaque assay. SEC-HPLC was used for determination of relative total ZikaV content (active + inactive) expressed as peak area, whereas the rel. ZikaV peak purity is given as relative content of virus monomer population to total virus peak.

- 5 Plaque assay states the content of total active virus particles in each sample. Experimental results are summarized in Table 4. The virus peak recovery by SEC-HPLC was only between 12 to 36% with peak purity after PS treatment in the range of >90% (no virus aggregates detected). The recovery of active virus particles by plaque assay was all > 100% (130-700%, range within the variability of the assay) showing that no active virus particles were lost during PS treatment. These results show that
- 10 during PS treatment only non-infective (immature and/or aggregated virus) particles were removed.

Table 4: ZikaV recovery by SEC-HPLC and plaque assay before and after PS treatment.

SEC-HPLC

	Peak area mAU*min			
Harvest day	30x conc	30x + PS	SEC Recovery (%)	rel. virus monomer content after PS (%)
Day 2	101.36	18.63	18	89%
Day 3	144.51	17.48	12	90%
Day 5	19.97	5.92	30	96%
Day 7	68.80	24.43	36	99%

Plaque Assay

	PFU/mL		
Harvest day	30x conc	30x + PS	Plaque Recovery (%)
Day 2	3E+08	5E+08	179
Day 3	2E+08	4E+08	193
Day 5	1E+08	9E+08	700
Day 7	3E+08	4E+08	132

Sucrose gradient centrifugation

- 15 The PS treated harvest was split in two parts and loaded on two centrifuge bottles. Sucrose density gradient centrifugation (SGC) was used for final concentration and polishing of the ZikaV material. The ZikaV PS treated concentrated harvest was loaded on top of a solution consisting of three layers of sucrose with different densities. The three sucrose layers were selected based on a preliminary study which showed the formation of a linear sucrose gradient and complete separation of the virus
- 20 particles from residual contaminants as demonstrated for ChikV (Fig. 15D). The optimal volumes of

the sucrose solutions were determined empirically. The volumes of individual layers for a centrifugation in 100 mL bottle scale are shown in Table 5.

Table 5: Individual layers/volumes for a centrifugation in bottle.

Solution	Volume (mL)
PS treated harvest in 10% sucrose (L)	40
15% sucrose (J)	15
35% sucrose (I)	15
50% sucrose (H)	20
Total volume	90

5

The sucrose gradient bottles were prepared by stratifying the individual sucrose layers. A plastic tube was attached to peristaltic pump tubing. The plastic tube was mounted on a laboratory stand using a clamp and placed into the centrifuge bottle. The nozzle of the plastic tube was touching the bottom of the bottle. Using a peristaltic pump the ZikaV material and the sucrose solutions were pumped into the cylinder. A measuring cylinder was used as feed vessel. The first solution pumped was the ZikaV material as it represented the solution of lowest density (10 % sucrose (w/w)). After the ZikaV material the sucrose solutions were pumped in ascending order starting with the 15 % (w/w) solution J, followed by 35 % sucrose solution I and finishing with the highest density sucrose solution H (50 % (w/w)). The described setup is shown in Figure 14. After all sucrose solutions were transferred the plastic tubing was carefully removed in order not to disturb the layers.

15

Prior to centrifugation the centrifuge was pre-cooled to 4°C. The prepared SG bottles were carefully transferred into the pre-cooled rotor. (Note: Sudden movement of the bottles during transfer to the rotor must be avoided in order not to disturb the sucrose layers.) The bottles were centrifuged at ~11.000 RCF max at 4 °C for at least 20 hours, no brake/deceleration activated. In case a different centrifuge system with a different rotor is used the necessary speed and centrifugation times need to be calculated based on the k-factor in order to achieve comparable centrifugation efficiency.

20

Harvesting of the sucrose gradient was done manually using a peristaltic pump. A plastic tube attached to peristaltic pump tubing was used for harvesting the sucrose gradient. The bottle containing the gradient was mounted onto a laboratory stand in a tilted position (~12°) using a clamp. The plastic tubing was then placed into the bottle touching the bottom edge of the bottle and was fastened in

25

position using a clamp. This resulted in a small gap of 1-2 mm between the tubing inlet and the bottom of the bottle (see Figure 14).

5 Using a peristaltic pump set to a flow rate of 30 mL per minute the gradient was harvested and manually split into 2 mL fractions. A total number of 32 fractions per bottle were harvested (~ 64 mL) and the remaining volume was discarded. The fractions were immediately tested by SDS-PAGE / silver stain to identify the virus containing fractions with sufficient high purity. Representative SDS-PAGE is shown in Figure 14. Fraction 10-14 were pooled and further processed.

10 The purified viral solution was inactivated by incubation with 0.02% formaldehyde over a period of ten days in a 22°C controlled-temperature incubator. The formaldehyde is neutralized by addition of sodium metabisulphite on the tenth day.

15 The sucrose gradient pool (~17mL after sampling) was further diluted 3-fold with PBS to a final volume of 51 mL in a PETG container. A volume of 1% formaldehyde (10,000 ppm) solution equivalent to 1/50 of the final volume of the pre-formaldehyde pool was added to this pool resulting in an effective concentration of 200 ppm. The formaldehyde-treated solution was mixed on a magnetic stirrer for 10 minutes. After sampling, the formaldehyde-treated viral solution was placed within a cooled incubator at 22°C ± 2°C. On Day 5 post addition of formaldehyde, the formaldehyde-treated viral solution was filtered through a 0.2 µm filter and then placed in the incubator at 22°C ± 20 2°C again. On Day 10, after removing the 10-Day inactivation final sample, a volume of 1 % (of the weight of the final formaldehyde-treated viral solution) of 200 mM-sodium metabisulphite solution (2mM final concentration) was aseptically transferred into the PETG container containing the formaldehyde-treated viral solution. After mixing for 5 minutes on a magnetic stirrer, the neutralized 25 inactivated viral solution is held at room temperature (20 to 25°C) for a minimum of 30 minutes. After sampling, the neutralized inactivated viral solution is stored at 5°C ± 3°C until further processing.

Inactivation by formaldehyde

30 Critical parameters for this step are final formalin concentration, temperature, mixing and transfer into a new container. A preliminary acceptance criterion for maximum pfu/mL (determined by plaque assay) has been set on the diluted pool pre formaldehyde treatment.

The quality of the neutralized inactivated viral solution was monitored by the following parameters: Plaque assay on Day 10, SEC-HPLC, SDS-PAGE/Western Blot.

Interestingly, SEC-HPLC analysis of samples taken during the inactivation period followed by neutralization with bisulfite showed more or less constant peak area throughout the inactivation period. This is in contrast to JEV where losses of viral particles up to 60% are observed using the process disclosed by Srivastava et al. Vaccine 19 (2001) 4557-4565. In a scale-down model the viral losses were even much higher due to surface/area ratio at smaller scale and high losses due to unspecific adsorption. Differences of the ZikaV inactivation experiment and JEV inactivation were noticed as follows:

A) Much higher purity of ZikaV SGP pool with regard to residual PS ($<2\mu\text{g/mL}$) compared to JEV. The 3-fold ZikaV inactivated sample contained therefore $<<1\mu\text{g/mL}$ of residual PS. Commercial JEV SGP pool contains on average $\sim 120\mu\text{g/mL}$ (up to $152\mu\text{g/mL}$ possible). The average dilution to inactivation solution of ~ 14 -fold results in a residual PS content up to $\sim 11\mu\text{g/mL}$. It may be that higher amount of residual PS could cause virus precipitation due to cross-linking / reaction with formalin.

B) ZikaV inactivation sample contained $\sim 10\%$ sucrose (3-fold dilution of SGP pool containing ~ 30 - 35% sucrose). Sucrose might have stabilizing effect of viral ZikaV particles during treatment with formalin.

Dilution to DS and Formulation with Aluminium hydroxide (DP)

For preparation of ZikaV drug substance used in mouse potency assay an antigen content (expressed as total viral particles or SEC peak area) of 5 times higher compared to Ixiaro was targeted. The basis for determination of antigen content was SEC-HPLC. Briefly, a Superose 6 10/300 Increase column (GE Healthcare) equilibrated with PBS + 250 mM NaCl, pH 7.4 at 1 ml/min and 25°C , was used to detect ZikaV at 214 nm detection wavelength in harvest samples and throughout the downstream process. In the current JEV process the antigen content in NIV is determined by a specific ELISA. A good correlation was observed between antigen content determined by ELISA and SEC-HPLC. On average, the antigen content in commercial NIV samples is in the range of 33 AU/mL corresponding to $\sim 5.2\text{mAU}$ JEV peak area, see Figure 21.

ZikaV NIV day10 (Zika peak $\sim 36\text{ mAU}$, analysed on Waters HPLC/Superose6 Increase column) was diluted with PBS to a target of 6.3 ($\sim 5.7\text{x}$ dilution). Aluminium hydroxide was added to a final concentration of 0.5 mg/mL Aluminium (1/20 v/v Alum 2% stock solution added) to prepare ZikaV Drug Product (DP). The DP was gently mixed for 5 min. An aliquot of the DP was removed, Alum sedimented by centrifugation and the clear supernatant analysed by SEC-HPLC. No ZikaV peak was detected in the supernatant indicating complete adsorption (estimated as $>95\%$) of viral particles on the mineral adjuvant. Formulated ZikaV DP was stored at 2 - 8°C .

The impurity profile of the inactivated Zika virus DS is comparable to the profile of JEV DS with the exception of a lower PS content (Table 6).

5 **Table 6:** Determination of impurity profile in Zika and JEV DS samples:

	Specification (JEV DS)	JEV	Zika
HCP (ng/mL)	<100 LOQ 12 ng/mL	<LOQ	<LOQ
DNA (pg/mL)	<200 LOQ 40 pg/mL	<40	<40
Aggregates by SEC-MALLS (%)	Not specified, part of characterization LOQ 5%	<LOQ	<LOQ
PS (µg/mL)	Specification only at SGP pool to demonstrate consistent process performance (19-152 µg/mL), *PS content in DS calculated based on PS content in SGP pool (~100 µg/mL) and average dilution factor (~28x) to DS; LOQ 2 µg/mL	~4*	<<LOQ

*Typical PS impurity in a JEV sample produced in accordance with protocol disclosed in Srivastava et al. Vaccine 19 (2001) 4557-4565.

SEC-MALLS Results

- 10 A representative SEC-HPLC elution profile of ZikaV NIV at 214 nm detection wave length is shown in Figure 16. Note that BSA (50 µg/mL) was added to the sample to minimize losses in HPLC glass vial due to unspecific surface adsorption. ZikaV monomer content was estimated as ~98% with a multimer content of ~2%.
- 15 SEC-MALLS analysis (Figure 17) of the sample confirmed the radius R_z of the monomer ZikaV population peak 1 as 21.6 nm and ~49 nm for the multimer peak 2. Cumulative particle size distribution showed that 89% of all viral particles are within a radius range between 18 to 25 nm (Figure 18).
- 20 Results confirm purity and homogeneity of ZikaV NIV.

Viral titer by plaque assay

Table 7: Active ZikaV pfus were quantified by plaque assay throughout the process.

Sample	Pfu/mL
Harvest day 2 (filtered)	6.4×10^7
Harvest day 3 (filtered)	1.0×10^8

Harvest day 5 (filtered)	1.5x10 ⁸
Harvest day 7 (filtered)	1.1x10 ⁸
PS treated harvest 300x concentrate (=SGP load)	9.0x10 ⁸
SGP pool	8.9x10 ⁸
Inactivation start (SGP pool 1:3 diluted)	3.4x10 ⁸
Inactivation day 5	<LOD
Inactivation day 10	<LOD

Comparison of PS and Benzonase on process performance

A direct comparison of DNA removal method of concentrated ZikaV harvest pool was done. One aliquot was treated with PS (2 mg/mL, 15min at room temperature), the other aliquot was treated with Benzonase (50 U/mL, 2 mM MgCl₂, 4h RT, 48h 2-8°C). Both samples were further purified by sucrose gradient as described in this report. Interestingly, the Benzonase treated samples did not yield any pure fractions after sucrose gradient centrifugation of the treated ZikaV harvest. In those fractions where the specific virus bands were detected, a high amount of host cell protein was detected throughout the collected fractions. The PS treated material resulted in pure ZikaV containing fractions as expected. This finding may suggest that PS is not only effective for DNA removal by precipitation; in addition it improves the recovery of virus particles in the gradient by disrupting interaction of DNA (fragments) and virus particles. Benzonase treatment does not remove DNA, it only results in its fragmentation. Residual DNA fragments might still interact with virus particles and residual HCPs resulting in cross-contamination and co-purification in the sucrose gradient. Pooled SGP fractions were also analysed by SEC-HPLC. Although a large peak was detected, SDS-PAGE confirmed that this sample was highly contaminated with HCPs. A large peak might be detected at UV214 and 280nm after SEC-HPLC analysis due to possible interaction of HCPs with large virus particles, changing the UV absorbance.

20 Immunogenicity of Vero grown Zika virus

Immunization of mice

Prior to immunization, groups of ten 6-week-old female CD1 mice were bled via vena facialis and pre-immune sera were prepared. One intraperitoneal immunizations of 200 µL were administered. A dose titration (12 µg, 3 µg, 1 µg, 0.33 µg, 0.11 µg, 0.037 µg and 0.012 µg, equivalent to the protein amount in IXIARO) of inactivated Zika virus formulated with aluminium hydroxide (Al(OH)₃) at a final concentration of 0.7%. Three weeks after immunization, blood was collected and immune sera were prepared. All animal experiments were conducted in accordance with Austrian law (BGB1 Nr. 501/1989) and approved by "Magistratsabteilung 58".

Plaque reduction neutralization test (PRNT)

Twelve well plates were used for PRNT. Each well was seeded with 1 mL medium containing 4×10^5 Vero cells and incubated 35°C with 5% CO₂ overnight. Pools of heat inactivated sera from each dose group were tested in triplicate. The target viruses (H/PF/2013 (SEQ ID NO: 13) or MR766 (SEQ ID NO: 11)) were diluted to 100 pfu/165 µL. Equal volumes of target virus and serum dilution were incubated at 35°C with 5% CO₂ for 1 hour. The cell culture medium was aspirated from the Vero cells and 330 µL of the mixture target virus/serum dilution were added to each well and the plates were rocked back and forth 5 times before incubating for 2 hours at 35°C with 5% CO₂. To each well 1 mL of a 2% methylcellulose solution containing EMEM and nutrients was added, the plates were then incubated for 5 days at 35°C with 5% CO₂ before staining the cells for 1 hour with crystal violet/5% formaldehyde and subsequently washed 3 times with deionized water. The plates were air dried and the numbers of plaques in each well were manually counted.

Results

Neutralization was observed with serum pools from mice immunized with inactivated Zika virus vaccine (H/PF/2013) down to 37 ng (dosing equivalent to the amount protein in IXIARO®) against Zika viruses of both the Asian (H/PF/2013) and African (MR766) lineages (Figures 19 and 20, respectively). Complete inhibition was seen at the 1:20 serum dilution with an immunization dose down to 110 ng (dosing equivalent to the amount protein in IXIARO®). The neutralization of both the Asian (H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

Another neutralization assay was performed using the microneutralization assay as described by Larocca, et al. (2016, Nature doi:10.1038/nature18952). It was found that the inactivated Zika virus of the current invention had an MN50 (microneutralization) titer of 90 at 1 µg of inactivated purified virus.

Further methods: The immunogenicity of inactivated Zika virus preparations is assessed using a mouse model of Zika infection. Groups of adult mice are immunized subcutaneously (s.c.) with 500, 50, or 5 ng of inactivated Zika virus with adjuvant (e.g. aluminium hydroxide with or without IC31®), or without adjuvant. An additional group of mice receive PBS as a negative control. Each group is administered the indicated inoculum at t=0 and in some cases also at three to four weeks later (t=3/4). Beginning approximately three weeks after administration of the last immunization, serum samples

are obtained from each of the mice at regular intervals. The serum samples are tested for the presence of neutralizing antibodies using PRNT.

- The *in vivo* protective efficacy of the inactivated Zika virus preparations is also assessed using a mouse model of Zika infection, *i.e.* IFN-alpha/beta receptor knock-out mice (A129) (see *e.g.* Dowall et al., 4. March 2016, <http://dx.doi.org/10.1101/042358>) or blocking of the IFN-alpha/beta receptor by administration of anti-IFN-alpha/beta receptor monoclonal antibodies to C57BL/6 or BALB/c mice (see *e.g.* Pinto et al., 7. December 2011, DOI: 10.1371/journal.ppat.1002407). For protection assays, groups of 10 three- to eight-weeks-old A129, C57BL/6 or BALB/c mice are inoculated subcutaneously in the hindquarters with inactivated Zika virus with adjuvant (aluminium hydroxide) or without adjuvant at t=0. Age-matched controls are inoculated with PBS or non-specific antigens in alum. Mice are optionally boosted with a second administration of the indicated inoculation three to four weeks later. The mice are then challenged subcutaneously at three to eight weeks post immunization by inoculation with a deadly dose of live Zika virus. One day prior to challenge of C57BL/6 and BALB/c mice, they are passively administered (intraperitoneally) anti-IFN-alpha/beta receptor monoclonal antibodies. Challenged mice are monitored daily for morbidity and mortality for up to twenty-one days. Another alternative is to challenge intracranially adult vaccinated/non-vaccinated adult mice and observe protection.
- It is expected that the Zika virus produced by the process of the invention will provide very similar functional read-outs in *in vitro*, *in vivo* and finally human trials as the currently licensed JEV vaccine in the EU and US and elsewhere, IXIARO®. The dosage may alter but due to the very similar impurity profile and almost identical manufacture, a very similar efficacy and safety result will be expected as was determined for the currently licensed JEV vaccine (licensed in the EU and US and elsewhere).

Discussion & Conclusion

- The existing manufacturing platform for production of inactivated JEV vaccine IXIARO® was used as a basis for a manufacturing feasibility study of inactivated ZikaV vaccine candidate (Asian strain H/PF/2013). The virus was produced on Vero cells cultivated in roller bottles. The virus was purified by PS treatment followed by an optimized sucrose gradient. Inactivation was done by formalin treatment (0.02 %, 10 days at 22 °C). For exploratory immunization studies in mice, a DP formulated with Alum was prepared with an estimated 5-fold higher virus particle content compared to IXIARO®, the commercial JEV Vaccine. The impurity profile of the DS met all criteria as defined in the specification for IXIARO®, the commercial JEV vaccine. The neutralization of both the Asian

(H/PF/2013) and African (MR766) lineages of the Zika virus was equivalent, which indicates high cross-neutralization between different Zika virus strains of the inactivated Zika virus vaccine (H/PF/2013).

5 The in vivo data regarding immunogenicity of the inactivated Zika virus vaccine of the current invention indicates that the virus is surprisingly potently immunogenic and also highly cross-protective (very similar immunogenicity in African and Asian strains). Data indicate that immunogenicity was higher than the recently reported inactivated Zika virus vaccine candidate (Larocca, et. al, 2016, supra.). Inactivated viruses are among the safest vaccines and especially
10 preferred for deliver to populations where safety is especially concerning, such as pregnant women, children and immunocompromised individuals, which makes the herein disclosed inactivated Zika virus particularly suitable. Obtaining a high titer of inactivated virus is a challenge in the field. The herein disclosed process for purifying inactivated Zika virus results in not only a high yield, but also a very pure drug substance.

15

Further more detailed aspects of the invention:

A1. A Zika virus vaccine comprising an inactivated Zika virus particle, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70%
20 probability.

A2. The Zika virus vaccine of A1, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability.

25 A3. The vaccine of A1 or A2, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.

30 A4. The vaccine of any one of A1-A3, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.

- A5. The vaccine of any one of A1-A4, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.
- 5 A6. The vaccine of A5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent to completely inactivate the Zika virus as measured by plaque assay.
- A7. The vaccine of A6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.
- 10 A8. The vaccine of A7, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.
- A9. The vaccine of any one of A5-A8, wherein the chemical activation is performed at about +4°C or about +22°C.
- 15 A10. The vaccine of any one of A1-A9, further comprising an adjuvant.
- A11. The vaccine of A10, wherein the adjuvant is an aluminum salt adjuvant.
- 20 A12. The vaccine of A11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.
- A13. The vaccine of any one of A10-A12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).
- 25 A14. The vaccine of A13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).
- 30 A15. The vaccine of any one of A1-A14, further comprising one or more pharmaceutically acceptable excipient.

A16. The vaccine of any one of A1-A15, wherein the vaccine contains protamine sulphate or fragments or break-down products of PS at amounts too low to detect by HPLC, i.e., below 1 µg/mL, especially below 100 ng/mL.

- 5 A17. The vaccine of A16, wherein said protamine sulphate or fragments or break-down products of PS can be detected by mass spectroscopy or another sensitive method.

10 B1. A kit comprising a Zika virus vaccine of any one of A1-A15.

B2. The kit of B1, further comprising a second vaccine.

B3. The kit of B2, wherein the second vaccine is a West Nile virus vaccine, a Japanese Encephalitis virus vaccine, a Yellow Fever virus vaccine, a Dengue virus vaccine or a Chikungunya virus vaccine.

15

C1. A method, comprising administering a first dose of a therapeutically effective amount of the Zika virus vaccine of any one of A1-A15 to a subject in need thereof.

20

C2. The method of C1, further comprising administering a second dose of a therapeutically effective amount of the Zika virus vaccine.

C3. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.

25

C4. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.

30 C5. The method of C1 or C2, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.

C6. The method of any one of C1-C5, wherein the administering results in production of Zika virus neutralizing antibodies.

35

- D1. A method of producing a Zika virus vaccine, comprising
(i) passaging a Zika virus on Vero cells, thereby producing a culture supernatant comprising the Zika virus;
5 (ii) harvesting the culture medium of (i);
(iii) precipitating the harvested culture medium of (ii), thereby producing a Zika virus supernatant; and
(iv) optimally inactivating the Zika virus in the Zika virus supernatant of (iii) thereby producing an inactivated Zika virus.
10
- D2. The method of D1, further comprising concentrating the culture medium of (ii) prior to step (iii).
- D3. The method of D1 or D2, wherein the precipitating of (iii) comprises contacting the culture
15 medium of (ii) with protamine sulfate or benzoate.
- D4. The method of any one of D1-D3, further comprising (v) dialyzing the inactivated Zika virus of (iv), thereby producing a dialyzed Zika virus.
- 20 D5. The method of D4, further comprising (vi) filtering the dialyzed Zika virus of (v).
- D6. The method of any one of D1-D5, wherein the inactivating is by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.
- 25 D7. The method of D6, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for at least 4 days.
- D8. The method of D6 or D7, wherein the chemical inactivation agent comprises formaldehyde.
- 30 D9. The method of any one of D6-D8, wherein the chemical activation is performed at about +4°C or about +22°C.
- D10. The method of D8 or D9, further comprising neutralizing the formaldehyde.
- 35 D11. The method of D10, wherein the neutralizing is performed with sodium metabisulfite.

- 5 E1. The use of the optimally inactivated Zika virus vaccine of any one of A1-A15 for the treatment and/or prevention of a Zika virus infection.
- E2. The use of E1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.
- 10 E3. The use of E2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.
- E4. The use of E3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.
- 15 E5. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 14 days after the first dose of the Zika virus vaccine.
- E6. The use of E3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.
- 20 E7. The use of any one of E1-E6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.
- 25 F1. A pharmaceutical composition for use in the treatment or prevention of a Zika virus infection, wherein said pharmaceutical composition comprises the optimally inactivated Zika virus vaccine of any one of A1-A15.
- 30 F2. The pharmaceutical composition of F1, wherein the inactivated Zika virus vaccine is administered in a first dose of a therapeutically effective amount to a subject in need thereof.
- F3. The use of F2, wherein the inactivated Zika virus vaccine is administered in a second dose of a therapeutically effective amount to the subject.

- F4. The use of F3, wherein the second dose of the inactivated Zika virus vaccine is administered about 7 days after the first dose of the Zika virus vaccine.
- F5. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 14
5 days after the first dose of the Zika virus vaccine.
- F6. The use of F3, wherein the second dose of the Zika virus vaccine is administered about 28 days after the first dose of the Zika virus vaccine.
- 10 F7. The use of any one of F1-F6, wherein the vaccine administration results in production of Zika virus neutralizing antibodies.
- G1. Use of an optimized sucrose gradient centrifugation for removal of protamine sulphate from
15 purified infectious Zika virus particles.
- G2. The use according to G1, wherein said optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% +/- 1% (w/w) sucrose solution and three further layers of sucrose solutions with different densities, i.e. a first sucrose solution with 15% +/- 1% (w/w) sucrose, a
20 second sucrose solution with 35% +/- 1% (w/w) sucrose, and a third sucrose solution with a 50% +/- 1% (w/w) sucrose.
- G3. A process of purification of infectious Zika virus particles, comprising the steps of:
- 25 a) providing a crude harvest (a) comprising virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
- 30 c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/mL, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05 µg/mL.
- 35

- 5 G4. The process of G3, wherein said optimized sucrose density gradient centrifugation comprises a virus comprising fraction in a 10% +/- 1% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% +/- 1% (w/w) sucrose, a second sucrose solution with 35% +/- 1% (w/w) sucrose, and a third sucrose solution with a 50% +/- 1% (w/w) sucrose.
- 10 G5. The process of any one of G3 to G4, additionally comprising a further purification step of: (d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.
- 15 G6. The process of any of G3 to G5, wherein the residual host cell DNA content of the Zika virus preparation (c) is less than 10 ng/mL and the residual host cell protein content of the final virus preparation (c) is less than 100 ng/mL.
- G7. The process of any of G3 to G6, wherein said crude harvest (a) comprising Zika virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).
- 20 G8. The process of G7, wherein the one or more pre-purification step(s) comprises
a) filtration using a filter having a pore size equal to or less than 0.2 μm ; and/or
b) digestion of host cell genomic DNA by enzymatic treatment; and/or
c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.
- 25 G9. The process of any one of G3 to G8, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.
- 30 G10. The process of any one of G3 to G9, wherein the enrichment of infectious Zika virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

- G11. The process of any one of G7 to G10, wherein the one or more pre-purification step(s) prior to step (b) of any of G8 to G11 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .
- 5 G12. The process of any one of G3 to G11, wherein the residual impurity of the Zika virus preparation (c) is less than 10%.
- G13. The process of any one of G3 to G12, wherein the Zika virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa
10 cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.
- G14. The process of G13, wherein said cell line is a Vero cell line.
15
- G15. The process of any one of G3 to G14, wherein said infectious Zika virus particle is an infectious virus particle that is a live virus, a live attenuated virus, a chimeric virus, a modified live virus, or a recombinant live virus.
- 20 G16. The process of any one of G3 to G15, wherein said Zika virus is preferably a strain of the Asian lineage.
- G17. The process of any one of G3 to G16, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by
25 formaldehyde.
- G18. Use of the process according to any one of G3 to G17 for manufacturing a composition for immunization against a virus infection.
- 30 G19. The use according to G18, wherein said virus infection is an infection caused by a Zika virus.
- Q1. A process of purification of infectious Zika virus particles, comprising the steps of:
(a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;

(b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);

(c) further purifying the virus preparation (b) by an optimized sucrose density gradient centrifugation, wherein the optimized sucrose gradient is provided such that the protamine can be completely or almost completely separated from the virus fraction; and wherein the protamine concentration is reduced by this step to the extent that the protamine concentration in the final drug substance is below 1 µg/ml, preferably below 0.5 µg/mL, more preferably below 0.1 µg/mL, most preferably below 0.05µg/mL.

Q2. The process of Q2, wherein the virus particles are from Zika virus.

Q3. The process of Q1 or Q2, additionally comprising the step of:

(d) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and collecting the virus particles.

Q4. The process of any of Q1 to 3, wherein the residual host cell DNA of the virus preparation (c) is less than 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.

Q5. The process of any of Q1 to 4, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).

Q6. The process of Q5, wherein the one or more pre-purification step(s) comprises

(a) filtration using a filter having a pore size equal to or less than 0.2 µm; and/or

(b) digestion of host cell genomic DNA by enzymatic treatment; and/or

(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

Q7. The process of any one of Q1 to 6, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml or 2 mg/ml.

Q8. The process of any one of Q1 to 7, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

- 5 Q9. The process of any one of Q5 to 8, wherein the one or more pre-purification step(s) prior to step (b) of any of Q5 to 8 is performed using a filter having a pore size equal to or less than 1 μm , preferably 0.2 μm .

- 10 Q10. The process of any one of Q1 to 9, wherein the residual impurity of the virus preparation (c) is less than 10%.

- 15 Q11. The process of any one of Q1 to 10, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

Q12. The process of Q11, wherein said cell line is a Vero cell line.

- 20 Q13. The process of any one of Q1 to 12, wherein the infectious virus particles is an infectious Zika virus particle that is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

- 25 Q14. The process of any one of Q1 to 13, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

- 30 Q15. The process of any one of Q1 to 14, wherein said process resulting in final virus preparation (c) or (d) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

Q16. Use of the process according to any one of Q1 to 15 for manufacturing a composition for immunization against a virus infection.

- 35 Q17. The use according to Q16, wherein the composition for immunization against a virus infection is an infection caused by Zika virus.

- Q18. A composition comprising the virus particles obtainable or obtained by the process of any one of Q1 to 17 for treating and/or preventing an infection, such as e.g. a Zika virus infection.
- 5 Q19. A Zika virus vaccine comprising an inactivated Zika virus particle grown on vero cells, wherein the Zika virus particle is able to seroconvert a subject that is administered the Zika virus vaccine with at least a 70% probability and comprises minor amounts of protamine sulphate, preferably below the detection limit.
- 10 Q20. The Zika virus vaccine of Q19, wherein the Zika virus particle is able to seroconvert the subject that is administered the Zika virus vaccine with at least a 80%, 85%, 90%, or 95% probability, preferably a 80% probability.
- 15 Q21. The vaccine of Q19 or 20, wherein the Zika virus particle has a RNA genome corresponding to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 and able to pack a virulent Zika virus.
- 20 Q22. The vaccine of any one of Q19, 20 and 21, wherein the Zika virus particle has an E protein selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69 or 72, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 or 72 and able to pack a virulent Zika virus.
- 25 Q23. The vaccine of any one of Q19, 20 to 22, wherein the Zika virus obtained by culturing on Vero cells is purified by protamine sulfate precipitation and sucrose gradient centrifugation.
- Q24. The vaccine of Q23, wherein the sucrose gradient centrifugation is an optimized sucrose gradient centrifugation.
- 30 Q25. The vaccine of Q24, wherein the optimized sucrose gradient centrifugation comprises a virus comprising fraction in a 10% (w/w) sucrose solution and three layers of sucrose with different densities, i.e. a first sucrose solution with 15% (w/w) sucrose solution, a second sucrose solution with 35% (w/w) sucrose solution, and a third sucrose solution with a 50% (w/w) sucrose solution.

Q26. The vaccine of any one of Q19, 20 to 25, wherein the Zika virus is inactivated by chemical inactivation, thermal inactivation, pH inactivation, or UV inactivation.

5 Q27. The vaccine of Q26, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.

10 Q28. The vaccine of Q27, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.

Q29. The vaccine of Q28, wherein the formaldehyde inactivation comprises contacting the Zika virus with formaldehyde for between 2-10 days.

15 Q30. The vaccine of any one of Q27-29, wherein the chemical activation is performed at about +4°C or about +22°C.

Q31. The vaccine of any one of Q19 to 30, further comprising an adjuvant.

20 Q32. The vaccine of Q31, wherein the adjuvant is an aluminum salt adjuvant.

Q33. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.

25 Q34. The vaccine of Q32, wherein the aluminum salt adjuvant is aluminium hydroxide with less than 1.25ppb Cu based on the final pharmaceutical composition comprising the Zika virus, preferably the inactivated Zika virus.

Q35. The vaccine of any one of Q19 to 34, further comprising one or more pharmaceutically acceptable excipient.

30 R1. Use of protamine, preferably a protamine salt, to separate infectious and non-infectious Zika virus particles, host cell proteins and/or undefined low molecular weight materials.

R2. A process of purification of infectious Zika virus particles, comprising the steps of:

- (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b), wherein the enrichment of infectious virus particles in the virus preparation (b) relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.
- 5
- R3. The use of R1 or the process of R2, wherein the virus particles are from Zika virus.
- R4. A process of purification of infectious Zika virus particles, comprising the steps of:
- 10 (a) providing a crude harvest (a) comprising Zika virus particles and impurities, wherein the impurities are generated from growing said virus particles on a cell substrate;
- (b) reducing impurities from the crude harvest (a) by precipitation with an agent comprising protamine, preferably a protamine salt, more preferably a protamine sulphate, even more preferably a recombinant protamine sulphate, to obtain a virus preparation (b);
- 15 (c) further purifying the virus preparation (b) by one or more size exclusion methods such as (i) a sucrose density gradient centrifugation, (ii) a solid-phase matrix packed in a column comprising a ligand-activated core and an inactive shell comprising pores, wherein the molecular weight cut off of the pores excludes the virus particles from entering the ligand-activated core, and wherein a molecule smaller than the molecular weight cutoff of the pores can enter the ligand-activated core and
- 20 collecting the virus particles, and/or (iii) size exclusion chromatography to obtain a virus preparation (c) comprising the infectious virus particles, wherein the residual host cell DNA of the virus preparation (c) is less than 100 ng/mL and the residual host cell protein and the residual aggregates of infectious virus particles of the final virus preparation (c) is less than 1 µg/mL.
- R5. The process of R4, wherein the residual host cell DNA of the virus preparation (c) is less than
- 25 10 ng/mL and the residual host cell protein of the final virus preparation (c) is less than 100 ng/mL.
- R6. The process of any of R2 to 5, wherein the crude harvest (a) comprising virus particles and impurities is subjected to one or more pre-purification step(s) prior to step (b).
- R7. The process of R6, wherein the one or more pre-purification step(s) comprises
- (a) filtration using a filter having a pore size equal to or less than 0.2 µm; and/or

(b) digestion of host cell genomic DNA by enzymatic treatment; and/or

(c) ultra/diafiltration using a hollow fiber membrane having a pore size equal to or greater than 300 kDa, preferably equal to or greater than 100 kDa.

5 R8. The process of any one of R2 to 7, wherein the concentration of protamine sulphate is 0.5 to 3 mg/ml, more preferably 1 to 2 mg/ml, more preferably 1.2 to 1.8 mg/ml, more preferably 1.4 to 1.6 mg/ml, most preferably 1.6 mg/ml.

R9. The process of any one of R2 to 8, wherein the enrichment of infectious virus particles in the virus preparation (c) or any final virus preparation relative to total virus products in the crude harvest (a) is in the range from at least 50% to 95%, preferably at least 80%.

10 R10. The process of any one of R6 to 9, wherein the one or more pre-purification step(s) prior to step (b) of any of R6 to 9 is performed using a filter having a pore size equal to or less than 1 μ m, preferably 0.2 μ m.

R11. The process of any one of R2 to 10, wherein the residual impurity of the virus preparation (c) is less than 10%.

15 R12. The process of any one of R2 to 11, wherein the virus is propagated in a cell line selected from the group consisting of an EB66 cell line, a Vero cell line, a Vero- α His cell line, a HeLa cell line, a HeLa-S3 cell line, a 293 cell line, a PC12 cell line, a CHO cell line, a 3T3 cell line, a PerC6 cell line, a MDSK cell line, a chicken embryonic fibroblast cell line, a duck cell line, and a diploid avian cell line.

20 R13. The process of R12, wherein said cell line is a Vero cell line.

R14. The process of any one of R2 to 13, wherein the Zika virus is a live virus, an attenuated live virus, a chimeric virus, a modified live virus, or a recombinant live virus.

R15. The process of any one of R2 to 14, wherein the Zika virus is a Zika virus strain of the Asian lineage or an immunogenic variant thereof.

25 R16. The process of any one of R2 to 15, wherein said process resulting in final virus preparation (c) is followed by an inactivation step, wherein the virus is inactivated preferably by formaldehyde.

R17. Use of the process according to any one of R1 to 16 for manufacturing a composition for immunization against a virus infection.

R18. The use according to R17, wherein the composition for immunization against a virus infection is an infection caused by a Zika virus.

R19. A composition comprising the virus particles obtainable or obtained by the process of any one of R2 to 16 for treating and/or preventing an infection.

CLAIMS

What is claimed is:

- 5 1. A Zika virus vaccine comprising an inactivated Zika virus particle, wherein said Zika virus vaccine is able to confer seroprotection on at least 70% of subjects that are administered the Zika virus vaccine.
2. The Zika virus vaccine of claim 1, wherein the Zika virus particle is able to confer
10 seroprotection on at least 75%, 80%, 90%, 95%, 96%, 97%, 98%, or at least 99% of vaccinated subjects that are administered the Zika virus vaccine, preferably on at least 80% of subjects.
3. The vaccine of claim 1 or 2, wherein the Zika virus particle has a RNA genome corresponding
15 to the DNA sequence provided by any one of the nucleic acid sequences of SEQ ID NOs: 2-13 or 72, or a variant nucleic acid sequence that is at least 88% identical to any one of SEQ ID NOs: 2-13 or 72 and able to pack a virulent Zika virus.
4. The vaccine of any one of claims 1 to 3, wherein the Zika virus particle has an E protein
20 selected from the amino acid sequences provided by any one of SEQ ID NOs: 14-69, or a variant amino acid sequence that is at least 95% identical to any one of SEQ ID NOs: 14-69 and able to pack a virulent Zika virus.
5. The vaccine of any one of claims 1 to 4, wherein the Zika virus is inactivated by chemical
25 inactivation, thermal inactivation, pH inactivation, or UV inactivation.
6. The vaccine of claim 5, wherein the chemical inactivation comprises contacting the Zika virus with a chemical inactivation agent for longer than is required to completely inactivate the Zika virus as measured by plaque assay.
- 30 7. The vaccine of claim 6, wherein the chemical inactivation comprises contacting the Zika virus with formaldehyde.
8. The vaccine of claim 7, wherein the formaldehyde inactivation comprises contacting the Zika
35 virus with formaldehyde for between 2-10 days.

9. The vaccine of any one of claims 5 to 8, wherein the chemical activation is performed at about +4°C or about +22°C.
10. The vaccine of any one of claims 1 to 9, further comprising an adjuvant.
- 5 11. The vaccine of claim 10, wherein the adjuvant is an aluminum salt adjuvant.
12. The vaccine of claim 11, wherein the aluminum salt adjuvant is aluminium hydroxide or aluminium phosphate salt.
- 10 13. The vaccine of any one of claims 10 to 12, wherein the vaccine comprises or further comprises an adjuvant comprising a peptide and a deoxyinosine-containing immunostimulatory oligodeoxynucleic acid molecule (I-ODN).
- 15 14. The vaccine of claim 13, wherein the peptide comprises the sequence KLKL5KLK (SEQ ID NO: 71) and the I-ODN comprises oligo-d(IC)13 (SEQ ID NO: 70).
15. The vaccine of any one of claims 1 to 14, further comprising one or more pharmaceutically acceptable excipients.
- 20 16. The vaccine of any one of claims 1 to 15, wherein the vaccine contains protamine sulphate or fragments or break-down products of PS at amounts too low to detect by HPLC, i.e., below 1 µg/mL, especially below 100 ng/mL.
- 25 17. The vaccine of claim 16, wherein said protamine sulphate or fragments or break-down products of PS can be detected by mass spectroscopy or another sensitive method.